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ABSTRACT
The aim of this dissertation was to study the absorption, 
and subsequent toxic side effects of transition metal based 
pharmaceuticals following oral administration to rats. 
Administration of cisplatin (30mg/kg), carboplatin (37mg/kg) 
and iproplatin (42mg/kg) by oral gavage resulted in their 
rapid absorption so that respective peak blood levels of 
2.63pg platinum/ml, 1.48pg platinum/ml and 3.13pg 
platinum/ml were achieved within 2-4 hours. Approximately 
3-4% of the dose was excreted in the urine, but the major 
route of elimination was the faeces (>75%). This indicated 
that although rapid, absorption was relatively poor. 
Absorption was enhanced by employing a period of starvation 
prior to administration. A series of novel platinum (IV) 
mixed amines were absorbed to a greater extent than 
cisplatin and its congeners, carboplatin and iproplatin. 
However, absorption was somewhat slower with peak blood 
levels being attained some 24 hours after administration. Of 
the other transition metal complexes studied, auranofin and 
ruthenium acetylacetonate were particularly well absorbed so 
that peak blood levels of 12.53pg gold/ml and 6.4pg 
ruthenium/ml were achieved respectively. Urinary clearance 
of the ruthenium complex was especially significant with 
upto 45% of the administered dose being eliminated by this 
pathway within 48 hours.
In vitro everted gut sac and in situ perfusion techniques 
confirmed the in vivo finding that cisplatin is absorbed 
from the small intestine more readily than carboplatin. No 
evidence for active or carrier-mediated transport was found 
and kinetic studies confirmed that absorption was by passive 
diffusion.
Toxicology studies after oral administration of cisplatin
(57 or 30mg/kg) or carboplatin (282mg/kg) indicated that the 
toxicities associated with the perenteral use of the 
complexes would also apply to the oral route. This was 
exemplified by the fact that oral cisplatin was profoundly 
nephrotoxic, whereas carboplatin was not. In addition, 
gastro-intestinal toxicity manifested as acute necrotizing 
enteritis and ulcerogenicity of the stomach was potentiated 
by the oral route. Studies in the ferret indicated that 
cisplatin is significantly more emetogenic than carboplatin. 
Examination of liver morphology indicated changes, such as 
mitochondrial swelling and vesiculation of the endoplasmic 
reticulum, that might indicate a higher incidence of
hepatotoxic responses associated with administration of 
platinum complexes by the oral route.
Both cisplatin and carboplatin induced a degree of
myelosuppression but the most pronounced haematological 
lesion associated with oral administration was severe 
erythrocytosis which occurred as a result of a dehydration 
related decrease in plasma volume.
Electrothermal atomic absorption analysis of tissues excised 
from cisplatin and carboplatin rats indicated that platinum 
deposition was highest in the kidney. In an attempt to 
explain the prolonged retention of cisplatin in this 
organ, the intracellular location of the compound was 
studied using electron microprobe analysis and subcellular 
fractionation. The various lysosome populations of the 
proximal tubule were identified as sites of concentration of 
platinum and it was hypothesised that sequestration within 
these organelles might be an important mechanism of 
detoxification.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 CHEMOTHERAPY AND TRANSITION METALS
Chemotherapy is a field of cancer treatment which has evolved over 
the last forty years, and its use has escalated enormously in the last 
ten to fifteen years. Although records of the use of transition metals 
for the treatment of various ailments go back as far as the ancient 
Greeks, prior to 1969 most cancer research was centred on the 
potential carcinogenicity of metals and their salts rather than any 
potential anticancer properties. (Furst 1971.) The first metal-based 
drug to undergo extensive clinical testing was Fowler’s solution, of 
which the active ingredient is arsenic. (Furst 1963.) Although this 
particular remedy suffered from substantial toxic side effects, sodium 
and potassium arsenite and various organoarsenicals are still used 
clinically today, particularly in the treatment of leukaemias. (Bardos et 
al. 1966.)
One of the earliest surveys of the antitumour activity of inorganic 
compounds was made by Collier and Krauss (1931). In this, sixty-four 
compounds based upon the metals copper, lead, chromium, manganese, 
iron, cobalt, nickel, ruthenium, rhodium and osmium were tested and 
several were shown to be active against Ehrlich carcinomas in mice. 
After these initial findings many transition metals including copper, 
rhodium, palladium, ruthenium, indium and cobalt were examined for 
antitumour activity but the world of clinical oncology was not ready to 
accept the potential carcinostatic properties of elements regarded as 
non selective poisons.
This way of thinking was to change overnight by a discovery made in 
a laboratory at Michigan State University by a physicist investigating 
the effect of an electromagnetic field upon cell division. (Rosenberg 
et al. 1965.) This discovery, that a platinum based compound could 
inhibit cell division, but allow cell growth was to have a significant
impact on cancer chemotherapy and renew interest in the carcinostatic 
properties of metal based compounds. It had heralded the arrival of a 
new class of anticancer drugs: the transition metal coordination
compounds.
1.2 THE DISCOVERY OF THE FIRST METAL BASED ANTITUMOUR AGENT 
As for many other developments in science, the discovery of 
antitumour activity of ■ platinum ammine complexes was somewhat 
fortuitous. When Barnett Rosenberg initiated a series of experiments 
to determine the effect of an electromagnetic field on cell division, 
nobody, especially himself, could have imagined that the results of 
this experiment would lead to the development of one of the most 
successful anticancer drugs known to man. In the experiments, an AC 
current was passed through E. coli bacteria in a growth medium 
containing ammonium chloride via a set of platinum electrodes. Under 
the influence of the current, the bacteria underwent filamentous 
growth which implied that cell division had been inhibited, while cell 
growth was unaffected. A long series of control experiments showed 
that the current itself was not responsible for the filamentous growth 
but was causing some lOppm of platinum to dissolve from the 
electrodes. Further analysis (Rosenberg et al. 1967) showed that the 
species responsible for inhibiting cell division was the classic 
Peyrone’s chloride, cis-dichlorodiammine platinum (II) or its higher 
oxidation state equivalent cis-tetrachlorodiammine platinum (IV). In 
later experiments both the cis and trans platinum (II) species were 
tested against the same model bacteria system and it was discovered 
that only the cis compound caused filamentation. Bacterial tests on a 
variety of platinum ammine species also showed that neutral complexes 
as opposed to charged species tended to inhibit cell division. This
property of inhibiting cell division, but not cell growth, suggested 
that these compounds might have antitumour properties. Initially four 
compounds, cis-dichlorodiammine platinum (II), cis-tetrachlorodiammine 
platinum (IV), dichloroethylenediamine platinum (II) and 
tetrachloroethylene diammine platinum (IV) were tested against Sarcoma 
180 in the ICR strain of mice and were found to be effective in 
inhibiting the tumour growth (Rosenberg 1969), leaving some animals 
tumour-free (Figure 1.1). The two cis compounds were submitted to 
the U.S. National Cancer Institute and were screened against L.1210 
leukaemia in mice. Cis-dichlorodiammine platinum (II) , now referred to 
in the pharmaceutical industry as cisplatin or platinol, proved to be 
the most potent of the original compounds and has now been widely 
accepted as a market leader in the field of cancer chemotherapy, 
receiving the approval for clinical use in the U.K. in March 1979.
The discovery of antitumour activity in platinum based compounds 
initiated the quest for metal-based compounds with greater antitumour 
activity and less inherent toxicity than cisplatin. As a result, second 
and third generation platinum complexes which fulfil some of these 
criteria have been synthesised and tested. These complexes are 
discussed in more detail in Section 1.6.
1.3 REACTIONS OF PLATINUM COORDINATION C O M P L E X E S  WITH 
BIOLOGICAL MOLECULES.
1.3.1 PLATINUM CHEMISTRY
Upon consideration of the chemistry of platinum it is seen that both 
platinum (II) and platinum (IV) occur frequently. The platinum (II) 
compounds usually have a square-planar geometry, whereas the 
platinum (IV) compounds are octahedrally coordinated. Contrary to 
many other metal compounds, the platinates exhibit very slow ligand
NH NH,
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(a) cis-dichlorodiammine platinum (II)
(b) cis-tetrachlorodiammine platinum (IV)
■(c)- dichloroethylenediamine platinum (II)
(d) tetrachloroethylene diammine platinum (IV)
Figure 1.1 The chemical structures of the first four platinum 
coordination complexes found to have anticancer 
activity.
exchange reactions. It has been known for some time that certain 
ligand exchange reactions of platinum occur relatively faster than
others. These relative reaction velocities can be predicted from the 
so called "trans labile effect". According to this rule, ligands in 
positions opposite (trans) to a certain ligand in a platinum (II)
complex, are more or less readily exchanged compared to others. This 
has resulted in sequences of reactivity. For instance, ligands trans 
to the following c o m p o u n d s  in the s e q u e n c e  
CN“>phosphine>N02“>Br">Cl">NH3“>H20 are more easily replaced.
In addition to this trans effect rule, one should know that
platinum-ammine ligand bonds are usually very stable whereas 
platinum-H20 bonds and platinum-Cl bonds are rather labile (Van
Kralingen 1979) and that of the commonly occurring ligands in
biological fluids the order of affinity for platinum II is as follows:
sulphur>nitrogen>chloride>water (Basolo and Pearson 1967). These facts 
imply that the ligands present in platinum coordination complexes and 
in any surrounding biological fluid play a large part in determining 
the chemical and biological reactivity of the complex.
1.3.2 CORRELATION BETWEEN STRUCTURE AND ACTIVITY OF PLATINUM 
COMPOUNDS.
Following the discovery of antitumour activity in cisplatin, much work
has been carried out to seek, by variation of the ligands attached to
platinum drugs, ways of maximising the potency and/or minimising the 
toxicity of the metal complex. (Connors et al. 1972, Braddock et al. 
1975, Cleare et al. 1978.). Simple criteria for anticancer activity of 
platinum compounds namely the requirement for a neutral complex with 
adjacent (cis) reactive groups, were established in the early days of 
the analogue studies and have held for all compounds tested to date.
Other structural requirements that have subsequently been shown to 
be required for antitumour activity in complexes of the form 
(ammine)2Pt(II)X2 or (ammine)2Pt(IV)Y2X 2 are that the x ligands should 
be good leaving groups, such as Cl", SO42", oxalate(2"), malonate (2"), 
citrate (2"), ascorbate (2~) and that in the case of platinum (IV) 
compounds the Y ligands are trans to each other; so far only Y=OH 
has resulted in active compounds. The other major requirement is that 
the ammine ligands, or at least one of them, should have a hydrogen 
bond donor function (i.e. should be a primary or secondary ammine.)
1.3.3 HYDROLYSIS REACTIONS OF PLATINUM COMPLEXES 
It is widely believed that platinum complexes such as cisplatin are 
themselves unreactive and require activation prior to eliciting 
biological effects (Horacek and Drobnik 1971, Johnson et al. 1980). In 
the case of cisplatin, activation is thought to occur via loss of the 
labile chloride ligands with formation of the highly reactive aquated 
species (Le Roy et al. 1979). These hydrolysis products are 
approximately one thousand times more reactive than the parent 
compound (Daley-Yates and McBrien 1982a). The kinetics of this 
hydrolysis reaction was reported many years ago by Reishus and 
Martin (1961) and more recently by Cleare et al. (1978). Based upon 
this work it is now generally accepted that the hydrolysis scheme as 
depicted in Figure 1.2 operates inside the cell. This aquation reaction 
is strongly implicated as the rate limiting step in the biological 
reaction of platinum based pharmaceuticals. In the case of cisplatin 
the presence of high chloride ion concentrations (>100mM) as found in 
plasma substantially suppresses the formation of aquation reaction 
products, and hence almost all of the drug will be in the unreactive 
form.
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However, in most cells of the body, the intracellular chloride ion 
*
concentration is much lower than in the extracellular fluid (approx. 
3 m M  - 4mM) and hence aquation products may form in high 
concentrations. These products can then react covalently with various 
intracellular molecules bearing nucleophilic sites.
The identification of platinum (II) as a class b metal (Ahrland et al. 
1958) suggests that biomolecules containing atoms of sulphur, carbon 
and/or nitrogen (i.e. "soft" ligands) will form the most stable 
complexes with platinum (II). Metal binding is kinetically controlled, 
at least initially, and the nucleophilicity of the potential ligand, 
together with its leaving group ability, is an important consideration. 
The degree of structural accessibility of a potential ligand and its 
relative concentration are also important factors. Platinum 
coordination complexes are therefore able to react with numerous 
intracellular targets with the formation of the various adducts 
depending upon the kinetics of the different reactions (Segal et al. 
1985).
1.3.4 PLATINUM II AMINO ACID BINDING
The binding of platinum (II) to amino acids generally, and to sulphur 
containing units in particular, was reviewed in 1972 by McAuliffe et al. 
Selected amino acids containing potential donors for platinum (II) on 
their side chains and corresponding affinities for the metal at neutral 
pH are summarised in Table 1.1. The sulphur containing species 
cysteine and methionine have the highest affinity for platinum (II) 
(Howe-Grant and Lippard 1980). The binding of platinum (II) to 
methionine occurs through the sulphur atom and chelate ring 
formation, through both terminal groups (Melius and Friedman 1978).
TABLE 1.1
Amino acids containing donor atoms for platinum (II)a
AMINO ACID pKa
RESIDUE SERVING AS 
BINDING SITE
AFFINITY FOR 
Pt (II)
Cysteine 8.30 Sulphur atom Very high
Methionine Sulphur atom Very high
Histidine 6.00 Imidazole nitrogen High
Arginine 12.48 Amine Moderate
Lysine 10.53 Amine Moderate-low
Tryptophan Cyclic nitrogen atom Moderate-low
Aspartic acid 3.86 Carboxylate Low
Glutamic acid 4.25 Carboxylate Low
Asparagine Amide Low
Glutamine Amide Low
Tyrosine 10.07 Phenolate Low
Serine Alcohol Very low
Threonine Alcohol Very low
a Amino acids are listed in approximate order of affinity for 
platinum (II) at neutral pH.
From Howe-Grant and Lippard (1980)
The reaction of any platinum (II) complex containing a labile ligand 
with the methionine sulphur is rapid with the trans-labilising effect of 
the bound sulphur atom often aiding the addition of a second 
methionine. Whereas in many cases the substitution of platinum (II) 
with sulphur containing ligands leads to the formation of more stable, 
less reactive complexes, it has been shown that the formation of 
certain complexes between cisplatin and methionine can lead to 
increased reactivity of the platinum complex towards enzymes in vitro 
(Daley-Yates and McBrien 1982a). As with methionine, cysteine also 
coordinates to platinum (II) complexes through the sulphur atom, 
which in this case loses a proton upon binding. Histidine contains a 
pyridine-type imidazole nitrogen atom and this too has a high 
nucleophilicity for platinum (II). Coordination is reported to be 
through the imidazole and a-amino nitrogen atoms. Arginine, although 
positively charged, is similar to imidazole, having one tertiary nitrogen 
atom that would have a reasonably high affinity for platinum (II). The 
primary amine, lysine is also positively charged at neutral pH and will 
bind to the metal with loss of a hydrogen ion. The cyclic nitrogen 
atom of tryptophan is nonaromatic, but binding to platinum is 
enhanced by the loss of the proton. The remaining potential donors 
consist of carboxylates, amides, and alcohols all of which have low or 
very low affinities for platinum (II) and are good leaving groups.
Amino acids with no potential donor atoms in their side chains e.g. 
glycine and alanine, bind platinum (II) through their terminal amino 
and carboxyl groups. At neutral pH, stable five membered chelate 
rings form, whereas under acidic or basic conditions the amino acid is 
monodentate.
Under acidic conditions, the proton competes successfully with the 
metal for the carboxyl group and under basic conditions and 
sufficiently high amino acid concentrations the greater affinity of the 
amine group becomes evident.
Information about other amino acids is scarce. Platinum (II) has been 
shown to bind to lysine and aspartate but no evidence for binding to 
such amino acids as tyrosine, serine or threonine has been reported.
1.3.5 PLATINUM II POLYPEPTIDE AND PROTEIN BINDING 
Every protein or polypeptide chain has at least as many potential 
metal binding sites as there are peptide linkages. The carboxylate and 
amino ends of the protein or peptide chains are also potential ligands 
for platinum binding* Carboxylates have fairly low nucleophilic 
reactivity constants and are reasonably good leaving groups. 
Conversely, the affinity of amines for platinum (II) is high and these 
ligands are known to be poor leaving groups, unless trans-labilised. 
The N-terminus is thus a better ligand for divalent platinum than the 
C-terminus. The amide nitrogens and carbonyl oxygen atoms of the 
peptide linkages of a protein are present in high concentrations and 
although they have a low affinity for platinum (II) at least some of 
these groups are accessible for platinum binding, regardless of the 
proteins tertiary structure. Binding to peptide nitrogen and
oxygen atoms, especially if deprotonated, should therefore be 
considered a possibility, but by far the most common sites of platinum 
binding in a protein are to side chains of its constituent amino acids, 
especially those containing sulphur or nitrogen ligands. Due to the 
strict geometry of platinum coordination complexes, the composition 
and tertiary structure of a protein or polypeptide dictates the number 
of available binding sites. These have been determined for a number
of proteins by x-ray crystallography and were reported by 
Howe-Grant et al. (1980). It is obvious that this platinum-protein 
binding could potentially have a dramatic effect on the structure and 
function of essential proteins. In recent years much work has 
therefore been undertaken to study the nature and effect of platinum 
binding to enzymes, plasma proteins and metal binding proteins such 
as metallothionein.
Several enzymes have been shown to be inhibited by platinum 
compounds, although in only one case has the reacting group, 
responsible for the inhibition of an enzyme, been identified; this is 
thymidylate synthase, where the platinum compound apparently reacted 
with sulphydryl groups (Aull et al. 1977). Friedman et al. (1974) 
demonstrated in vitro that platinum complexes inhibited malate 
dehydrogenase, lactate dehydrogenase and alcohol dehydrogenase. All 
of these enzymes also have catalytically important sulphydryl groups 
(Banaszak et al. 1975, Holbrook et al. 1975, Branden et al. 1975). It is 
therefore not surprising that it has been speculated that enzyme 
inhibition by platinum compounds is primarily due to reaction with 
essential sulphydryl groups. Glyceraldehyde-3-phosphate 
dehydrogenase, aldolase and glucose-6-phosphate dehydrogenase all 
containing essential sulphydryl groups are inhibited by platinum 
compounds, whereas enzymes not known to contain essential 
sulphydryl groups, catalase, peroxidase and tyrosinase were not 
inhibited. The only exception to the rule is leucine aminopeptidase, 
which is not known to contain essential sulphydryl groups but was 
inhibited by platinum complexes (Guthrie et al. 1971). A notable 
problem with these interpretations is that enzyme activity was shown 
to be inhibited only after prolonged in vitro exposure to relatively 
high platinum complex concentrations.
Both glutathione and metallothionein have been implicated in platinum 
tissue binding and perhaps toxicity of cisplatin. Glutathione levels and 
activity of glutathione-dependant transferases have been shown to be 
affected by cisplatin (Litterst et al. 1982) and several authors have
studied the changes in sulphydryl content after cisplatin treatment
(Borch et al. 1979, Levi et al. 1980, Leyland-Jones et al. 1983). The 
general conclusion is that cisplatin can alter the sulphydryl content of
tissues but not by a direct interaction with the free sulphydryl
group. Depletion of glutathione (GSH) by administration of 
diethylmaleate (DEM) results in a dramatic increase in cisplatin toxicity 
when administered at a time of GSH depletion (Litterst et al. 1986). It 
is believed that this increase in toxicity associated with DEM treated 
rats is due to the removal of reactive sites (i.e. GSH) allowing more 
free platinum to interact with tissue binding sites. It appears 
therefore that the role of non-protein thiols in platinate toxicity is of 
great importance.
Several papers (Sharma et al. 1983, Zelazowski et al. 1984. Litterst et 
al. 1986) have reported that platinum is largely associated with a 
metallothionein-like protein in kidney cytosols after pretreatment of 
rats with cisplatin. When Cadmium Chloride (CdCte), known to induce 
the synthesis of metallothionein, was administered prior to cisplatin 
treatment, a striking increase in the binding of platinum to the low 
molecular weight binding protein occurred (Figure 1.3). This increased 
binding, however, did not correlate with a dramatic decrease in the 
toxicity of cisplatin, except at very high doses. Metallothionein was 
first implicated in platinum complex toxicity by Bakka et al. (1981) who 
showed a correlation between cytotoxicity of cisplatin and 
metallothionein levels in cell cultures.
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Figure 1.3 G-75 sephadex elution profiles of rat kidney cytosol 8 hours
195mafter an iv injection of Pt labelled cisplatin (3mg/kg).
1 95mProfiles show increase in binding of Pt after CdCI^ 
pretreatment to a protein which elutes at a volume which 
corresponds to metallothionein [from Litterst et al, 1984].
Subsequently, this group demonstrated the same finding in tumours in
vivo (Endresen et al. 1984). Naganuma et al. (1985) showed a
protective effect of pretreatment with inducers of metallothionein but 
that protection did not appear to correlate with tissue levels of the 
protein. This appears to support the findings of Litterst et al (1986) 
where pretreatment with metallothionein inducers failed to result in 
significant changes in subcellular platinum distribution. The general 
consensus, with one exception, (Mason et al. 1984) is that the metal 
binding protein associated with platinum is metallothionein. Positive 
evidence of this was presented by Zelazowski et al. (1984) using an 
antibody raised to the protein. Whilst there appears to be positive 
evidence for the association of platinum with metallothionein, it 
appears that cisplatin is unable to induce its biosynthesis and 
therefore the role of the protein in platinate toxicity is still unclear. 
The nature of platinum reactions in serum is another important protein 
binding problem that is receiving much attention. Platinum complexes 
differ from most drugs in that they can react irreversibly with 
biological components, particularly to proteins in plasma and plasma 
fractions (Repta et al. 1980). The non-protein bound platinum fraction 
appears to be the biologically active one (Cole et al. 1981, Takahashi 
et al. 1985) and therefore the irreversibility of the protein bound form 
has significant consequences to any proposed dosage regime. Cisplatin 
has been found to be bound mainly to albumin in plasma (Manaka et 
al. 1978) although binding to gamma globulins (Gullo et al. 1980) and 
transferrin (Sykes et al. 1985) has been demonstrated. The amount of 
platinum in red blood cells is only a few percent of the total amount 
in blood but a large proportion of this platinum is present in the 
cytosol associated with haemoglobin (Litterst 1984). Since protein 
bound platinum complexes are not biologically active, the nature and
reversibility of the platinum-protein bond is essential to the
anticancer activity of the drugs. Siddik et al. (1984a ^ followed the
plasma binding of two platinum complexes, cisplatin and carboplatin 
(Figure 1.7), to rat plasma in vivo. Cisplatin exists entirely in the 
’’free" form for the first five to ten minutes whilst thereafter, plasma 
binding increased rapidly; so that by sixty minutes free platinum was 
not detectable. Carboplatin, on the other hand, becomes reversibly 
bound to plasma proteins to the extent of about twenty percent 
immediately after its administration. This binding remained constant 
during the first sixty minutes, but the "free" platinum gradually 
decreased thereafter due to irreversible binding to plasma proteins. 
There is some debate as to whether once protein bound, platinum 
complexes can act as reservoirs or stores for the free drug. Studies 
by Repta et al. (1980) and Cole et al. (1980) indicate that cisplatin 
protein binding is totally irreversible and that any decrease in 
platinum levels in plasma is due to normal protein turnover rather 
than any sort of reversibility of the reactions of the complexes with 
endogenous nucleophiles. On the other hand, Daley-Yates (1986) has 
shown by equilibrium dialysis that cisplatin is capable of 35% 
reversible binding, whereas carboplatin is 75% reversibly bound. One 
interpretation of this result is that carboplatin is able to form weak 
(reversible) complexes with macromolecules whereas cisplatin is more 
or less coordinately bound, although there is a degree of reversibility 
which would allow some protein bound cisplatin to act as a store for 
free cisplatin.
Since ultrafilterable (free) platinum concentrations may influence the 
pharmacokinetics of platinum based pharmaceuticals, in particular their 
plasma clearance and volume of distribution, which in turn influences 
the therapeutic activity and toxicology of the drugs; studies on
protein binding are of immense importance in the development of more 
efficacious compounds.
1.3.6 PLATINUM II NUCLEIC ACID BINDING: POSSIBLE MECHANISMS OF 
ANTITUMOUR ACTION
Much evidence is now available which suggests the cytotoxicity of 
platinum compounds is due to their reactions with DNA or chromatin. 
This evidence is based largely on studies of the interaction of 
platinum compounds with DNA in vitro or the DNA of cultured 
mammalian cells and on studies of the biochemical responses of both 
prokaryotic and eukaryotic cells to modifications of their DNA by 
platinum compounds. Probably the first observation of an effect of, a 
platinum coordination complex on a biological system that implicated 
DNA as a target macromolecule in the cytotoxicity of cells was the 
induction of filamentous growth in bacteria observed by Rosenberg et 
al. (1965). Filamentous growth is almost certainly indicative of the 
ability of an agent to react with DNA, leading to a selective inhibition 
of DNA synthesis, with no accompanying effect on other biosynthetic 
pathways such as those of RNA or protein.
Further important evidence for a selective inhibition of DNA synthesis 
has been demonstrated both in vivo (Howie et al. 1970) and in vitro 
(Pascoe et al. 1974). By measuring the incorporation of 
[3H]-thymidine, [3H]-uridine, and [14c]-leucine into tumour cells 
treated with cisplatin, the rates of DNA, RNA and protein synthesis 
were determined. These studies indicated an initial suppression of the 
rates of synthesis of DNA, RNA and protein but persistent suppression 
only of DNA synthesis. Furthermore, when cell survival time was 
related to the amount of cisplatin bound to the macromolecules, it 
became apparent that there was far more reaction with DNA than with
RNA or protein, and it could be deduced that the levels of reaction 
with RNA or protein would be too low to produce their inactivation 
within the cell. It has been possible for some years to determine the 
actual amount of platinum bound to DNA at measured levels of cell 
survival in a number of cell lines and it appears that the maximum 
amount of platinum bound to the DNA is approximately 6-10nmoles/g 
DNA (Courtenay et al. 1982, Pera et al. 1982). This compares well with 
the level of binding to DNA of cells isolated from patients receiving 
cisplatin chemotherapy (Roberts et al. 1986). If, as this evidence 
suggests, the lesion responsible for cytotoxicity is the binding of 
cisplatin to DNA it is necessary to know more about the nature of this 
association.
DNA is a polynucleotide of monomer units consisting of a 
phosphodiester, a pentose ring, and an organic base. Each portion of 
this nucleotide contains a potential binding site for platinum (II). 
Apart from the ring oxygen on the sugar, the 3- and 5 -  oxygen atoms 
of the phosphodiester linkage are also potential ligands. However, the 
organic bases of the nucleotides offer the best potential donor atoms 
for platinum (II) coordination. DNA is composed of purine bases, 
adenine and guanine, and pyrimidine bases, thymine and cytosine. All 
of these bases have heterocyclic nitrogen atoms that have been found 
preferentially to coordinate transition metal ions (Gellert et al. 1979). 
However, binding at thymine can only occur after deprotonation at N3, 
which does not occur under physiological conditions. To understand 
the process of platinum coordination complex binding to DNA, 
investigations were started into the binding preferences of the four 
nucleotides. It was soon apparent that adenine could bind platinum 
(II) through the N7 atom and through the N1 atom (Figure 1.4a), 
whereas cytosine could coordinate through the N3 atom (Figure 1.4c).
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In guanine, binding was possible at N7 and at deprotonated N1 under 
alkaline conditions (Figure 1.4b). Of all these binding modes, those at 
N7 atoms of adenine and guanine seem most likely in DNA, since the 
other sites are involved in the so called Watson-Crick base pairing of 
the double helix, and are less accessible for the binding of platinum 
(Gellert et al. 1979). There is now much consensus that the initial 
binding of cisplatin, and probably platinum complexes in general, to 
DNA occurs via the N7 nitrogen atom of guanine. However, platinum 
(II) coordination complexes usually have two reactive sites, in cisplatin 
and carboplatin the NH 3 ligands are not reactive enough under 
physiological conditions, and hence after binding to one guanine N7 a 
second reaction should occur. The site where the second binding 
occurs cannot be predicted with certainty and studies concerning this 
reaction have yielded conflicting results.
A number of secondary binding modes could theoretically be possible 
and these include:
1. Stabilization of the monofunctional binding through
hydrogen bonding of the ammine ligands and/or H 2O or Cl (Figure 
1.5a).
2. Chelation to an 06 group of the same guanine.
3. Chelation to a base in the opposite strand of double
helical DNA, which may be a guanine or another base. ( ie.interstrand 
cross linking) (Figure 1.5b).
4. Chelation to a (next) neighbouring guanine N7 in the same DNA 
strand.( ie.intrastrand cross-linking) (Figure 1.5c).
5. Chelation to another guanine on the same DNA strand (not next 
neighbour).
6. Chelation to another base next to guanine in the same strand; 
likely candidates are adenine (N7 or Nl) and cytosine (N3).
FIGURE 1.5
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7. DNA-protein crosslink (Figure 1.5d).
Studies with purified DNA have provided evidence for bifunctional 
binding of cisplatin to the same base (Macquet and Butour 1978), the 
formation of intrastrand crosslinks between guanines (Kelman and 
Buchbinder 1978) and the formation of interstrand crosslinks (Drobnik 
and Horacek 1973). The formation of DNA-protein crosslinks has been 
noted after the treatment of mammalian cells with cisplatin (Pascoe and 
Roberts 1974), however the DNA intrastrand crosslink is the 
predominant DNA adduct formed whereas the interstrand crosslink has 
been shown to account for less than one percent of the platinate sites 
on DNA (Eastman 1983). Fichtinger-Schepman et al. (1985) have shown 
by immunochemical techniques that this predominant intrastrand 
crosslink is a chelate between two neighbouring guanines, although 
smaller amounts of intrastrand crosslinking between adenine and 
guanine, interstrand crosslinks between two guanines and 
monofunctional ad ducts occur.
A difference between sensitive and resistant cells in their capacity to 
remove either total or specific platinate damage to DNA would be the 
most compelling evidence for the importance of lesions in DNA in 
inducing toxicity. The decreased ability of a repair deficient mutant 
Chinese hamster ovary cell,sensitive to cisplatin, to remove DNA 
interstrand crosslinks (Meyn et al. 1982) would appear to support the 
argument indicating the importance of interstrand crosslinks in the 
cytotoxic action of cisplatin. On the other hand, both sensitive and 
resistant Walker cells treated with cisplatin excised total DNA adducts, 
DNA-protein crosslinks and DNA interstrand crosslinks with equal 
efficiency (Roberts et al. 1984). Thus at the present time the DNA 
adduct responsible for cytotoxicity is unknown.
It is important here to distinguish between two not necessarily related 
phenomena: cytotoxicity and anticancer activity. The former is
nonselective, while the latter is very selective. For example, both cis 
and trans dichlorodiammine platinum (II) are cytotoxic at appropriate 
dose levels, but the former is an anticancer agent and the latter is 
not. In fact all anticancer active platinum (II) complexes are 
invariably in the cis configuration. Rosenberg (1985) thus suggested 
that to illustrate the platinum-DNA adduct responsible for anticancer 
activity, one must look for differences between cis and trans platinum 
(II) reactions with DNA. A  number of differences have been identified. 
Pascoe (1974) and associates found one such significant difference. For 
equitoxic doses in tissue culture, more trans molecules are bound to 
DNA than are cis. Zwelling and Kohn (1979) later showed that this was 
due to an excess of DNA-protein crosslinks caused by the trans 
isomer, and that when these were removed by proteinase treatment, 
both the cis and trans isomers at equitoxic doses caused the same 
number of interstrand crosslinks on DNA. This was suggested to be 
proof that DNA interstrand crosslinks were responsible for cellular 
toxicity, but not for anticancer activity.
Johnson et al. (1986) have shown that E.coli treated with cis-DDP 
undergo 100 times more excision repair than when treated with the 
trans isomer. This surprising result could be due to the trans 
labilising effect of protein binding on to the platinum-DNA adduct that 
occurs with trans-DDP which allows the adduct to be removed without 
the need for excision repair. As well as these two examples of 
differences between the reaction of DNA with trans and cis platin, 
there are a number of hypotheses that involve chelate formation 
within the bases of DNA.
The stereoselectivity of anticancer activity argues for a rigid 
identifying structure to adequately distinguish the two isomers. Since 
DNA itself is a relatively plastic structure it is thought that the
stereoselectivity could be due to a cisplatin-base reaction. A number 
of workers (Dehand et al. 1976, Goodgame et al. 1975, Macquet et al. 
1976) have suggested that the adduct responsible for anticancer 
activity of cisplatin is the closed ring chelate of N7 and 06 of guanine 
(Figure 1.4b) since only the cis isomer can form this: the trans
cannot. Rosenberg (1977) proposed that this adduct would lead to a 
base substitution mutation GC— AT and if "normal" cells could repair 
the 06 adduct on guanine before replication but the cancer cell could 
not, the burden of mutations in the cancer cell would increase beyond 
the limits of survivability so explaining the selectivity in the cytotoxic 
activity of cisplatin towards tumour cells. This type of
stereoselectivity of platinum DNA adduct formation was also envoked 
by Lippard et al. (1987) to explain the anticancer activity of the cis 
isomer. In this case they suggested that whilst cis isomer is able to 
coordinate to N7 atoms of two adjacent guanosine nucleosides forming 
a 17 membraned ring, the trans isomer cannot. Thus whilst cisplatin 
forms a 1,2 intrastrand crosslink, the trans isomer is more likely to 
form a 1,3 intrastrand crosslink between the adjacent guanines. This 
difference in crosslinking of the two isomers could be enough to
result in anticancer activity of the cis but not the trans isomer.
A novel hypothesis for the mechanism of selective destruction of 
cancer cells by platinum anticancer drugs which does not involve 
specific base pairing configurations has been proposed by Rosenberg
(1983). This argument suggests that treatment of cancer cells with 
cisplatin increases the antigenicity of the cells which then triggers an 
increased immune reaction by the host against them.
Evidence for this mechanism emerged from studies on the staining of 
cells with electron-dense " platinum-pyrimidine blues" for electron 
microscopy. These complexes are ionic, positively charged polymers 
that react selectively with nucleic acids. The cells exhibited electron 
density in the nuclear chromatin (DNA), the nucleolus > (RNA) and the 
cytoplasmic ribosomes (RNA). Additional sites of staining occurred in 
tumour cells on the cell surface. These stainable surface sites were 
removed by gentle treatment with DNase, which infers the existence of 
cell surface associated DNA in cancerous but not normal cells. 
Rosenberg (1975) speculated that the low immunogenicity of nucleic 
acids may, by the trivial mechanism of masking antigens, serve to 
decrease the antigenicity of tumour cells. Juckett and Rosenberg 
(1982) demonstrated that when tumour cells are treated in vivo with 
cisplatin they lose their cell surface associated nucleic acids and 
antigenicity is enhanced. Other evidence more relevant to 
immunosuppression by cell surface associated nucleic acids has been 
reported by Russell and Golub (1978). Lymphocytes from strain AKR 
mice with spontaneous leukaemia can suppress the immune reaction of 
normal AKR anti-sheep erythrocyte antibody response. The same cells 
from non-leukaemic mice do not suppress this reaction. If the cells 
from the leukaemic mice are gently treated with DNase, they no longer 
suppress. Treatment of leukaemic animals with cisplatin also abrogates 
the suppressor activity of these cells. Thus, a direct link in at least 
one tumour system is established between cell surface nucleic acids 
and immunosuppression that is consistent with Rosenberg’s 
speculation.
It is clear that although much work has been undertaken to determine 
the mechanism of anticancer activity of platinum coordination 
complexes, the precise adduct or adducts responsible for selective
action against tumour cells have not been unequivocally identified.
1.4 THE PHARMACOKINETICS OF CISPLATIN
1.4.1 EXCRETION RATES
The beginning of a study of the pharmacologic distribution of a drug 
requires some knowledge of the excretion rates. These have been most 
conveniently followed by the use of the radio isotope 195®Pt. 
Hoeschele and Van Camp (1972) first reported the removal of 195“Pt 
labelled cisplatin after i.p injection into mice that were either 
tumoured or non-tumoured. Their results, showing also the elimination 
of the trans isomer (Figure 1.6) indicate that the urinary excretion of 
these drugs follows a biphasic pattern. The initial rapid phase (a) of 
cisplatin elimination has a half-life of T* = 1.5hr; while the second slow 
phase (6) has a half-life of T* = 20hr. More detailed studies by Wolf 
and Manaka (1977) and later by Litterst et al. (1976) which suggest 
even more rapid excretion are summarised and listed for some 
different animals in Table 1.2. Platinum is rapidly cleared from the 
blood after initial injection,with more than ninety percent of the 
radioactive platinum in the poor distribution phase being protein 
bound (DeConti et al. 1973). This clearance is largely due to excretion 
in urine, although urinary excretion in rats only represents 
forty-seven percent of the administered dose over the first four 
hours (Siddik et al. 1984). Calculations of fractional renal clearance 
rates (ratio of platinum clearance to inulin clearance) indicate that 
this urinary excretion of cisplatin exceeds the glomerular filtration 
rate and hence an active renal secretory mechanism may occur (Siddik 
et al. 1984, Caterson et al. 1983, Osman and Litterst 1983, Daley-Yates 
and McBrien 1982b.).
FIGURE 1.6
Rate of loss of a pulse-injected dose of cisplatin and its trans 
isomer, both containing radioactive 195"Pt in mice. Measured with 
a small animal, whole body scintillation counter. There is an early 
rapid loss phase, followed by a slower second phase.
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TABLE 1.2
Half-lives for elimination of cisplatin in various 
animals
SPECIES a
T£
P TECHNIQUE
Mouse 1.5 hr 20.0 hr Whole-body scintillation 
counting
Rat 5.9 min 15.6 hr Dynamic blood loop
Rat 8.6 min 44.9 days Serial sacrifice
Rat 16.1 min 6.6 days Tumoured; serial sacrifice
Rat 9.7 min 35.7 hr Control group; serial 
sacrifice
Rat 12.0 min 22.9 hr Hydrated group; serial 
sacrifice
Dog 22.0 min 5.0 days Cannulated
Rat 43.0 min 2.0 days Serial sacrifice
Shark 71.0 min 17.5 days Serial sacrifice
From Rosenberg (1985)
Little or no excretion of cisplatin appears to occur via the faeces 
(Rosenberg 1985) and biliary excretion represents only 0.4% - 1.2% of 
the dose (Siddik et al. 1984a,DeSimone et al. 1979, Van Der Vijgh et al.
1985). There is therefore a large discrepancy between the plasma 
(total) clearance of cisplatin and its combined renal, faecal and biliary 
clearances. This suggests significant retention of cisplatin which 
would involve the rapid and extensive binding of the chemically 
unstable cisplatin to tissues.
1.4.2 ORGAN DISTRIBUTION
The distribution of cisplatin after both i.p and i.v administration 
shows that the highest concentrations can be found in the kidneys, 
followed by the liver, adrenals, lungs and skin (Litterst et al. 1977, 
Wolf and Manaka 1977, Lange et al. 1972, Litterst et al. 1976.).Table 1.3 
taken from the data of Wolf and Manaka (1977) lists the percentage of 
the injected cisplatin, containing the radioisotope 195mPt, per gram of 
wet tissue for a variety of organs of the rat. Three hours after 
injection, one can see that the organ whose impaired function is 
dose-limiting after cisplatin treatment, i.e. the kidney, contains the 
highest concentration of 195®Pt whilst the tumour exhibited no 
particularly significant uptake compared to normal tissues. A most 
informative study of the organ distribution of cisplatin after i.v 
administration of i95mpt labelled cisplatin to mice and subsequent 
whole body autoradiography was carried out by Benard et al. (1983). 
This technique showed that the kidney exhibited very high uptake of 
i95®Pt equivalents as early as five minutes after dosing and that 
there was an intense incorporation of radioactivity in urine in both 
the ureter and the bladder. A high intestinal content of i95»pt at 
four to seven hours which rapidly fell to zero by sixteen hours was
TABLE 1.3
Organ distribution of Cisplatin in 
Walker-256-Carcinosarcoma-Bearing rats 
(3 hours after Pulse Injection)
Organ % of injected dose 
per gram of tissue
Blood 0.378
Skin 0.495
Thyroid 0.119
Liver 0.755
Spleen 0.334
Pancreas 0.306
Stomach 0.110
Small Intestine 0.411
Large Intestine 0.351
Kidneys 1.747
Adrenals 0.614
Heart 0.166
Lung 0.569
Brain 0.035
Muscle 0.002
Tumour 0.226
Bone 0.584
Marrow 0.234
Bladder 0.520
Tendon 0.675
From Rosenberg (1985)
thought to be related to biliary excretion of cisplatin. Uptake of 
radioactive material was also noted in the liver, bone marrow, skin, 
hair and teeth. Contrary to the results of Wolf and Manaka (1977), 
animals implanted with Sarcoma 180 appeared to concentrate ^ “Pt in 
the tumour. This uptake was measured and found to be between 0.5% 
and 1.5% of the delivered dose (Benard et al. 1981). Litterst et al.
(1984) noted that pretreatment of animals with lOmg/kg cisplatin prior
to i.v administration of 195“Pt labelled cisplatin resulted in greater 
concentrations of ^ “Pt in tissues of the pretreated animals when 
compared to control levels. It was concluded that pretreatment with 
cisplatin damages the kidney severely enough for subsequent doses of 
cisplatin not to be excreted as efficiently, thus leading to a greater 
tissue deposition.
Tissue distribution of 195“Pt labelled cisplatin has also been studied 
in humans (Smith et al. 1974) where the patterns found were similar to
those found in the animal model with high uptake of radioactive
platinum found in the kidneys, liver and intestine. Brain scans and 
brain tissue samples suggested poor penetration of the drug into the 
central nervous system (Hill et al. 1975).
1.5 CISPLATIN TOXICITY
Since cisplatin is able to bind to a variety of essential macromolecules 
once inside a cell (Section 1.3), and is accumulated and retained in 
particular tissues, it is not surprising that this compound is also 
toxic. The toxic side effects of cisplatin are exhibited predominantly 
in the kidneys, gastrointestinal tract, bone marrow, ear, and possibly 
the peripheral nervous and immune systems. The results of a number 
of toxicological studies were reviewed by Guarino et al. (1979) and are 
described in Table 1.4.
TABLE 1.4
Major clinical toxicities of cisplatin in various 
animal species
TYPE OF TOXICITY
SPECIES
MOUSE RAT DOG MONKEY
GASTROINTESTINAL
Emesis + +
Anorexia + + + +
RENAL
BUN increase + + ■ + +
Creatinine increase ND» + + -
Polyurea ND + + +
Tubular necrosis + + + +
HEMATOLOGIC 
WBC decrease ND + + +
Platelet decrease ND + + +
Bone marrow 
hypocellularity + + + +
OTOLOGIC ND + ND +
aND = not determined. 
From Rosenberg (1985)
1.5.1 NEPHROTOXICITY
Nephrotoxicity is the principal dose-limiting toxicity of cisplatin. The 
prominent feature of cisplatin nephrotoxicity is acute tubular necrosis 
which is clinically manifested by elevations in BUN, serum creatinine, 
proteinuria and hyperuricemia (Madias et al. 1978). Other clinical 
indices of renal functional impairment include decreased creatinine 
clearance (Jones et al. 1980), elevated urinary 
N-acetyl-0-glucosaminidase, leucine aminopeptidase and 0- glucuronidase 
(Diener et al. 1981) and increased urinary excretion of 02-microglobulin 
(Jones et al. 1980). Light microscopic studies of human kidneys have 
revealed focal acute tubular necrosis affecting primarily the distal
tubule and collecting ducts (Gonzalez-Vitale et al. 1977). However,
laboratory animal data indicate that cisplatin nephrotoxicity primarily 
involves widespread tubular necrosis of the corticomedullary region, 
predominantly in the S3 or straight portion of the proximal tubule 
(Safirstein et al. 1981), a region that has been shown to selectively 
accumulate platinum.
Because the gross characteristics of cisplatin nephrotoxicity are 
similar to those of other heavy metals (e.g. mercury) it has been 
assumed that the nephrotoxicity of cisplatin is related to the toxicity 
of the platinum atom (Choie et al. 1981b). Heavy metals and cisplatin 
nephrotoxicity have a number of characteristics in common, such as 
acute tubular necrosis affecting the pars recta, increased size and 
number of renal lysosomes (Aggarwal et al. 1980) and depletion of 
protein bound SH groups (Desimone et al. 1979),
However, several lines of evidence suggest that the nephrotoxicity of 
cisplatin is quite distinct. These include:
(a) Time Course and Development
The earliest detectable changes in the kidney appear several days
following cisplatin treatment (Goldstein et al. 1981) and tubular
regeneration is not complete even fourteen days after treatment. In 
contrast, renal function following administration of even a small dose 
of a heavy metal such as mercuric chloride is compromised within 
twenty-four hours and tubular regeneration complete within fourteen 
days.
(b) Stereospecificity of Cisplatin
Although administration of cis-dichlorodiamminoplatinum (II) and its 
trans isomer result in similar renal concentrations of platinum 
(Hoeschele et al. 1972), the trans isomer does not produce renal 
toxicity (Van Den Berg et al. 1981), indicating that the geometry of 
these complexes, rather than the presence of the platinum atom, plays 
a crucial role in the development of nephrotoxicity.
(c) Structure-activity Relationships
Modification of the ligands of the dichlorodiamminoplatinum complex 
significantly alters the incidence and severity of nephrotoxicity. This 
suggests that kidney toxicity is not only related to the platinum atom. 
Although this evidence suggests that cisplatin does not behave like a 
classic heavy metal nephrotoxin, its mechanism of nephrotoxicity has 
yet to be elucidated. Whether it is due to a DNA adduct, and DNA 
synthesis has been shown to be inhibited after cisplatin treatment in 
kidneys (Braunschweiger et al. 1982), or interaction with an essential 
enzyme such as Na+/K+ ATPase (Daley-Yates and McBrien 1982c) is 
unclear and much work has yet to be undertaken on this subject.
1.5.2 GASTROINTESTINAL TOXICITY
While many anticancer drugs cause some degree of nausea and 
vomiting in the patient, cisplatin is considered to be one of the most 
emetogenic agents administered to man (Vermorken et al. 1982a). 
Indeed, this toxicity can be sufficiently severe to cause refusal by the 
patient to further courses of therapy. Toxicology studies of cisplatin 
in mice, rats, dogs and monkeys revealed effects similar to those 
reported for radiomimetic compounds, causing a profound reduction in 
crypt cell production rate leading to villus stunting and diminished 
function (Allan et al. 1986, Choie et al. 1981a). Acute toxicity in dogs 
consisted of emesis, anorexia, dehydration, weight loss and diarrhoea
(Vermorken et al. 1982b) and severe morbidity resulted from the
consequences of haemorrhagic enterocolitis. Both central mechanisms 
(Borison et al. 1983) and peripheral mechanisms (Akwari 1983) are 
thought to be involved in the acute emesis associated with cisplatin 
and antagonism of emesis by metoclopraraide in the dog and ferret 
suggests a dopaminergic component (Florczyk et al. 1982).
1.5.3 HAEMATOLOGICAL TOXICITY
Whilst cisplatin has been shown to be myelosuppressive with severe 
bone marrow hypoplasia occurring in dogs, monkeys and mice 
(Prestayko 1981, Zac et al. 1972), this is generally not considered to 
be dose-limiting and it is much less severe than for most other 
anticancer drugs. In humans, myelosuppression occurs in 20%-30% of 
patients (Stark et al. 1978) and reports of cisplatin induced anaemia 
have also been made (Getaz et al. 1980). An acute toxicology study of 
the effects of cisplatin in male rats (Kociba et al. 1971) revealed that 
haematological changes were maximum three days after i.p injection of 
12.2mg/kg with leucocytopenia, reticulocytopenia and platelet
depression being the main side effects. With the advent of regimes 
that reduce cisplatin nephrotoxicity such as hydration (Stark et al. 
1978), mannitol (Pera et al. 1978) and furosemide (Lehane et al. 1979) 
diuretics, and chelation with diethyldiothocarbamate (DDTC) (Dedon et 
al. 1986) it is possible to increase the dose of cisplatin and it is in 
these high dose treatments that myelosuppression is likely to become 
dose-limiting.
1.5.4 OTHER CISPLATIN INDUCED TOXICITIES
Although the liver is second only to the kidney in its capacity to take 
up cisplatin, reports of cisplatin induced hepatotoxicity are rare. 
These are usually detected as transient increases in transaminase 
levels (PoHera et al. 1987, Masaru et al. 1985) and in only one case 
(Cavalli et al. 1978) has the hepatic damage been sufficiently severe to 
cause discontinuation of treatment. Ototoxicity, manifested as tinnitus 
and hearing loss in the high-frequency range (4000-8000Hz) occurs in 
11% of patients treated with cisplatin (Talley et al. 1973). This 
unusual form of toxicity has also been demonstrated in animals treated 
with the drug and is believed to be due to the destruction of hair 
cells in the organ of corti (Fleischman et al. 1975).
Cases of anaphylactic-like reactions possibly secondary to cisplatin 
treatment have been reported (Rozencweig et al. 1977). The reactions 
consisted of facial edema, wheezing and hypotension that could be 
controlled with intravenous adrenaline or antihistamines.
A more sinister and problematical cisplatin induced toxicity is 
neurotoxicity. Like myelosuppression, this has become more of a 
problem with the use of high dose cisplatin in the clinic.
Neurotoxicity is characterised by peripheral neuropathies, including 
paresthesia in both upper and lower extremities, leg weakness, tremor 
or even seizure (Von Hoff et al. 1979).
1.6 SECOND GENERATION PLATINUM BASED PHARMACEUTICALS 
Although cisplatin is a weU established drug in cancer chemotherapy 
and is widely used, its inherent toxicity has led to a quest for second 
generation analogues which exhibit comparable activity but reduced 
toxicity. Structure activity studies in the late 1970*8 (Section 1.3.2) 
provided the ground rules in the design of active platinum complexes 
and since then screening of cisplatin analogues has focused on an 
assessment of relative toxicity and pharmacology rather than 
antitumour activity alone. From thousands of complexes tested, a very 
limited number of clinically viable analogues have been identified. 
These include carboplatin (JM8), Iproplatin (JM9) and spiroplatin 
(TN0--6).
1.6.1 CARBOPLATIN (JM8)
Carboplatin (Figure 1.7) is a cisplatin analogue selected for clinical 
study on the basis of reduced nephrotoxicity in rats and increased 
antitumour activity against several test systems (Harrap et al. 1980, 
Wilkinson et al. 1978).
A preclinical toxicologic profile of carboplatin carried out by Rose et 
al. (1985) revealed the complex caused less elevation in BUN and fewer 
renal lesions and was clearly less nephrotoxic than cisplatin. The 
effects of carboplatin on total W B C  and neutrophil counts indicated 
that the drug caused myelosuppression in mice, dogs and rats. It has 
since been identified that thrombocytopoenia is dose-limiting in 
humans (Calvert et al. 1982).
Figure 1.7 The chemical structures of second generation 
antican.cer platinum compounds
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Carboplatin caused emesis in both ferrets and dogs, but this was less 
severe than for cisplatin. Reports from clinical observations indicate 
that the preclinical toxicology test systems were accurate in predicting 
the nephrotoxic, emetic and myelosuppressive effects of carboplatin 
relative to cisplatin (Table 1.5). In an attempt to explain the
differences in toxicology, the comparative pharmacokinetics of the two 
compounds has been evaluated (Siddik et al. 1984a), For both platinum 
complexes, the kidney plays a major role in their excretion, although 
excretion of cisplatin is about half that of carboplatin. In addition, 
the excretion of the latter compound is largely as the unchanged drug 
(Newell et al. 1984). It has been suggested that the differential
nephrotoxicity of cisplatin and carboplatin could be due to the extent 
of active tubular involvement in their renal excretions (Siddik et al. 
1984a). However,it is just as likely that it is merely due to the
relative abilities of the two compounds to interact with essential 
intracellular macromolecules.
Antitumour activity as well as cellular toxicity appears to be related to 
the relative stability of cisplatin and carboplatin (Knox et al. 1986). 
The replacement of the two independent chloro-ligands of cisplatin by 
the bidentate CBDCA ligand of carboplatin produces a molecule that is 
more resistant to water (Cleare 1974). Roberts et al. (1986) have 
proposed that the rates of reaction of DNA with cisplatin (6.3mgPt/g 
DNA/h) and carboplatin (81pgPt/g DNA/h) reflect their different rates 
of aquation although the adduct formed is identical. If this is the 
case, it suggests that the mechanism of antitumour activity of all 
platinum (II) complexes thus far synthesised is identical and
differences in therapeutic index are merely a function of chemical 
reactivity and pharmacokinetics.
TABLE 1.5
S '
)
Results from a phase III trial (Royal Marden 
Hospital) comparing carboplatin (JM8) and cisplatin 
toxicity on patients with ovarian cancer.
ORGAN/TISSUE SYSTEM TOXICITY INCIDENCE/PERCENTAGE
CISPLATIN CARBOPLATIN
Kidney 71 15
Bone marrow 31 36
Hearing 87 36
Peripheral nervous 
system 48 15
Gastrointestinal cisplatin>carboplatin
From Barnard et a l . (1986)
1.6.2 IPROPLATIN (JM9)
Studies by Lelieveld et al. (1984) and Harrap et al. (1980) have
indicated that Iproplatin (Figure 1.7) does not cause the renal toxicity 
in rats associated with cisplatin treatment. Like carboplatin, in animal 
tests it showed similar antitumour activity to cisplatin, with reduced 
emetic potential, though it still depressed the white blood cell count. 
Phase 1 clinical trials indicated a similar pattern of toxicity to 
carboplatin, though with a slightly lower maximum tolerated dose and 
more severe gastrointestinal effects and diarrhoea (Barnard et al.
1986).
1.6.3 SPIROPLATIN (TNO-6)
Unlike carboplatin and Iproplatin, this compound (Figure 1.7) is
kinetically more reactive than cisplatin. Animal data (Lelieveld et al. 
1984) indicated that the complex is nephrotoxic, as expressed by 
elevated urea and creatinine concentrations, as well as 
myelosuppressive causing a depression in the number of leucocytes 
and platelets. Emesis was seen in all animals studied, although less 
severe than cisplatin. Phase II clinical trials were initiated with the 
compound but clinical investigations were stopped at the end of 1984,
when incidences of kidney toxicity that could not be overcome by
hydration become more frequent.
1.7 CLINICAL USE OF PLATINUM BASED DRUGS
1.7.1 CISPLATIN
The first clinical trials on cisplatin in 1971 confirmed that it was 
active against several human tumours, and that it had the side effects 
as described in Section 1.5, even at low doses (20mgm"2). It was not 
until 1977 that it was demonstrated that pre and post hydration
treatment of the patients combined with slow infusion of the drug 
over twenty-four hours could overcome the major dose-limiting toxicity 
and allow doses of up to 120mgm-2 to be used. The drug was 
licensed by Bristol-Myers and registered for the treatment of 
testicular and ovarian tumours in the U.S.A.in 1978. International 
registration of the drug followed, with approval in the U.K. in 1979 
and Japan in 1984. It is now also being used in the treatment of other 
tumours, particularly those in the bladder, head and neck. These 
tumours are treated using surgery and radiotherapy, in addition to 
cisplatin in combination with other drugs.
The advent of cisplatin has changed the prognosis for long term 
survival for testicular patients from approximately twenty per cent to 
eighty per cent.
1.7.2 CARBOPLATIN
Carboplatin received a U.K. product licence for first and second line 
therapy of ovarian cancer and small cell carcinoma of the lung in 
March 1986. The maximum tolerated doses, dependent upon patient 
status and the dosage schedule, were estimated to lie between 300 and 
500mgm*^ (Canetta et al. 1985). Phase II trials have indicated that 
carboplatin shows a better response rate for the treatment of small 
cell lung cancer than cisplatin (Smith et al. 1985), but lower response 
rates in other cancer types (e.g. bladder and cervical cancers). The 
pattern of clinical responses for carboplatin is not identical to that of 
cisplatin, probably due to pharmacokinetic and distribution 
differences. Thus, the existing data (Canatta et al. 1985) indicate that 
carboplatin appears to be a viable alternative to cisplatin and may 
even be used in combination with the parent compound as it appears 
that there is non-overlapping toxicity.
1.7.3 IPROPLATIN
Phase II trials indicated that this compound was active against ovarian 
cancer with an overall response rate of forty-six per cent. Maximum 
tolerated doses appear to be approximately 95mgnr2 a week for four 
weeks (Harrap 1983a),Trials at Roswell Park Cancer Institute have 
indicated that like carboplatin this complex is active against cisplatin 
resistant tumours, namely small cell lung cancer.
1.8 OTHER TRANSITION METAL BASED COMPLEXES
The studies with platinum have stimulated considerable interest in 
other metal complexes and several studies over the last few years 
have established a large variety of coordination activity (Cleare 1974). 
These complexes range from rhodium (Cleare 1974a),ruthenium (Clarke 
1980, Sava et al. 1987), palladium (Livingstone et al. 1970, Deakon 
et al. 1987) and gold (Mirabelli et al. 1985) which are not normally 
found in cells, to naturally occurring elements such as copper (Tsipis 
et al. 1987) zinc and iron (Kopf-Maier 1987).
It is very unlikely that all of these active metal compounds act in the 
same way and hence it is hoped that some may have a different 
spectrum of activity to the platinum based complexes. Recent data on 
the activity of gold phosphine complexes (Berners-Price et al. 1986) 
suggest that other heavy metal compounds will be an active area of 
research into the 1990*s.
1.9 AIMS OF THE PROJECT
Although 2000 analogues of cisplatin are estimated to have been 
synthesised in the past twenty years, much research continues for a 
third generation complex. Criteria for more effective platinum 
anticancer compounds include higher activity per unit dose compared 
with carboplatin and ideally cisplatin though the latter is still one of 
the most potent compounds in animals. In addition, ways of increasing 
the selectivity of antitumour activity of platinum complexes such as 
linkage to immunoglobulins (Hurwitz et al. 1982), hormones (Kidani
1987) and water soluble polymers (Gill et al. 1987) have been studied. 
An alternative manoeuvre explored in the quest for high antitumour 
activity with minimal host toxicity has seen the study of different 
routes of administration.
Local applications, e.g. intraperitoneal (tenBokkel Huinink et al. 1985) 
and intraarterial (Okamoto et al. 1986) have been used clinically with 
cisplatin whilst liposomes (Perez-Soler et al. 1987) and embols as 
application forms have also been studied. Recent animal studies 
carried out at the Institute of Cancer Research of Sutton, England 
demonstrated that cisplatin and carboplatin are orally absorbed and 
that the nephrotoxicity of cisplatin is significantly reduced using this 
route of administration (Siddik et al. 1984). Moreover, this study and 
the study of Hasegawa et al. (1985) indicated that oral cisplatin was 
effective against several murine tumours. The recent success of 
Auranofin, an orally administered gold pharmaceutical, has highlighted 
the desirability of orally administered metal drugs. However, in view 
of the limited studies on the intestinal absorption of metal compounds 
it is desirable to obtain detailed information about the absorption of 
current and potential transition metal based pharmaceuticals from both 
a therapeutic and toxicological standpoint.
The object of this study was to carry out a detailed investigation into 
the absorption of platinum based pharmaceuticals after oral 
administration to rats , although other transition metal complexes are 
briefly discussed. Both in vivo and in vitro models are used to 
obtain more detailed pharmacokinetic information about the oral route 
of administration with the extent and rate of absorption being 
quantified. Toxicology of the gastrointestinal tract, kidney, blood 
components and haemopoietic organs being the tissues most affected 
by i.v. administration, and liver, as the organ that will receive the 
highest dose of complexes after first pass absorption from the small 
intestine, is studied.
In addition, the deposition of platinum in the liver and kidney after 
oral administration of cisplatin is studied using subcellular 
fractionation and electron microprobe analysis. It is hoped that the 
conclusion reached by this project will help to establish whether oral 
administration of cisplatin and platinum compounds is justified.
CHAPTER 2
PHARMACOKINETICS OF ORALLY ADMINISTERED 
TRANSITION METAL BASED PHARMACEUTICALS
2.1 INTRODUCTION
The pharmacokinetics and organ distribution of platinum after cisplatin 
administration by both i.p and i.v. routes has been the subject of 
several reports (De Conti et al. 1973, Taylor et al. 1973, Wolf et al. 
1973, Belt et al. 1979) and was briefly reviewed in Section 1.4. 
Although much pharmacokinetic data now exists concerning parenteral 
administration of cisplatin and its congeners, carboplatin (JM8) and 
Iproplatin (JM9), little is known about the deposition of platinum in 
the various body fluids and tissues following oral administration. In 
this study, the organ distribution and pharmacokinetics of total 
platinum following oral administration of a number of platinum based 
compounds are evaluated in the rat model. In addition, the 
pharmacokinetics of several gold based compounds as well as a novel 
ruthenium compound is studied. It is hoped that the data generated 
from these studies will provide a basis for rationalising 
structure-activity relationships for inorganic pharmaceuticals that 
could result in the development of efficacious metal based drugs that 
are capable of oral delivery.
2.2 MATERIALS AND METHODS
All chemicals and biochemicals were of analytical grade and were 
obtained either from BDH Chemicals Ltd, Poole, Dorset, England or from 
the Sigma Chemical Co Ltd, Poole, Dorset, England.
Tragacanth BP. powder was obtained from Evans Medical Ltd, 
Greenford, Middlesex, England.
Sodium Pentobarbitone (Sagatal) was obtained from May and Baker Ltd, 
Dagenham, England.
All test compounds were the kind gifts from Johnson Matthey 
Technology Centre, Sonning Common, Reading, Berkshire, England.
2.2.1 ANIMAL HUSBANDRY AND TREATMENT
Male albino wistar rats of the University of Surrey strain weighing 
200 - 250g were used in all pharmacokinetic studies. Animal room 
temperature was controlled at 21°C±2°C, with a 50% humidity and lighting 
controlled to give 12 hours of light and 12 hours of darkness per 24 
hours. Upon receipt, the condition and body weights of all animals 
were noted and they were placed in individual glass metabolic cages. 
The animals were allowed free access to food (Spratts No. 1) and water 
(the outlet of the water bottle being carefully positioned above the 
diet dish to minimise dilution of the urine) in all studies except for 
the starvation study. For this study, food was withheld for 12 hours 
prior to administration of the test compounds and for a further 6 
hours after administration, although free access to water was allowed.
Test substances were suspended in a tragacanth mucilage (1.25% 
tragacanth powder w/v + 2.5ml 90% ethanol, made up to 100ml with 
water) and were administered by oral gavage at a dose of O.lmmole/kg 
body weight (Table 2.1). Control animals received an appropriate dose 
of tragacanth mucilage alone. For any intravenous studies, done as a 
comparison of pharmacokinetic and toxicological properties, compounds 
were dissolved in 0.9% saline at appropriate doses and were 
administered by tail vein injection. After dosing, each animal was 
returned immediately to the metabolic cage.
After the appropriate time interval, (1, 2, 4, 24, 48 hours) animals 
were removed from the metabolic cages and the tip of the tail was 
amputated using a sterile scalpel blade. 25pl of blood was collected 
using a lOOpl blood pipette containing 50pl of 0.05M sodium EDTA. The 
sample was then expelled into a LP3 tube (Luckham Limited, Burgess 
Hill, Sussex, England) and a further 50pl of EDTA was added.
TABLE.2.1
SUMMARY OF DOSAGE PROTOCOLS FOR 
ORAL ABSORPTION OF TRANSITION 
METAL BASED PHARMACEUTICALS.
DOSE
(og/kj)
NH
NH.
CAUOPUXIN
(JM8)
0.1
.CH.
NH,'' 'CH.
CH.
O.t
OH
‘NH.
OH
0.07
SUTHETflUM
ACOTLACSTOtUIE
(JM1017)
IL
Urine and faecal samples were collected cumulatively over 24 and 48 
hours and volumes and weights respectively were noted. The samples 
of blood, urine and faeces were stored at 4°C until analysis.
The experiments were terminated 48 hours after dosing, when the 
animals were killed by cervical dislocation and any tissues required 
were removed, weighed and stored at -18°C until they were processed 
for analysis by atomic absorption.
2.2.2 BILE DUCT CANNULATION
Cisplatin and carboplatin were orally administered to male wistar rats 
(200g) at a dose level of O.lmmole/kg body weight as described in 
Section 2.2.1. At a predetermined time after dosing the rats were 
anaesthetized with sodium pentobarbitone (Sagatal,May + 
Baker,Dagenham)(0.1ml i.p/lOOg body weight) and the bile duct exposed 
by a mid-line incision of first the skin and then the abdominal wall. 
Polythene tubing (0.8mm internal diameter) was then inserted into the 
bile duct through a transverse cut made in the wall of the vessel. The 
cannula was retained in position by two ligatures. To prevent 
dehydration of the animal the cut edges of the abdominal wall were 
stitched together and the skin incision closed with clips. The bile duct 
cannula emerged from the stitched abdominal wall. A rectal 
thermometer was used to monitor body temperature, which was 
maintained at 35-366 C by placing the rat on a heated blanket, to avoid 
changes in bile flow and composition. Bile was collected from the 
cannula at 30 minute intervals into plastic conical vials (Alpha Labs 
LW2072) and stored at -18°C until analysis.
2.2.3. PLATINUM ANALYSIS
REAGENTS:
(1) Dichlorotetra-ammonium platinum (IV).[Pt(NH3)4Cl2] stock 
solution, (lmg Pt/ml)
172mg of Pt(NH3)4Cl2 were dissolved in lOmls of 6M HC1. Distilled 
water was then added to make the volume up to 100ml.
(2) Platinum Chloride stock solution (lmg Pt/ml)
Spectrosol Atomic absorption grade.
BDH Chemicals Ltd, Poole, Dorset, England.
(3) Lanthanum Chloride (10% w/v) Spectrosol Atomic 
absorption grade.
BDH Chemicals Ltd, Poole, Dorset, England.
(4) Horse Blood.
Oxoid Ltd, Basingstoke, Hants, England.
Acids used were Aristar grade.
BDH Chemicals Ltd, Poole, Dorset, England.
METHOD
(a) BLOOD
A modification of the method described by Farago et al. (1982) was 
used. Whole blood samples were diluted 1 in 20 with reverse osmosis 
deionised water (ie.lOpl sample + 190pl water) prior to analysis by 
electrothermal atomic absorption spectrophotometry on either a Pye 
Unicam SP9 or 9090 spectrophotometer fitted with deuterium 
background correction. Platinum standards ranging from 0.05 to 
l.Oppm were made from a lOOOppm Pt(NH3)4Cl2 stock solution( or where 
stipulated lOOOppm platinum chloride) and were diluted with horse 
blood containing 0.05M Sodium EDTA so that the matrix of sample and
standard were matched. Figure 2.1 illustrates the effect of standard 
composition and matrix on the peak height obtained after 
electrothermal atomic absorption analysis of the two platinum reference 
standards.In water, 0.5% HC1 ,and urine a higher peak height was 
obtained using Pt(NH3)4Cl2. However,dilution in whole blood resulted 
in the PtCl4 standard producing the higher peak height . In 
subsequent analysis the Pt(NH3)4Cl2 stock solution was used, as the 
signal produced by this standard appeared to be less dependant upon 
the sample matrix.
PROGRAM DEVELOPMENT
Operating wavelength and bandpass conditions were obtained from the 
"Atomic Absorption Data Book" (Whiteside and Milner 1981). High purity 
argon was used as the inert gas.(BOC, Southampton, England). Hollow 
cathode lamps obtained from Cathodeon Ltd, Cambridge were used in 
all platinum determinations.
DRYING PHASE
Using an injection of 10pl of sample a phase 1 drying temperature of 
95 °C for 10 seconds with zero ramp followed by a phase 2 drying 
temperature of 105 °C for 20 seconds with a ramp of 9 were established. 
This was achieved by watching the evaporation of the sample with a 
dental mirror.
ASH PHASE
The maximum temperature to which samples containing platinum could 
be ashed out was found to be 1500 °C for 20 seconds with a ramp of 5 
(Figure 2.2).
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FIGURE 2.1
THE EFFECT OF MATRIX ON THE PEAK HEIGHT 
OBTAINED AFTER ELECTROTHERMAL ATOMIC 
ABSORPTION SPECTROPHOTROMETRY OF PLATINUM.
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FIGURE 2. 2.
ASHING CURVE FOR AQUEOUS PLATINUM.
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ATOMISATION PHASE
The optimum atomisation temperature of 28006 C for 3 seconds with zero 
ramp was used (Whiteside and Milner 1981). Pyrolytic coated graphite 
tubes (Pye Unicam Cambridge) and Deuterium background correction 
were found to be required to optimise analysis.
CLEANING PHASE
A final phase with temperature 2900 °C for 4 seconds and zero ramp 
was put into the program to clean the tube between samples. Final 
conditions used for analysis of platinum by electrothermal atomic 
absorption are illustrated in Table 2.2.
(b) URINE
Prior to analysis, samples were spun at 2,000xg for 5 minutes to 
remove any particulate matter. Urinary platinum concentrations were 
then determined by electrothermal atomic absorption spectrophotometry 
using Pt(NH3)4Cl2 standards as described for whole blood (table 2.2). 
Standards were matrix matched by dilution with control urine and test 
samples were diluted 1 in 10 with reverse osmosis deionised water 
prior to analysis.
(c) FAECES
After weighing "wet" the faecal samples were dried overnight at 105 °C 
until constant weight had been achieved. The "dry” weight was noted 
and the samples were then ground to a fine powder using a pestle 
and mortar. Weigh ,ed aliquots were then transferred to 50ml conical 
flasks and 15ml of concentrated nitric acid was added. After the 
initial vigorous reaction had subsided, samples were heated to 170°C on 
a hotplate until they were completely digested and dryness had been 
achieved. Excess nitric acid was then removed by addition of 1M HC1.
TABLE 2.2
Instrumental conditions used with Pye Unicam
SP9090 Video Furnace for the determination of platinum by
electrothermal atomic absorption spectroscopy.
Phase Temp
(°C)
Ramp rate 
(° C sec “ 1 )
Time
temp
held at 
(s e c )
1 DRY 95 10 0
2 DRY 105 20 9
3 ASH 1500 20 5
4 ATOMISE 2800 3 0
5 CLEAN 2900 4 0
Wavelength 265.9nm , band pass 0.5nm , lamp current 12ma. 
Deuterium background correction ON. Sample volume 10pl. 
Pyrolytic coated graphite tubes were employed.
During the atomise phase the temperature control and peak 
timer options were applied. Temperature control was also 
applied to the clean phase. Auto zero was operated at the 
start of the atomise phase.
It is important to carry out this procedure as nitric acid has been 
shown to significantly decrease the sensitivity of platinum analysis by 
atomic absorption spectrometry (Matsumoto et a!.1984«Adriaenssens et 
aL1973,Farago et aL1982) .After the samples had once more been taken 
down to dryness, 1% Hcl containing 1% Lanthanum Chloride (LaCk) was 
added. The sample was then quantitatively transferred to a 10ml 
graduated vokimetric flask and made up to 10ml by further addition of 
1% Hcl containing LaCk. Calibration solutions of Pt(NH3)4Ck ranging 
from 5 - 50ppm Pt. in 1% HC1 containing 1% LaCk were then made and 
analysis was carried out by atomic absorption spectrophotometry on an 
Instrumentation Laboratories Model 353 or a Pye SP9 atomic absorption 
spectrophotometer by aspiration into the flame. A lean air/acetylene 
flame was appropriate for the platinum determination. Instrumentation 
conditions used are shown in Table 2.3
(d) TISSUE
After weighing, wet tissues were dried overnight and reweighed as for 
faeces. They were then "wet1* ashed in concentrated nitric acid at 
170°C in a DG-1 block digestor (Techne Limited, Cambridge, England) 
until a pale yellow or colourless solution had been obtained, taken 
down to dryness and excess nitric acid driven off by the addition of 
1M Hcl. After the sample had once again been taken down to dryness, 
1% Hcl was added. Samples in 1% Hcl were then quantitatively 
transferred to a 10ml volumetric flask and made up to 10ml with the 
1% Hcl diluent. Analysis was then carried out on a Pye SP9090 atomic 
absorption spectrophotometer using the method described in Table 2.2. 
A standard curve was constructed from the Pt(NH3)4Ck stock diluted 
in 1% HC1.
TABLE 2.3
Instrumental operating conditions used for the
analysis of platinum by atomic absorption spectroscopy.
IL.353. S P 9 .
Lamp current (mA) 10 10
Wavelength (nra) 265.9 265.9
Slit width (pm) 320 500
Photomultiplier voltage (v) 530 -
Scale expansion x 2.5 -
Flame (air/acetylene) lean lean
(e) BILE 
METHOD (i)
This was the method as described by Van der Vijgh et al. (1985). Bile 
samples were diluted with a solution of 0.15M NaCl in 0.4M HC1 prior to 
analysis as illustrated in Table 2.2. Standards were made up from 
l,000ppm stock of Pt(NH3)4Cl2 diluted in 0.15M NaCl/0.4M HC1 and 
matrix matched with samples by addition of appropriate volume of 
control bile. Figure 2.3 shows the effect of bile on peak height 
obtained from standards analysed by this method. This method was 
rejected due to two problems.
(i) High absorbance of blank (e.g. 1 in 4 dilution of control bile gave 
a peak height of 0.201)
(ii) Even high dilutions of test samples resulted in peak heights that 
were on the non-linear portion of the standard curve. This made 
accurate determinations impossible.
METHOD (ii)
Standards were prepared from Pt(NH3)4Cl2 stock solution diluted with 
1% HC1. These were matrix matched by addition of appropriate 
volumes of control bile prior to analysis as described in Table 2.2. 
Test bile samples were diluted 1 in 10 with 1% HC1 and analysed as 
previously described (Table 2.2). A typical standard curve as 
produced from this method is shown in Figure 2.4 and illustrates w h y  
this method was chosen in preference to that described by Van der 
Vijgh . Although greater lineality was achieved, significant signal 
depression is produced by the presence of bile.
0 1
QO
35H
W
a
w
35H
K*
PQ
S5M
<2
>-< m 
Pi oo <j CTi
PM
PQ
Pm
O
H
P
oo
wPi
PoM
Pm
,ctoo
•r~>•H
>
p-l<UP
9Pi 
P  co 
<3W Pm
S O
ecO
>
o
00
o
o
o
m
a ► o
om
o  o o o
CO
■H *H O
•H *H
4-1 4J
O
CMCO
•IH0I3H 3V33
PL
AT
IN
UM
 
CO
NC
EN
TR
AT
IO
N,
 
(
j
u
g
/m
l)
ptlo
H
Zw
sw
Piz
CO
<
aopt-i
Q W 
Z  t—I < 
H 
PQ 
O
w
5zo
< zQ M
1 3
H Z 
CO P-t
i *M M 
ZM 
PQ
CU>-<H
w
Pizo
_ o
CTN
_ 00 
o
in
•H
•H •H 
"O Z•v
O
ro
o  clcu coDu
vO
o
in
o
<r
o
n
o
C\J
o
^qSiaq >iEad
2.2.4 GOLD ANALYSIS
REAGENTS:
(1) Gold Chloride stock solution (lmg Au/ml).
Spectrosol atomic absorption grade
BDH Chemicals Ltd, Poole, Dorset, England
All other chemicals were as described for platinum
analysis.
(a) BLOOD
As for platinum determination, whole blood samples were diluted 1 in 
20 with reverse osmosis deionised water prior to analysis by 
electrothermal atomic absorption spectrophotometry on a Pye Unicam 
SP9 instrument. Standards ranging from 0.1 -l.Oppm gold were 
constructed from the gold chloride stock solution and were 
appropriately matrix matched to test samples with use of horse blood. 
Once the maximum ashing temperature had been determined (Figure 
2.5) a program was constructed (Table 2.4) by reference to the 
"Atomic Absorption Data Book" (Whiteside and Milner 1981). High purity 
argon and pyrolytic coated graphite tubes were used as with platinum 
analysis.
(b) URINE
Samples were treated as described previously for platinum urinary 
analysis. The program as illustrated in Table 2.4 was used, with 
matrix matched gold chloride standards prepared from the lOOOppm 
stock solution.
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FIGURE 2.5
ASHING CURVE FOR AQUEOUS GOLD.
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TABLE 2.4
Instrumental conditions used with Pye SP9
video-furnace for the determination of gold by
electrothermal atomic absorption spectroscopy.
Phase Temp
r c )
Ramp rate 
(* C s e c ■ 1)
Time
temp
held at 
(s e c )
1 DRY 85 0 1
2 DRY 115 5 30
3 ASH 1050 20 3
4 ATOMISE 2500 4 0
5 CLEAN 2600 5 0
Wavelength 242.8nm, band pass 0.5nm, lamp current 10mA 
Deuterium background correction ON. Sample volume 5^1. 
Pyrolytic coated graphite tubes were employed.
During the atomise phase, temperature control, gas stop, and 
peak timer options were applied. Auto zero was operated at 
the start of the atomise phase.
2.2.5 RUTHENIUM ANALYSIS
REAGENTS
(1) Ruthenium chloride (RuCb) stock solution (lmgRu/ml). 24.7mg
RuCb (42.1% Ru) were dissolved in lOmls of 6M HC1. Distilled water
was then added to make volume up to 100ml.
(a) AQUEOUS
A range of standards from 0.1 to lpg/ml were made from the RuCb 
stock solution by dilution with reverse osmosis deionised water. 
Optimum drying phases were determined by use of a dental mirror and 
an ashing curve was constructed. (Figure 2.6). The optimum 
atomisation temperature was determined by reference to the ’’Atomic 
Absorption Data Handbook" (Whiteside and Milner 1981) and a program 
was constructed (Table 2.5). The major ruthenium absorption band is 
at 349.89nm where the deuterium background correction lamp is 
ineffective, therefore background correction cannot be used. The 
advantages of using uncoated or total pyrolytic graphite tubes
compared to the coated tube was investigated prior to analysis of test
samples. Analysis using total pyrolytic tubes produced a linear 
standard curve when using aqueous standards; however the short 
lifetime of each tube together with increased emission effects produced 
using biological matrices (Figure 2.8) precluded their use. Uncoated 
tubes proved equally unsuitable due to poor sensitivity and peak 
shape (Figure 2.7) and hence pyrolytically coated tubes were 
employed.
(b) BLOOD
The presence of blood was shown to cause interference with the
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FIGURE 2.6
ASHING CURVE FOR AQUEOUS RUTHENIUM.
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TABLE 2.5
Instrument conditions used with Pye SP9090 
video-furnace for the determination of ruthenium by 
electrothermal atomic absorption spectroscopy.
Phase Temp
(°C)
Ramp rate 
(* C sec ~1)
Time
temp
held at 
(s e c )
1 DRY 95 10 0
2 DRY 115 20 9
3 ASH 800 20 5
4 ATOMISE 2700 3 0
5 CLEAN 2850 4 0
Wavelength 349.9nm, band pass 0.5nm, lamp current 10mA 
Deuterium background OFF. Sample volume lOpl.
Pyrolytic coated graphite tubes were employed.
During the atomise phase temperature control and peak timer 
options were applied. Auto zero was operated at the start 
of the atomise phase.
FIGURE 2.7 PEAK SHAPES OBTAINED AFTER ELECTROTHERMAL
ATOMIC ABSORPTION ANALYSIS OF RUTHENIUM USING UNCOATED
GRAPHITE TUBES AND STANDARDS IN;
(a) Reverse osmosis deionised water.
(b) Control urine diluted 1 in 10 with reverse osmosis deionised 
water.
(a) (b)
PEAK HT .026 COOL 27 
ABS AR . 0101
. 03r
ABS
PEAK IIT .149 COO L  15 
AR .1324
0 . 2r
0 3SEC
(i) Blank (i) Blank
ABS
PEAK HT .033 COOL 29 
AR .0329 ABS
PEAK HT .157 C O O L  27 
AR .1865
0 3 SEC 0
(ii) O.lppm Ruthenium (ii) O.lppm Ruthenium
PEAK HT .075 COOL 29 PEAK HT .184 C O O L  02
ABS AR .0722 ABS AR .3119
. 08
0 3 3EC 0
SEC
S E C
(iii) 0.25ppm Ruthenium (iii) 0.25ppm Ruthenium
FIGURE 2.8 PEAK SHAPES OBTAINED AFTER ELECTROTHERMAL
ATOMIC ABSORPTION ANALYSIS OF RUTHENIUM USING TOTAL
PYROLYTIC GRAPHITE TUBES AND STANDARDS IN;
(a) Reverse osmosis deionised water.
(b) Control urine diluted 1 in 10 with reverse osmosis deionised 
water.
(a) .(b)
P E A K  HT  .033 COOL. 26 PEAK HT .90S C O O L  23
f»BS AR . 0JL±JL AOS AR .4298
j l  .  a
0 3 SEC 0 ' 3
(i) Blank (i) Blank
P EAK HT . JL2* COOL 22 
ABS AR . 096JL
0 . 2
30
(ii) O.lppm Ruthenium
PEAK HT . 2JLJL COOL 28 
ABS AR . JL73X
0 . 3
30
PEAK I1T JL. 224 C O O L  26 
ABS AR .6847
0
(ii) O.lppm Ruthenium
SEC
SEC
SEC
(iii) 0.25ppm Ruthenium
analysis of ruthenium and resulted in high background absorbance 
values (Figure 2.9c). The use of background correction by the 
two-line method using the atomic absorption line of 349.9nm and the 
background measurement line of 352.0nm showed that there was 
considerable background absorption (Figure 2.10a). The following
method was shown to decrease these interferences due to non-atomic 
absorption (i.e. background absorption).
(i) Standards were matrix matched to samples by addition of horse 
blood.
(ii) 5% HNO 3 was then added to matrix matched standards and the 
resulting precipitate was removed by spinning at 3000xg for 3
minutes.
(iii) Test samples were diluted to 1 in 20 with reverse osmosis 
deionised water.
(iv) 200pl of diluted sample was then added to 200pl of 5% HNO 3 and the
resulting precipitate was removed by spinning at 3000xg for 3
minutes.
(v) supernatants obtained from standards and samples were then 
analysed by electrothermal-atomic absorption using the method 
described in Table 2.5.
Although this method allowed a linear standard curve to be drawn 
from 0.05ppm to lppm ruthenium and reduced non atomic
absorption interference in the standards (Figure 2.10a(ii)) the samples 
still exhibited an interfering peak 1 second after the atomisation had 
been started (Figure 2.10b). This peak, which was probably due to 
the EDTA(which was present in the test samples but not the 
standards), meant that concentrations of ruthenium below O.lyg/ml had 
to be determined by direct observation of the video peak shape 
(Figure 2.10b).
FIGURE 2.9 PEAK SHAPES OBTAINED AFTER ELECTROTHERMAL
ATOMIC ABSORPTION ANALYSIS OF RUTHENIUM USING PYROLYTIC
COATED GRAPHITE TUBES AND STANDARDS IN;
(a) Reverse osmosis deionised water.
(b) Control urine diluted 1 in 10 with reverse osmosis deionised 
water.
(c) Whole blood diluted 1 in 20 with reverse osmosis deionised 
water
(a) (b) (c)
PEAK HT .009 CO O L  2 ?  PEAK H T  .191 COOL 27 PEAK HT .168 COOL 23
A BS A R — .0069 ABS AR .1048 ABS AR .1220. 01 0 . 2
3 SEC 3 SECa o
(i) Blank (i) Blank (i) Blank
PEAK HT .110 COOL 26 
AR .0833 ABS
PEAK HT .XT'S COOL 22 
AR .1800
a
PEAK H T  .404 COOL 24 
AR .2322
0.2
3a
0 . 3
(ii) O.lppm Ruthenium (ii) O.lppm Ruthenium (ii) O.lppm Ruthenium
PEAK HT 
AR
.171 COOL 24 
. 1343
PEAK HT 
AR
.191. COOL 28 
.2382
0 . 2 3
PEAK HT 1 . 0 4 9  COOL 20 
AR .4141.
3 3EC
(iii) 0.25ppm Ruthenium (iii) 0.25ppm Ruthenium (iii) 0.25ppm Ruthenium
FIGURE 2.10 PEAK SHAPES OBTAINED AFTER ELECTROTHERMAL 
ATOMIC ABSORPTION ANALYSIS OF RUTHENIUM IN ACID 
PRECIPITATED WHOLE BLOOD USING PYROLYTIC COATED GRAPHITE 
TUBES;
(a) Ruthenium standards in acid precipitated blood supernatant or 
whole blood.
(b) Rat blood supernatants after dosing with Ruthenium 
acetylacetonate.
(a) (b)
AB3
PEAK HT .3 3 3  COOL 23 
AR . JL793
0 . *
3 SEC
A O S
PEAK HT .093  COOL 26  
AR .0026
0 . 1.
3 SEC
(i) lppm Ruthenium in blood supernatant 
^ = 349.9nm
PEAK HT .0 3 3  COOL 26 
nDS AR— . 02-49
.04..
A:
(i) Rat blood supernatant 1 hour after dosing 
with Ruthenium acetylacetonate
AHS
PEAK fIT .0 6 2  COOL 23  
AR .0699
»EC 30  SEC
(ii) lppm Ruthenium in blood supernatant 
^ = 352.Onm
(absorbance due to background non 
atomic absorption)
A B S
PEAK HT 
AR
.2 7 9  COOL 27 
2793
0 . 3 r
(ii) Rat blood supernatant 4 hours after dosing 
with Ruthenium acetylacetonate
PEAK HT .0 3 3  COOL 27
. 0JL87'
O 3 SEC
(iii) lppm Ruthenium in whole blood diluted
1 in 40 with reverse osmosis deionised water 
A = 352.Onm
(absorbance due to background non 
atomic absorption)
0 3 SEC
(iii) Rat blood supernatant 48 hours after 
dosing with Ruthenium acetylacetonate
(c) URINE
(i) DETERMINATION OF URINARY RUTHENIUM BY ELECTROTHERMAL 
ATOMIC ABSORPTION SPECTROMETRY
Prior to analysis using the program shown in Table 2.5, all urine 
samples were spun at 2000xg to remove particulate matter and diluted 
1 in 10 with deionised water. RuCb standards were matrix matched 
by dilution in control urine. Only pyrolytic coated tubes were found 
to be suitable in the determination of ruthenium in urine, and analysis 
was still hampered by an interfering peak 0.6 seconds after 
atomisation (Figure 2.9b). This peak, which was probably due to high 
NaCl concentrations, could be removed totally by increasing the ashing 
temperature to 1500 #C for 30 seconds but this also resulted in loss of 
sensitivity. At an ashing temperature of 800 °C the interfering peak 
meant that a detection limit of 0.25ppm applied if direct observation of 
peak shape, as was undertaken with blood determinations, was to be 
avoided. All samples analysed fell above this detection limit even at 
the 1 in 10 dilution that was used.
(ii) DETERMINATION OF RUTHENIUM IN URINE BY PLASMA SOURCE 
MASS SPECTROMETRY
Due to the problems in analysis of ruthenium by electrothermal atomic 
absorption spectrophotometry it was decided to use a second method 
to check the results obtained. For this, samples were prepared as 
for atomic absorption but were diluted 1 in 20 with reverse osmosis 
deionised water and standards of RuCb ranging from 0.1 -5ppm 
ruthenium were prepared in matrix matched control urine. Standards 
and samples were then analysed for the ruthenium isotopes 101, 102, 
104 by aspiration into an argon plasma source of an inductively
coupled plasma-source mass spectrophotometer (V.G Isotopes Limited).
The form of this equipment has been described in a number of recent
papers (Gray et al. 1983, Houk et al. 1983). This technique has
several advantages over electrothermal atomic absorption 
spectrophotometry, the most important being the ability to achieve 
multielemental analysis at levels well below lng.ml"1 with minimal or 
reduced interference due to biological matrices.
2.3 RESULTS
2.3.1. PHARMACOKINETICS OF PLATINUM BASED COMPOUNDS 
(i) CISPLATIN, CARBOPLATIN (JM8) AND IPROPLATIN (JM9)
Oral administration of these compounds resulted in rapid absorption 
from the gastrointestinal tract into the systemic circulation. 
Administration of cisplatin (30mg/kg) resulted in a peak blood 
concentration of 2.63 ± 0.16pg Pt/ml 2 hours after administration (Figure 
2.11). Absorption of carboplatin (37mg/kg) and Iproplatin (41mg/kg) 
was somewhat slower with respective peak blood concentrations of 
1.48±0.4pgPt/ml (Figure 2.12) and 3.13±0.28pg Pt/ml (Figure 2.13) occurring 
4 hours after administration. Carboplatin and Iproplatin appeared to 
be eliminated from the blood at a greater rate than cisplatin, but 
because of inadequate data definitive elimination half-lives (t£) could 
not be calculated accurately. However, these were estimated to be 
approximately 22 hours for cisplatin, 18 hours for Iproplatin and 11 
hours for carboplatin. Higher peak blood concentrations were 
obtained by employing a period of starvation prior to administration of 
cisplatin and carboplatin (Figure 2.14). By withholding food for 12 
hours prior to the administration of the compounds, peak platinum 
concentrations in whole blood after cisplatin and carboplatin rose to 
160% and 147% respectively of that found in fed animals.
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FIGURE 2.11
WHOLE BLOOD PLATINUM LEVELS AFTER ADMINISTRATION
OF CISPLATIN TO MALE WISTAR RATS.
•CISPLATIN,30mg/kg (P.O) 
ACISPLATIN,1mg/kg (I.V)
2.0 -
TIME (hours)
results are means,±sem (n=6)
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FIGURE2.12
WHOLE BLOOD PLATINUM LEVELS AFTER ADMINISTRATION
OF CARBOPLATIN TO MALE WISTAR RATS.
2.
• CARBOPLATIN,37mg/kg.(P.0)
CARBOPLATIN,1.5mg/kg.(I.V)
20 2510 155
TIME (hours) 
results are means,±sem (n=6)
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FIGURE 2.13
WHOLE BLOOD PLATINUM LEVELS AFTER ORAL ADMINISTRATION
OF IPROPLATIN(JM9) TO MALE WISTAR RATS.
4.0-
• IPROPLATIN(JM9),42mg/kg. (P.O)
3.0-
5 10 15 20 4825
TIME (hours).
results are means,±sem (n=3).
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FIGURE 2.14
THE EFFECT OF FOOD CONSUMPTION 
ON WHOLE BLOOD PLATINUM CONCENTRATIONS 
AFTER ORAL ADMINISTRATION OF PLATINUM 
BASED PHARMACEUTICALS.
4_
2 -
48
TIME (hours)
# CISPLATIN,30mg/kg (p.o) :STARVED.
O CISPLATIN,30mg/kg (p.o) :FED.
A CARBOPLATIN,37mg/kg (p.o) :STARVED
a CARBOPLATIN,37mg/kg (p.o) :FED. 
results are means,±sem (n=3).
The data in Table 2.6 indicates that after oral administration of 
cisplatin, carboplatin or Iproplatin the greatest part of a single dose 
is excreted in the faeces. Over a 48 hour period, more than 75% of 
these compounds was eliminated by this pathway. Excretion in the 
urine is also significant with approximately 2.75% of cisplatin, 3.5% of 
carboplatin and 2.5% of Iproplatin being eliminated in 48 hours (Figure 
2.15). Urinary excretion of platinum was significantly increased after 
employing a period of starvation prior to oral administration of the 
compounds (Table 2.7). Together with the increase in blood platinum 
levels found, this data demonstrates that dietary factors play a large 
role in determining how well a compound is absorbed. Biliary 
excretion over 5 hours represented only 0.2% of the dose after 
cisplatin and 0.079% after carboplatin administration. Peak biliary 
platinum levels occurred 2 hours after oral administration of 30mg/kg 
cisplatin and 3 hours 30 minutes after administration of 37mg/kg 
carboplatin (Figure 2.16). It can therefore be concluded that the 
faecal content of platinum following oral administration is mostly 
unabsorbed platinum. When biliary and urinary excretion plus the 
tissue content of platinum in the kidney and liver were summed, a 
platinum absorption estimation of 3.29% for cisplatin and 3.68% for 
carboplatin was obtained.
Kidney and liver platinum levels found 48 hours after oral 
administration of cisplatin, carboplatin or Iproplatin are shown in 
Tables 2.8 and 2.9 respectively. In these Tables a comparison is made 
between the platinum concentrations found after oral administration 
and the concentration found after i.v. administration of doses 
approximating to the amount of platinum absorbed into the systemic 
circulation after oral delivery (i.e. 3.29% of oral dose for cisplatin 
and 3.68% of oral dose for carboplatin).
TABLE 2.6
Faecal platinum levels after oral administration of
O.lmmole/kg cisplatin, carboplatin or Iproplatin (JM9)
COMPOUND DOSE X DOSE IN FAECES X DOSE IN FAECES n
■>8/kg
0 - 24h 24 - 48h
Cisplatin 30 22 ± 10.20 53 ± 10.60 6
Carboplatin 37 58 ± 4.74 47 ± 12.30 10
Iproplatin 42 43 ± 17.00 86 ± 12.71 3
Results are means (±SEM)
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FIGURE 2.15
URINARY PLATINUM LEVELS AFTER ORAL 
ADMINISTRATION OF PLATINUM BASED 
PHARMACEUTICALS AT A DOSE OF O.lramole/kg,
4
3
2
• CARBOPLATIN;37mg/kg (n=10)
▲ CISPLATIN;30mg/kg (n=6)
■ IPROPLATIN;42mg/kg (n=3)
1
TIME (days)
results are means.
TABLE 2.7
The effect of food consumption on urinary excretion 
of platinum following oral administration of 
platinum based pharmaceuticals
COMPOUND
Cisplatin 
30mg/kg 
(P.O.)
TREATMENT URINARY PLATINUM LEVELS (% DOSE)
FED
STARVED
0 - 24h 
2.58 ± 1.14 
5.53 ± 1.10
24 - 48h 
0.59 ± 0.199 
1.13 ± 0.150
Carboplatin FED 
37mg/kg
(P.O.) STARVED
4.46 ± 0.97 
5.66 ± 1.08
0.30 ± 0.060 
0.71 ± 0.290
Results are means, ±SEM, (n = 3)
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TABLE 2.8
Kidney platinum levels 48 hours after administration
of platinum based pharmaceuticals
COMPOUND ROUTE OF DOSE PLATINUM PLATINUM TOTAL PLATINUM X DOSE X DOSE
ADMIN. ng/kg CONC. CONC. CONTENT OF IN 1 IN BOTH
pg/g DRY WT. pg/g WET WT. 1 KIDNEY (pg) KIDNEY KIDNEYS
Cisplatin oral 30.00 20.620 ± 1.160 5.610 ± 0.290 3.960 ± 0.100 0.096 0.193
Cisplatin i.v. 1.00 5.150 ± 2.050 1.690 ± 0.640 1.470 ± 0.500 0.910 1.820
Carboplatin oral 37.00 3.690 ± 1.740 1.070 ± 0.470 0.860 ± 0.320 0.021 0.043
Carboplatin i.v. 1.50 0.705 ± 0.115 0.255 ± 0.050 0.190 ± 0.030 0.096 0.193
Iproplatin oral 42.00 9.300 ± 2.500 2.500 ± 0.680 1.820 ± 0.460 0.044 0.088
Iproplatin i.v. ND ND ND ND ND ND
Results are means (±SEM) n = 3
ND = not determined
TABLE 2.9
Liver platinum levels 48 hours after administration
of platinum based pharmaceuticals
COMPOUND ROUTE OF DOSE PLATINUM CONCENTRATION TOTAL Pt % DOSE
ADMIN. mg/kg CONTENT OF IN
pg/g DRY WT. pg/g WET WT. LIVER (pg) LIVER
Cisplatin oral 30.0 3.010 ± 0.28 0.890 ± 0.09 6.160 ± 0.12 0.15
Cisplatin i.v. 1.0 0.920 ± 0.01 0.322 ± 0.02 3.180 ± 0.15 1.97
Carboplatin oral 37.0 0.590 ± 0.16 0.192 ± 0.05 2.230 ± 0.83 0.06
Carboplatin i.v. 1.5 ND ND ND ND
Iproplatin oral 42.0 2.670 ± 0.35 0.830 ± 0.14 7.030 ± 1.10 0.17
Iproplatin i.v. ND ND ND ND ND
Results are means (±SEM) n = 3
ND = not determined
After both dosage regimes, significantly higher platinum 
concentrations were attained in the kidney; the highest concentrations 
being found after administration of cisplatin. Although platinum 
concentrations were much higher in the kidney than the liver, the 
total amount of platinum present in each tissue was approximately the 
same, except after oral administration of Iproplatin where the hepatic 
platinum content was in excess of that found in the kidney. In 
kidney and liver, higher platinum concentrations were attained after 
oral administration. However, a larger percentage of the dose was 
recovered in both tissues after administration by the i.v. route.
(ii) NOVEL PLATINUM COMPOUNDS
The pharmacokinetics of a series of platinum (IV) mixed amines, 
AJS/B27/17, RLP/B90/12, MJA/B67/54 and MJA/B67/33 (Table 2.1) were 
compared to carboplatin. All of these novel compounds were absorbed 
at a slower rate than carboplatin, with peak blood concentration being 
attained 24 hours after administration (Figure 2.17). Although 
absorption was slower, all compounds attained a higher blood 
concentration than carboplatin. Maximal blood concentrations were 
obtained with the compound containing five carbon atoms in the cyclic 
hydrocarbon side-chain (MJA/B67/54). Replacing the chloride ligands 
by hydroxide moieties also appeared to increase absorption. Although 
this series of compounds appeared to be absorbed to a greater extent 
than carboplatin, again by far the greatest part of the dose was 
excreted in the faeces with an excess of 70% being eliminated by this 
pathway in 48 hours.
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FIGURE 2.17
WHOLE BLOOD PLATINUM LEVELS AFTER ORAL 
ADMINISTRATION OF NOVEL PLATINUM BASED 
PHARMACEUTICALS AT A DOSE OF 0.1mmole/kg 
BODY-WEIGHT.
PtCl0(OH)„NH.(c-C.HqNHJ
PtCl2(OH)2NH3(c-C6H11NH2) 
PtCl0(OH)0NH„(c-C.H7NHJ
CARBOPLATIN3
✓
2
-d
10 485 15 20 25
TIME (hours) 
results are means,±sem (n=3)
2.3.2 PHARMACOKINETICS OF GOLD BASED COMPOUNDS
The absorption of JM1036 and JM1064 (Table 2.1), two novel gold 
containing compounds, was compared to that of Auranofin. Auranofin, 
a commercially available orally absorbed coordinated gold compound 
used for the treatment of rheumatoid arthritis, was absorbed at a far 
slower rate than cisplatin and its congeners. Although absorption was 
relatively slow, high blood gold concentrations (12.53pg Au/ml) were 
achieved 24 hours after administration (Table 2.10). No such blood 
gold concentrations were obtained after administration of the two 
novel compounds with levels peaking at only 1.33pg Au/ml for JM1036 
and 0.46pg Au/ml after JM1064 (Table 2.10).
As was found with the platinum based compounds, the major route of 
excretion of these compounds was in the faeces. However, in the case 
of Auranofin excretion in the urine was far more complete with 7.65% 
of the dose being excreted in a 48 hour period after administration 
(Table 2.11). Unlike the platinum based compounds, elimination in the 
period 24-48 hours after administration accounted for the major part 
of the metal excreted in the urine. Urinary excretion of JM1036 and 
JM1064 was poor with only 1.09% and 0.142% respectively being 
eliminated in the first 48 hours (Table 2.11). This data suggests that 
whilst Auranofin is absorbed to a greater extent than any of the 
platinum compounds studied, JM1036 and JM1064 are poorly absorbed.
2.3.3 PHARMACOKINETICS OF A NOVEL RUTHENIUM BASED COMPOUND 
Oral administration of ruthenium acetylacetonate(JM1017), (Table 2.1) 
resulted in very rapid absorption so that a peak blood level of 
6.4±0,61pg Ru/ml was obtained 1 hour after dosing (Figure 2.18).
TABLE 2.10
Whole blood gold levels after oral administration of 
gold based pharmaceuticals
COMPOUND DOSE WHOLE BLOOD GOLD CONC. (jig/ml) AT TIMES
mg/kg ---------------------------------------- — --------------
lhr 2h 4h 24h 48h
Auranofin 68 2.86 ± 0.69 3.06 ± 0.57 2.86 ±0.19 12.53 ± 0.29 11.26 ±0.66
JM1036 39 0.60 ± 0.20 0.66 ± 0.26 0.86 ± 0.26 1.33 ± 0.83 0.60 ±0.30
JM1064 30 0.46 ± 0.06 0.43 ± 0.12 0.46 ± 0.06 0.33 ± 0.06 0.20
Results are means, ±SEM, (n = 3)
TABLE 2.11
Urinary gold levels after oral administration of 
gold based pharmaceuticals
COMPOUND DOSE URINARY GOLD LEVELS (% DOSE) AT TIMES
(mg/kg) ------ ----------------------------------------
0 - 24h 24 - 48h
Auranofin 68 2.480 ± 0.24 5.170 ± 0.67
JM1036 39 0.208 ± 0.14 0.890 ± 0.07
JM1064 30 0.033 ± 0.07 0.109 ± 0.06
Results are means, ±SEM, (n = 3)
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FIGURE 2.18
WHOLE BLOOD RUTHENIUM LEVELS AFTER ORAL 
ADMINISTRATION OF RUTHENIUM ACETYLACETONATE 
(JM 1017) AT A DOSE OF 0.1mmole/kg BODY-WEIGHT.
7-
6 -
5-
4-
5 10 15 20 25
TIME (hours).
results are means,±sem. (n=3)
TABLE 2.12
Urinary ruthenium levels after oral administration 
of ruthenium acetylacetonate (JM1017)
METHOD OF URINARY RUTHENIUM LEVELS (% DOSE) AT TIMES
ANALYSIS -------------------------------- ---------------------
0 - 24h 24 - 48h
Electrothermal
Atomic Absorption 14.2 ± 3.15 5.05 ± 0.28
Spectroscopy
Plasma Source 42.4 ± 0.97 3.44 ± 1.21
Mass Spectroscopy
Results are means ±SEM, (n = 3)
Elimination from the blood was far slower than was found for cisplatin 
and its congeners, with an elimination half-life (t|) estimated to be 
approximately 42 hours.
Urine collected after administration of the compound had a bright red 
appearance. Tests for the existence of blood using a Bili/Labstix 
reagent strip (Ames Division, Miles Laboratories Ltd, Stoke Poges, 
Slough, Berkshire, England) were negative indicating that the red 
colouration may be a water soluble metabolite of the original ruthenium 
complex. Analysis by electrothermal atomic absorption spectrometry 
indicated that 19.25% of the dose was eliminated in the urine within 48 
hours of administration of the compound (Table 2.12). However, plasma 
source mass spectrometry results indicated that urinary excretion 
could be as high as 45.84% of the original dose (Table 2.12). Both sets 
of results indicate that this compound is particularly well absorbed 
from the gastrointestinal tract and that urinary excretion is a major 
pathway for its elimination from the body,
2.4 DISCUSSION
2.4.1 THE PHARMACOKINETICS OF CISPLATIN, CARBOPLATIN A N D  
IPROPLATIN
The distribution kinetics of total platinum appeared to be consistent 
with published reports (Siddik et al. 1984, Hasegawa et al. 1985) with 
all three compounds being rapidly absorbed into the systemic 
circulation. The total amount of platinum absorbed, however, was 
relatively low (<6%). Unlike the data published by Siddik et al. (1984), 
oral administration of Iproplatin resulted in the highest blood 
concentration of platinum. Terminal plasma elimination half-lives were 
longest after cisplatin administration.
This may be attributed to the slow removal of platinum tightly 
associated with protein or could be a result of increased enterohepatic 
circulation, as indicated by the higher biliary platinum levels found 
after cisplatin treatment. Diet had a profound effect on the 
absorption of the compounds. This was exemplified by the higher blood 
and urinary platinum levels obtained after employing a period of 
fasting and could be due to a number of factors. These include:
(i) the components of the diet may physically absorb a fraction of the 
dose and hence reduce the biological availability of the drug.
(ii) the viscosity of the intestinal fluids in non-fasting animals may be 
increased to such an extent that diffusion of drug molecules from the 
lumen to the mucosal absorption site becomes the rate limiting step in 
the absorption process.
(iii) the presence of food in the gastric pouch may tend to decrease 
stomach emptying, thereby delaying absorption of the drugs from the 
small intestine. The literature contains numerous examples of the 
inhibiting effect of diet on drug absorption (Kirby et al. 1961, Klein et 
al. 1963) that are similar to that found in this study.
Since the kidney represents an important route of elimination for 
cisplatin, carboplatin and Iproplatin after per enteral administration, it 
was not surprising to find that urinary excretion is significant after 
oral administration of the drugs. The major part of the total urinary 
excretion occurred within 48 hours of oral administration with 
elimination being most complete after carboplatin (3.5%); probably 
reflecting the chemical stability and low level of tissue binding 
associated with this complex. This data is in contrast to that published 
by Siddik et al. (1984) where urinary excretion was more complete 
after oral administration of cisplatin (16-19%). It is noticeable that as 
a whole the urinary platinum levels reported here are significantly
lower than reported by Siddik (1984). This may reflect differences in 
the strain of rat used, dietary intake of the animals, or more probably 
in analytical technique.
After oral administration of cisplatin, carboplatin or Iproplatin, the 
greatest part of a single dose is excreted in the faeces. Over 48 hours 
more than 75% of the dose is eliminated by this pathway. The high 
faecal platinum content likely results from a combination of factors 
including incomplete absorption, absorption onto intestinal mucosal 
cells with subsequent sloughing into the lumen and, secretion through 
the intestinal wall and from the biliary tract. The cumulative % dose of 
platinum excreted in bile over the first five hours after administration 
was significantly greater for cisplatin than carboplatin. This 
represented only 0.2% of the administered dose (although it is a 
significant percentage of the amount absorbed). Therefore biliary 
excretion is unlikely to account for the high faecal platinum levels 
observed. Forty-eight hours after oral administration of the 
compounds the kidney retained a greater concentration of platinum 
than the liver. This has also been shown to occur after parenteral 
administration of the compounds (Choie et al. 1980. Harrison et al. 
1983, Taylor et al. 1973) and may be related to higher rates of 
activation of the platinum complexes in rat kidney than in the liver. 
However studies in vitro with tissue homogenates (Siddik et al. 1986) 
indicate that binding of platinum to the two rat tissues is similar, 
suggesting that some other mechanism, such as differences in organ 
blood perfusion, may be involved.
Data (Siddik et al. 1984a)has shown that cisplatin uptake by kidney 
and liver tissue slices is greater than that of carboplatin at an 
equimolar concentration. This was also found in vivo, after oral 
administration of equimolar concentrations of the complexes and
probably relates to the chemical reactivity of the molecules. The 
Ipropropyl platinum (IV) complex, Iproplatin, exhibited a somewhat 
different pattern of uptake to the other two agents.
Whereas oral administration of cisplatin and carboplatin resulted in 
kidney platinum concentrations that were approximately 6.5 times those 
found in the liver, administration of Iproplatin resulted in kidney 
concentrations that were only 3.48 times those found in hepatic tissue. 
The greater role of the liver in platinum uptake after oral 
administration of Iproplatin may have a profound effect on the toxicity 
associated with this compound.
2.4.2. NOVEL PLATINUM COMPOUNDS
Initially it was hoped that a large range of novel platinum compounds 
could be tested for their ability to be orally absorbed. Unfortunately 
only one series of compounds, a group of platinum (IV) mixed amines 
was tested so any definitive structure-activity relationships are 
difficult to obtain. All of the novel compounds studied had somewhat 
different pharmacokinetic profiles to cisplatin and the second 
generation platinum complexes discussed previously. Absorption was a 
great deal slower with peak blood levels being attained some 24 hours 
after dosing (cf. 4 hours for cisplatin) but was more complete. This 
difference is unlikely to be due to the lipid solubility of the 
compounds as the distribution coefficients between water and octanol 
was approximately 100 to 1 for all the platinum compounds studied. 
Using the series of platinum (IV) mixed amines as a model, the 
following structure-activity relationships can be tentatively suggested.
(i) The maximum number of carbon atoms present in a cyclic 
hydrocarbon side-chain for optimum absorption is five.
(ii) Replacement of Cl“ by OH“ ligands increases absorption.
(iii) In general, platinum (IV) complexes are absorbed to a greater 
degree than platinum (II) as indicated by area under the curve of 
blood platinum versus time plots.
2.4.3. OTHER TRANSITION METAL BASED COMPOUNDS
The search for metal based compounds capable of oral delivery has 
not been limited to platinum. Undoubtedly the most notable metal 
based compound capable of being orally absorbed found to date is 
auranofin. The pharmacokinetics of this compound described in this 
study are consistent with published reports (Intoccia et al. 1982, 
Gottlieb 1983). This gold based complex was absorbed at a far slower 
rate than cisplatin and its congeners with peak blood metal levels 
occurring 24 hours after administration. However, the concentration of 
metal that appeared in the systemic blood was 4-5 times that found 
after oral administration of an equimolar dose of any of the platinum 
based complexes. Urinary metal levels were also far higher after 
auranofin. Unlike the platinum based compounds, urinary excretion 
was maximal 24-48 hours after dosing. The differences in the 
pharmacokinetic profiles and degree of absorption between auranofin 
and the platinum based compounds studied to date can all be 
explained by the water/octanol partition coefficient of the former. 
Whilst all the platinum based compounds have been poorly lipid 
soluble, auranofin exhibits relatively high lipid solubility which allows 
for efficient diffusion through the intestinal epithelium . Absorption 
of other more water soluble experimental oral gold compounds, JM1064 
[trichloro (di isopropylamine) gold III] and JM1036 [dichloro 
(N,N-diethyl dithiocarbamato) gold III] was shown to be especially 
poor. Apart from auranofin, only one other compound was especially 
well absorbed.
This was a bright red ruthenium based complex , ruthenium 
acetylacetonate (JM1017),which like auranofin exhibits poor water 
solubility whilst being relatively lipid soluble. Unfortunately, the 
doubtful therapeutic activity and unwanted side effect of red 
colouration of the urine may prevent the further development of the 
compound. However, it is clear that it may serve as useful template for 
future metal based drugs capable of oral delivery.
The results presented here show that of all the metal based 
compounds studied only two were particularly well absorbed, auranofin 
and ruthenium acetylacetonate. The former being custom synthesised 
for oral delivery of gold. The other complexes studied, namely 
cisplatin and its congeners were all developed for i.v. administration 
and therefore by nature require to be as water soluble as possible. It 
is clear that for more efficient absorption from the gastrointestinal 
tract these compounds require greater lipid solubility. Hence if oral 
administration of platinum based anticancer agents is a serious idea, 
more lipophilic platinum complexes, or compounds that contain ligands 
capable of carrying the active platinum complex across the intestinal 
epithelium, such as amino-acid or carbohydrate analogues, must be 
specifically synthesised. The synthesis of a pro-drug in which the 
active parent compound is regenerated only after transport across the 
intestinal tract would be an extremely significant development in the 
quest for a platinum based anticancer drug capable of oral delivery. 
As well as modifying such pharmacokinetic properties as absorption, 
tissue distribution and excretion,a pro-drug could also reduce or 
eliminate the inherent gastro-intestinal toxicity developed after oral 
administration of such cytotoxic drug (section 4.3.1).
CHAPTER 3
ABSORPTION OF PLATINUM DRUGS FROM RAT SMALL 
INTESTINE USING IN VITRO AND IN SITU METHODS
3.1 INTRODUCTION
The gastrointestinal mucosa is a semipermeable membrane, across which 
are transported various nutrients as well as substances foreign to the 
body. These compounds are normally absorbed across the membrane 
into the blood by one or more of the following mechanisms : passive 
diffusion; pore transport; active transport; facilitated transport or 
diffusion.
The mechanism by which platinum based drugs enter cells has not 
been well characterised and all experiments to date have used isolated 
in vitro cell systems. Although some evidence exists for 
carrier-mediated cell uptake of cisplatin by an amino acid transport
system (Byfield et al. 1982) most evidence suggests that platinum
drugs passively diffuse through the plasma membrane of the cell (Gale 
et al. 1973, Andrews et al. 1987, Casey et al. 1987). The aims of this 
study were to characterise (i) the mechanisms of absorption and (ii) 
the kinetics of the absorption process of cisplatin and carboplatin in 
intact intestinal tissue systems.
A number of models exist to study the gastrointestinal transport of 
drugs. These include techniques involving isolated gastrointestinal 
tissue (in vitro methods) and methods involving anaesthetised animals 
(in situ methods). The former exemplified by the method of Wilson 
and Wiseman (1954) has advantages in that it is relatively simple and 
reproducible, is particularly suitable for studying the kinetics of the 
absorption process, and can readily distinguish between active and 
passive transport processes. The major disadvantage of this 
technique is that the intestinal preparation is removed from the animal 
as well as its blood supply. Hence the drug must traverse the entire 
thickness of the intestinal wall and underlying muscularis which may 
result in artifactual slow absorption rates.
The in situ preparation, in having an intact blood supply can be used 
to study the transport process under more physiological conditions. 
There have been few investigations to date in which two different 
techniques have been used to examine the absorption of a drug and it 
is hoped by doing this, the transport of platinum based 
pharmaceuticals across cell membranes will be clarified.
3.2 MATERIALS AND METHODS
All reagents and chemicals used were of analytical grade except where 
stated otherwise and were obtained from either BDH Chemicals Ltd, 
Poole, Dorset, England or Sigma Chemical Co Ltd, Poole, Dorset, 
England.
The 95% oxygen, 5% carbon dioxide gas mixture and oxygen-free 
nitrogen gas were supplied by the Medical Gases Division of the 
British Oxygen Co Ltd.
Sodium Pentobarbitone (Sagatal) was obtained from May and Baker Ltd, 
Dagenham, England.
All test compounds were the kind gifts from Johnson Matthey, 
Technology Centre, Sonning Common, Berkshire, England.
3.2.1 EVERTED GUT SAC TECHNIQUE
(a) ANIMAL HUSBANDRY AND TREATMENT
Animals (250g male wistar rats) were housed as groups of six in 
plastic-based cages and maintained as described in Section 2.2.1. 
Twenty-four hours prior to the experiment the animals were rehoused 
in plastic cages with wire mesh floors, which prevented them from 
coprophagy and eating the wood shavings. Food was withheld, but 
water was available at all times.
TABLE 3.1
Composition of Krebs-Henseleit medium 
(after Krebs and Henseleit 1932)
Chemical Volume Mixed (ml)
(1) 0.9% NaCl (0.154M) 100
(2) 1.15% KC1 (0.154M) 4
(3) 1.22% CaCla (0.11M) 3
(4) 2.11% K H 2P O 4 (0.154M) 1
(5) 3.82% M g S 0 47 H 20 (0.154M) 1
(6) 1.3% NaHCOa (0.154M) 21
Gas mixture with 95% oxygen, 5% carbon dioxide with which 
is vigorously gassed for 1 hour before use.
(The pH should be 7.3 to 7.4)
(b) EVERTED GUT SAC PREPARATION
Animals were anaesthetised with an i.p. injection of sagatal (O.lml/lOOg 
body weight) and the abdomen was opened by a midline incision. A 
rectal thermometer was used to monitor body temperature, which was 
maintained at 35 - 36 °C by placing the rat on a heated blanket. The 
upper duodenum was then cut and an L-shaped glass cannula 
inserted. This procedure was also undertaken at the ilealcaecal 
junction. Krebs-Henseleit medium (Table 3.1) at 376 C and gassed with 
95% oxygen, 5% carbon dioxide was then perfused through the small 
intestine using a Gilson Miniplus 2 perfusion pump at a flow rate of 
2mls/min. When all remnants of food had been removed the intestine 
was perfused with ice-cold Krebs-Henseleit medium and then rapidly 
excised from the animal and placed in a bath of ice-cold gassed 
medium. Several workers have demonstrated that different intestinal 
regions show different levels of transport activity (Barry et al. 1961, 
Pritchard et al. 1977). Hence, in order to reduce experimental 
variability a defined and reproducible region of the small intestine 
was selected (25-50cm from the stomach). This was inverted over a 
smooth glass rod (Figure 3.1a) as described by Wiseman (1961) and 
replaced into the ice-cold gassed medium. Care was taken not to 
puncture the intestine during this process and eversion was complete 
within 3 minutes from removal of the intestine from the animal.
(c) EXPERIMENTAL PROCEDURE FOR INTESTINAL TRANSPORT STUDIES 
One end of the inverted intestine was tied off with a thread ligature. 
The ligature was left for easy handling and a 5cm length of sac was 
cut. With minimal handling this was then placed over the end of a 
Venisystems Abbocath T short 18G cannula (Abbott Ireland Limited, 
Sligo, Republic of Ireland), the sharp needle having been removed
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FIGURE 3.1
PROCEDURE FOR EVERTED GUT SAC TECHNIQUE
prior to this procedure, which was attached to a 1ml syringe (Figure 
3.1b). A second ligature was tied around the cannula and 0.5ml of 
pregassed, 37 °C Krebs-Henseleit medium containing lOmM D-glucose was 
introduced into the sac (serosal fluid). Using the second ligature the 
sac was carefully withdrawn from the cannula and tied off. Four sacs 
from each animal were placed into 100ml conical flasks containing 75ml 
of test mixture (mucosol fluid). This test mixture consisted of the test 
compound at appropriate dose, and lOmM D-glucose in 37 °C gassed 
Krebs-Henseleit medium. A volume of 75ml was sufficient to permit 
adequate mixing when the flask was gently shaken. The shaking was 
carried out in a water bath at 37 #C gassing with 95% oxygen/5% carbon 
dioxide throughout the incubation period (Figure 3.1c). Shaking was 
kept down to 35 oscillations/minute to minimise the shedding of the 
mucosa.
Levine et al. (1970) showed that intestinal sacs progressively lose 
integrity during incubations at 37 #C Krebs-Henseleit medium. However 
using the method described here, sacs were shown not to leak (the 
preparative technique was checked by setting up sacs containing 
Indian Ink) and had good histological integrity in incubations 
exceeding one hour. At the end of the incubation period the sacs 
were removed from the flask with forceps, and washed by dipping in 
an ice-cold perfusion medium. They were then blotted on smooth 
hardened filter paper and weighed. The contents (serosal fluid) were 
removed with the use of a hypodermic syringe, placed in a LP3 tube 
and stored at -18°C until analysed. Samples of serosal fluid taken at 
the beginning of the experiment as well as mucosal fluid samples taken 
at the beginning and end of the incubation were also stored at -18 °C 
in LP3 tubes. Empty sacs were reweighed to give by difference the 
volume of serosal fluid at the end of the incubation period.
The ligatures were then cut off as close as possible to the point of tie 
and the sacs were weighted again to give the effective weight of 
fresh tissue. The tissue was dried overnight at 105°C, reweighed and 
stored if required for platinum analysis. Both the incubation medium 
(mucosal fluid) and the material collected from inside the sacs (serosal 
fluid) were later assayed for glucose. Since only those preparations 
in which glucose accumulates against the concentration gradient 
maintain functional tissue, only those were subjected to platinum 
analysis.
The effect of metabolic inhibitors upon transport was determined by 
incubation of sacs in medium containing 5mM potassium cyanide. Anoxic 
conditions were created by incubation in a medium gassed with 
oxygen-free nitrogen. Along with a test for transport against a 
concentration gradient it was hoped that these experiments could 
determine whether platinum based pharmaceuticals are transported 
through the small intestine passively or by an energy requiring 
carrier molecule.
(d) GLUCOSE ASSAY 
REAGENTS
(1) GLUCOSE COLOUR REAGENT 
0.2ml Glucose oxidase (sigma type V)
2mg Peroxidase (sigma type I)
5mg 4-aminoantipyrine
15pl N.N dimethylaniline
Make up to 100ml with 0.1M KH2PO4, pH5.6
(2) GLUCOSE STANDARD SOLUTION (lmg/ml)
METHOD
Serosal and mucosal samples were thawed and tubes containing 50pl of 
sample and 450pl of distilled water were set up. These were mixed well 
and duplicate tubes were set up containing 50pl of the diluted sample 
and 200pl of distilled water. Another set of duplicate tubes containing 
250pl of glucose standards ranging from 0-100pg/ml were set up and 1ml 
of glucose colour reagent was added to both standard and sample 
tubes. Tubes were incubated for 30 minutes at 37 °C in a shaking 
water bath and then the absorbance was measured at 550nm against a 
reagent blank.
(e) PLATINUM DETERMINATION
(i) SEROSAL AND MUCOSAL FLUIDS
Samples were appropriately diluted in reverse osmosis deionised water 
prior to analysis by electrothermal atomic absorption by the method 
described in Table 2.2. Standards were constructed from the 
Pt(NH3)4Cl2 stock matrixed matched by dilution in Krebs-Henseleit 
medium. Transport of platinum from mucosal to serosal compartments 
was calculated as pg platinum/minute/g dry weight tissue.
(ii) SAC TISSUE
After drying overnight at 105 #C the sac tissue was digested and 
treated as in Section 2.2.3(d) before being analysed by electrothermal 
atomic absorption spectrophotometry (Table 2.2).
3.2.2 IN SITU ABSORPTION STUDIES
(a) PERFUSION
Rats were housed and maintained as in Section 3.3(a). After being 
starved overnight, the animals were anaethetised by an i.p. injection 
of sagatal (O.lml/lOOg body weight) and the abdomen was opened by a
midline incision to expose the small intestine. The animal was placed on 
a heated blanket to maintain body temperature at 3 6 s0 - 3 7 * C and the 
entire small intestine, from the top of the duodenum to the ileacaecal 
junction, was cannulated as described in Section 3.2.1(b). The intestine 
was then perfused with perfusion medium (Table 3.2) at 37 6C using a 
Gilson Miniplus 2 peristaltic pump at a flow rate of 4.3ml/minute. This 
step removed any residual food material remaining in the small 
intestine. To prevent dehydration of the animal during the course of 
the experiment the cut edges of the abdominal wall were stitched 
together and the skin incision closed with clips. The test compound 
(cisplatin or carboplatin) was then dissolved in buffered medium 
(either Sorensen buffer pH6 or Tris-HCl saline buffer pH7.0, 7.5 or 
8.0) and perfused through the intestine at a flow rate of 4.3ml/minute 
(Figure 3.2). In all experiments the temperature of the test compound 
in buffer was maintained at 37 °C. This could be easily achieved since a 
reservoir of the dissolved test compound was placed in a calibrated 
cylinder which was incubated in a thermostatically controlled 
water-bath throughout the perfusion period. At regular intervals 
during the next 90 minutes a lOOpl sample of test solution was collected 
from the reservoir using a Hamilton syringe (Hamilton Company, Reno, 
Nevada, U.S.A.), diluted in distilled water and placed in an LP3 tube. 
This was stored at -18° C until analysis. The amount of platinum in the 
perfusate after rinsing the tube system with the test compound was 
chosen as the platinum concentration at zero time.
(b) BLOOD COLLECTION
Initial experiments involved collection of 20pl samples of portal blood 
by cannulation of the portal vein as described by Van der Voet et al. 
(1984). The poor success rate in the cannulation procedure (due to 
vasoconstriction of the vein) resulted in subsequent experiments
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SCHEMATIC DIAGRAM OF APPARATUS USED FOR 
IN SITU ABSORPTION STUDIES.
TABLE 3.2
Composition of perfusion medium used for 
in situ absorption studies
CHEMICAL CONCENTRATION
(MOLAR)
NaCl 1.45 X 10-1
KC1 4.56 X 10-3
CaCl2 1.25 X 10-3
NaH 2 P04 5.00 X IQ-3
Prewarm mixture to 3 7 eC before use.
employing collection of tail vein blood as was described in Section
2.2.1 for in vivo experiments. During the perfusion 25pl, of blood was 
taken from the tail vein and added to lOOpl of 0.05M EDTA at the same 
time intervals as the perfusate samples were taken. The amount of 
platinum in the blood after rinsing the intestine with perfusion 
medium in the absence of the test compound was taken as the 
platinum concentration at zero time.
(c) ANALYSIS OF PLATINUM IN PERFUSATE AND BLOOD
Platinum was determined by electrothermal atomic absorption 
spectrophotometry using the method described in Table 2.2. Standards 
were constructed from Pt(NH3)4Cl2 stock appropriately matrix matched 
with perfusion medium or horse blood.
(d) CALCULATIONS
For the correction of volume changes of the perfusate during the 
perfusion, a mathematical method (Van der Voet et al. 1984) was chosen 
rather than making use of polyethelene glycol or phenyl red as 
chemical markers for change in volume. By reference to the volume of 
perfusate remaining in the calibrated reservoir it could be seen that 
it followed a linear course over the chosen time period. After 
establishing this linear relationship , from zero time to the time point 
at the end of the perfusion, the volume loss at any time point in the 
perfusion period could be calculated. This was later used for 
correction of all platinum concentrations in the perfusate. Plots of 
logio platinum concentration against time were then constructed. The 
slope of these being Ka/2.3, where Ka = first order rate constant. 
The half-life (tf) for the absorption process was then calculated using 
the equation;
3.3 RESULTS
3.3.1 THE ABSORPTION OF CISPLATIN AND CARBOPLATIN FROM RAT 
SMALL INTESTINE IN VITRO
(i) TIME COURSE OF D R U G  UPTAKE
The time course of uptake into everted sacs of rat small intestine was
examined for cisplatin and carboplatin. Figure 3.3 shows that the 
uptake of these compounds increased linearly with time up to at least
60 minutes. As can be seen from Figure 3.3 cisplatin, with an
absorption rate of 2.75pg Pt/min/g dry tissue weight, was absorbed 
more rapidly than carboplatin which had an absorption rate of 1.66pg 
Pt/min/g dry tissue weight. After 60 minutes the amount of platinum 
absorbed across the intestine into the sac after incubation in cisplatin 
represented only 0.099% of the initial dose. However, the concentration 
of platinum in the sac was 12.9±0.73% (n=16) of that in the incubation 
medium. In comparison, the amount of platinum absorbed after a 60 
minute incubation in carboplatin was only 0.061% of the initial dose 
which represented a concentration 8.26±0.66% (n=16) of that present in 
the incubation medium.
(ii) CONCENTRATION DEPENDENCY OF INITIAL UPTAKE
Absorption rates of cisplatin and carboplatin were measured over a 
concentration range up to l.OmM . Figure 3.4 shows the relationship 
between the uptake rate and concentration of substrate in the medium 
for cisplatin and carboplatin. A linear dependance of the uptake rate 
on the mucosal drug concentration was observed for both compounds 
up to at least ImM. When a double reciprocal (Lineweaver-Burk) plot 
was drawn the lines for both compounds converged at the origin 
(Figure 3.5).
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FIGURE 3.3
TIME COURSE OF UPTAKE OF CISPLATIN AND 
CARBOPLATIN BY EVERTED SACS OF RAT INTESTINE
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FIGURE 3.4
INFLUENCE OF CISPLATIN AND CARBOPLATIN 
CONCENTRATIONS IN THE INCUBATION MEDIUM ON 
UPTAKE BY ISOLATED EVERTED INTESTINAL SACS.
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FIGURE 3.5
LINEWEAVER BURK PLOT OF THE UPTAKE OF 
CISPLATIN AND CARBOPLATIN BY EVERTED 
SACS OF RAT INTESTINE INCUBATED IN 
KREBS HENSELEIT MEDIUM FOR 60 MINUTES.
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(iii) EFFECTS OF METABOLIC INHIBITORS AND ANOXIC CONDITIONS ON 
DRUG UPTAKE
Incubation of intestinal sacs in a medium containing 5mM potassium 
cyanide significantly increased the absorption rates of both cisplatin 
and carboplatin when compared to sacs incubated in Krebs-Henseleit 
medium alone (Figure 3.6). This apparent increase in the uptake rate 
was also observed when sacs were incubated under nitrogen rather 
than in 95% oxygen, 5% carbon dioxide (Figure 3.6). Metabolic 
inhibitors and anoxic conditions also significantly increased the amount 
of platinum present in the intestinal tissue when compared to controls 
(Table 3.3).
(iv) TRANSPORT OF CISPLATIN AGAINST A CONCENTRATION GRADIENT 
Sacs of everted rat intestine were incubated in Krebs-Henseleit 
medium gassed with 95% oxygen, 5% carbon dioxide for 60 minutes. In 
each experiment, the initial concentration of test compound and 
glucose was the same on the two sides of the intestinal wall. After 
the 60 minutes incubation period it was found that there was a fall in 
the concentration of glucose on the mucosal side and a rise on the 
serosal side, indicating a net movement of glucose across the wall 
against a concentration gradient (Figure 3.7a). In contrast to this, 
the concentration of cisplatin in the serosal fluid was found to fall 
after the 60 minutes incubation (Figure 3.7a). When sacs were 
incubated under anoxic conditions (i.e. in medium gassed with 
oxygen-free nitrogen), transport of glucose from the mucosal to the 
serosal side of the gut wall, against the concentration gradient, failed 
to occur (Figure 3.7b). Although the concentration of cisplatin 
present in the serosal fluid fell under these conditions as it did when 
incubated under aerobic conditions, the fall was not as great (Figure 
3.7b).
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FIGURE 3.6
THE EFFECT OF METABOLIC INHIBITORS (CN ) AND 
ANOXIC CONDITIONS (Nj ON THE UPTAKE OF CISPLATIN 
AND CARBOPLATIN BY SACS OF EVERTED RAT INTESTINE.
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TABLE 3.3
Effect of metabolic inhibitors and anoxic conditions 
on the accumulation of platinum in the tissue of everted 
gut sacs after incubation in Krebs-Henseleit medium 
containing cisplatin (0.25mM)
TISSUE PLATINUM CONCENTRATION 
(pg/g dry weight) at t = 60 mins.
184 ± 16 (10)
256 ± 24 (6)*
332 ± 3 4  (5)*
Results are means (±SEM) with the number of experiments 
in parentheses,
* Significantly different from control (without inhibitor 
at p<0.05
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5mM KCN 
Anoxic (N2 )
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FIGURE 3.7
THE USE OF EVERTED SACS OF RAT 
INTESTINE TO STUDY THE TRANSPORT OF 
GLUCOSE AND CISPLATIN AGAINST A 
CONCENTRATION GRADIENT .
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results are means (±sem) of 4 experiments.
Hence it appears that the sacs of everted intestine are able to 
transport glucose from the mucosal to the serosal side of the gut wall 
against a concentration gradient under aerobic conditions but not 
anaerobically; whereas mucosal to serosal transport of cisplatin against 
the concentration gradient did not occur under aerobic or anaerobic 
conditions.
3.3.2 THE ABSORPTION OF CISPLATIN AND CARBOPLATIN FROM RAT 
SMALL INTESTINE IN SITU.
(i) DRU G  DISAPPEARANCE FROM THE INTESTINAL L UMEN
Cisplatin and carboplatin disappearance from the intestinal lumen was 
found to follow first order kinetics for the entire experimental period. 
At pH7.0, cisplatin with a first order rate constant (Ka) of 9.2xl0*3 
min “1 was found to be absorbed more rapidly than carboplatin 
(Ka=4.98xl0~3min_1). The half-life for absorption (t£) was calculated to 
be 75 minutes for cisplatin and 139 minutes for carboplatin (Table 3.4). 
The disappearance of carboplatin from the intestinal lumen was found 
to be dependent upon the pH of the perfusate; the lower the pH, the 
more rapidly the compound was absorbed (Table 3.4).
(ii) DRU G  APPEARANCE IN THE PERIPHERAL BLOOD
The time course for the appearance of cisplatin and carboplatin in 
peripheral blood, collected from the tail vein, is shown in Figure 3.8. 
It can be seen that after in situ perfusion of the rat small intestine 
with solutions containing the compounds, cisplatin appeared in the 
peripheral blood at a far greater rate. The appearance rate of 
carboplatin in peripheral blood was increased substantially after 
perfusion of the compound in Sorensens buffer pH6.0, when compared 
to perfusion in Tris-HCl saline pH7.0 (Figure 3.8). As was found with 
the disappearance rate of carboplatin from the intestinal lumen, the
TABLE 3.4
Half-lives and first order rate constants for the 
disappearance of platinum based pharmaceuticals from 
rat small intestine after in situ perfusion
DRUG<a > pH<b > MEAN HALF-LIFE, MEAN FIRST ORDER
t£ (min) RATE CONSTANT, Ka (min“
Cisplatin 7.0 75 9.20 X 10“3
Carboplatin 7.0 139 4.98 X lO-3
Carboplatin 7.5 164 4.21 X 10- 3
Carboplatin 8.0 180 3.83 X lO'3
(a) Cisplatin concentration was 2.9mM 
Carboplatin concentration was 2.8mM
(b) Buffer was Tris-HCl-saline adjusted to required 
pH with aristar HC1 or NaOH
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FIGURE 3.8
WHOLE BLOOD PLATINUM CONCENTRATIONS AFTER 
IN SITU INTESTINAL PERFUSION WITH PLATINUM 
BASED PHARMACEUTICALS.
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RELATIONSHIP BETWEEN INTRALUMINAL pH AND 
WHOLE BLOOD PLATINUM LEVELS AFTER IN SITU 
INTESTINAL PERFUSION OF CARBOPLATIN (2.8mM) 
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Each point is the mean (±sem) of three determinations.
appearance in peripheral blood was clearly dependent upon the pH of 
the perfusate (Figure 3. 9 ).
3.4 DISCUSSION
Uptake of cisplatin and carboplatin from the mucosal to the serosal 
side of sacs of everted intestine was linear with time up to 60 minutes 
and was not saturable up to a concentration of 1.0 mM. 
Lineweaver-Burk double reciprocal plots drawn for both compounds 
converged at the origin implying that the Michaelis-Menten constant is 
approximately infinite. Thus either the rate of formation of a carrier - 
substrate intermediate complex is essentially zero or the rate of 
breakup of the complex is infinitely slow. Incubation of sacs in medium 
containing a metabolic inhibitor or under anoxic conditions failed to 
inhibit the uptake of the compounds. Also, the sacs of everted 
intestine were unable to transport the compounds from mucosal to 
serosal sides against a concentration gradient. All of these findings 
mitigate against active or carrier mediated transport of platinum based 
pharmaceuticals across the small intestine and tend to suggest that 
they passively diffuse across the gastrointestinal tract into the 
systemic blood system.
It is interesting to note however that anoxic conditions or the use of 
metabolic inhibitors significantly increased the transport of the drugs 
from mucosal to serosal fluid. Moreover, deposition of the compounds 
within the intestinal tissue itself was increased under these 
conditions. This could imply that there is energy dependant re-uptake 
into the intestinal lumen or merely that the integrity of the cellular 
membrane was compromised. Although the latter is more probable, 
further evidence for active re-uptake into the lumen exists with the 
finding that anoxic conditions slow down the transport of cisplatin
from serosal to mucosal sides of an intestinal sac that initially had 
equimolar concentrations of the drug on both sides. The existence of 
re-uptake into the intestinal lumen (i.e. serosal to mucosal transport) 
could explain the comparatively low absorption found for platinum 
compounds in vivo.
The kinetic studies performed with both model systems correctly 
predicted the blood level data observed after oral administration of 
the compounds. In vitro, cisplatin was absorbed at a far greater rate 
and more completely (12.9%) than carboplatin (8.26%). Auranofin, a gold 
based compound known to be well absorbed after oral administration, 
was shown to be absorbed to the extent of 15% in this same model 
(Tepperman et al. 1984). One would expect auranofin to be absorbed to 
a far greater extent in vitro, as blood metal levels reach five times 
that of cisplatin after oral administration of equimolar concentrations 
of the drugs to rats (Chapter 2). However, as was shown in vivo, 
although auranofin is more completely absorbed it does so at a far 
slower rate; a fact that cannot be ascertained by the single time point 
measurements carried out by Tepperman (1984). As well as 
measurements of intestinal uptake Tepperman et al. (1984) also used 
the everted gut preparation to study the intestinal metabolism of 
auranofin. This methodology would be well applied to the platinum 
based pharmaceuticals as little is known about modifications in the 
structure of these drugs which may occur during intestinal uptake. 
Information concerning metabolism specific to administration by the 
oral route is indispensable as intestinal induced modifications in 
structure could potentially alter the toxicology and antitumour activity 
associated with the drugs.
As was found with the in vitro system, the in situ preparation 
identified the greater intestinal absorption capabilities of cisplatin. 
This was illustrated by lumenal disappearance half lives (t£) of 75 
minutes for cisplatin and 139 minutes for carboplatin. Sampling of 
peripheral blood from the tail vein also ably indentified the more 
rapid absorption and distribution of cisplatin. Moreover, the 
differences in absorption of the two compounds, as identified by this 
method was much more profound than in vivo. Although this in situ 
preparation is merely a model, the question has to be raised as to 
whether carboplatin remains unchanged prior to absorption by the 
small intestine in vivo and to what degree conditions in the stomach 
alter its structure. The stomach of a healthy adult human contains 
gastric juice of a pH ranging between 0.9 - 1.2. This contains water, 
hydrochloric acid (approx. 170mM), electrolytes such as sodium, 
potassium, calcium, phosphates, bicarbonates and various enzymes. The 
main anion present is chloride. Studies by Roos et al. (1987) have 
indicated that although carboplatin does not react with chloride at 
neutral pH, it readily does in acidic conditions forming cisplatin. The 
stomach offers ideal conditions for this reaction and so it is not 
inconceivable that after prolonged exposure to gastric juice, a 
proportion of the carboplatin administered orally will form cisplatin. 
This would explain any differences in the absorption of carboplatin 
relative to cisplatin found between in vivo and the in situ experiment 
where the stomach is bypassed. If carboplatin does form cisplatin 
after exposure to gastric juice, this would have a profound effect on 
the toxicology associated with its oral administration. It would 
therefore have been of immense value to study the metabolism of 
carboplatin using high performance liquid chromatography (HPLC) both 
in vitro by incubation of the complex in artificial gastric juice and
eventually in vivo by collecting biological fluids from the stomach and 
hepatic portal vein after cannulation. Unfortunately time did not 
permit this avenue to be explored.
A relationship was observed between absorption of carboplatin and pH 
of the in situ perfusion medium. It was seen that by decreasing the 
pH of the perfusate, carboplatin was increasingly absorbed. This pH 
dependency has also been seen with other metals such as aluminium 
(Van der Voet et al 1984). The pH dependance for absorption of 
carboplatin across the small intestine is not surprising since the 
platinum species available for absorption are expected to differ in 
chemical form and quantity from one pH to another. It was 
ascertained earlier by in vitro studies using everted intestinal sacs 
that carboplatin probably crosses gastrointestinal membranes by 
passive diffusion. In the case of this process it is widely believed 
that drugs are absorbed to a larger degree in the un-ionized form. 
The degree of ionization of a chemical depends both on its pKa and 
the pH of the solution in which it is dissolved. This relationship is 
described by the Henderson-Hasselbalch equation. Therefore, in the 
in situ experiment the pH of the perfusion medium could potentially 
alter the rate of absorption of carboplatin by changing its degree of 
ionization and hence lipid solubility. Alternatively, the pH of the 
perfusion medium could influence the absorption of the drug by 
encouraging its conversion to the more absorbable cisplatin. This 
would occur by replacement of the CBDCA ligand by chloride ions 
which are found in high concentration in the Krebs-Henseleit 
perfusion medium.
These studies indicate that in situ and especially in vitro techniques 
are useful tools in screening for absorption of transition metal based 
pharmaceuticals. The everted gut sac technique is particularly
suitable for screening in that it is relatively simple to undertake and 
reproducible, whilst giving a rapid assessment of the ability of 
potential drugs to cross the membranes of the gastrointestinal tract 
without recourse to initial extensive full-blown in vivo
pharmacokinetics involving the use of many animals. Transport of 
transition metal complexes could also be studied at the cellular level 
rather than in entire intestinal tissue using isolated plasma membrane 
vesicles (Hopfer 1977). This model has been successfully used to 
study the intestinal transport of a number of metals including iron 
(Simpson et al.1986) and copper (Fischer et al. 1985) and has the
advantage over the gut sac preparation in that it reduces the 
complexity of epithelial transport. This is achieved since brush border 
and basolateral membranes are separated so that transport across one 
membrane can be investigated independently from that across the 
other. Information derived from m e m b r a n e  vesicles could 
unequivocally identify the existence of the energy-dependant 
transport mechanism that allowed re-uptake of transition metal 
complexes from serosal to mucosal sides of an everted intestinal sac. 
The main disadvantages of the use of membrane vesicles are the 
length of time and complexity required in their preparation and the 
fact that compounds to be studied often need to be radio-isotopically
labelled. Therefore, although the technique could be an invaluable
tool in identifying the biochemical nature of the translocation of 
compounds across both the brush border and basolateral membranes of 
the small intestine, the everted sac is likely to be of more use in 
screening programmes.
CHAPTER 4
TOXICOLOGY ASSOCIATED WITH ORAL ADMINISTRATION 
OF CISPLATIN AND CARBOPLATIN
4.1 INTRODUCTION
The finding that oral administration of cisplatin to rats significantly- 
reduced the incidence of nephrotoxicity associated with the drug
(Siddik et al. 1984) raised the possibility that this route of
administration could modulate the toxicities associated with platinum 
based pharmaceuticals. Apart from the obvious advantages associated 
with a reduction in the organ toxic effects, oral delivery would be a 
major break through for the clinical management of cancer patients. 
The aims of this study were to characterise the toxic effects 
associated with oral administration of cisplatin and carboplatin to rats, 
to correlate these to tissue platinum levels, and to compare them with 
those reported for parenteral administration (Section 1.5).
It was hoped that this would determine whether oral administration 
offers significant advantages over conventional routes of 
administration in terms of reduced toxicity.
4.2 MATERIALS AND METHODS
All chemicals and biochemicals were of analytical grade except where 
stated otherwise and were obtained from either BDH Chemicals Ltd, 
Poole, Dorset, England or from Sigma Chemical Co Ltd, Poole, Dorset, 
England.
Mineral water sugar (sucrose for centrifugation work) was obtained 
from Tate and Lyle Ltd.
Test compounds were the kind gifts of Johnson Matthey Technology 
Centre, Sonning Common, Berkshire, England.
4.2.1 PREPARATION OF ANIMALS FOR ACUTE TOXICITY STUDY
Male albino wistar rats of the University of Surrey strain weighing 
200-250g were used in all toxicity studies. Animal room temperature 
was maintained at 218C±2eC. with a 50% humidity and lighting controlled 
to give 12 hours light and 12 hours darkness per 24 hours. Upon 
receipt, animals were examined and weighed. They were then caged 
either as a group of 6 or groups of 3 and an identification mark was 
applied to each tail. For feeding studies rats were fed powdered 
Spratts No. 1 (see Appendix 1) whilst in all other studies pelleted 
Spratts No. 1 rodent diet was used. Water was allowed ad libitum. A 
period of 1 week was allowed for acclimatisation before rats were 
reweighed and the test compound administered in a tragacanth 
mucilage by oral gavage. At predetermined times (usually 1, 2, 4, 7,
14 and 28 days after dosing) animals from test and control groups 
were selected and prepared for autopsy.
4.2.2 AUTOPSY PROCEDURE
The appearance and activity of animals were noted and an accession 
number was allocated. This was a number unique to that animal and 
one used to identify all tissues from it. The animals were weighed and 
an i.p. injection of sagatal (O.lml/lOOg body weight) was administered. 
When unconscious, an incision through the abdominal skin and muscle 
wall was made. The viscera were deflected to the right and a blood 
sample from the posteria vena cava was taken. The kidneys and liver 
were then removed, weighed and sections for light and electron 
microscopy were taken. The remaining liver and kidney cortex were 
then placed in ice-cold homogenisation media for biochemical analysis 
or kept at -18 °C until analysis for platinum by electrothermal atomic 
absorption spectrophotometry. After removal of the liver and kidneys,
the small intestine, stomach, large intestine, spleen, pancreas and 
genital apparatus were removed and fixed in 10% neutral buffered 
formalin pH7.4 (and in the case of the small intestine, also prepared 
for electron microscopy and atomic absorption). The sternum was 
removed, trimmed free of muscle and fat and fixed in 10% neutral 
buffered formalin pH7.4. Muscles from the hind leg were then stripped 
and both' ends of the femur were dislocated so that it could be 
removed. The femoral marrow was then prepared for a smear if 
required.
4.2.3. LIGHT MICROSCOPY
(a) FIXATION OF TISSUES
REFERENCE: Lillie and Fullmer (1976) Histopathologic Technic and
Practical Histochemistry, 4th Edition.
Slices of tissues taken at autopsy were placed in a pot containing 10% 
neutral buffered formalin. The tissue was left in fixative for at least 1 
week before being processed for wax embedding.
(b) PREPARATION OF PARAFFIN WAX EMBEDDED SECTION 
REFERENCE: Culling, C. (1974) Handbook of Histopathological and 
Histochemical Techniques, 3rd Edition.
Tissues were removed from the formalin and trimmed to remove any 
excess tissue so that the organ could be placed in a plastic cassette. 
This cassette was labelled with an accession number and placed in a 
tissue basket which was then fitted to the Histokinetic automatic 
tissue processor. (British American Optical Co. Ltd, Slough, Berkshire, 
England.) In this machine tissues were transferred automatically from 
one beaker of reagent to the next. The processes of dehydration, 
clearing and impregnation with wax were carried out as follows;
PROCESS BEAKER CONTENT T ME (HR)
Further Fixation 1 10% neutral 
buffered formalin
1
Dehydration 2 70% I.M.S. 1
3 80% I.M.S. l*
4 90% I.M.S. n
5 100% I.M.S. 2
6 100% I.M.S. 2
7 100% I.M.S. 2
Clearing 8 Toluene 1
9 Toluene H
10 Toluene 2£
Wax impregnation Wax Bath 
1
Molten paraffin 
wax 60°C
3
Wax Bath 
2
Molten paraffin 
wax 60°C
3
Once processing had been completed, the plastic cassettes were 
removed from the tissue basket, ready for the tissues to be embedded 
using a Tissue-TEK 11 embedding centre. An appropriate sized metal 
mould was selected in which to embed the tissues and into it was 
dispersed sufficient molten wax to cover its base. Using electrically 
heated forceps, the tissue was carefully positioned within the molten 
wax so that the surface to be cut faced the base of the mould. The 
metal mould was slid across to the cold spot of the Tissue-TEK where 
the accession numbered plastic processing cassette was placed on top 
of it.
It was then filled to the brim with molten wax and placed on to 
a chiller plate so that the wax could harden. When the wax had 
completely hardened, the tissue blocks were lifted out of the base 
mould and were ready for cutting.
The blocks were mounted on a Rotary Microtome (R.Jung Rotary 
Microtome, Heidleberg, West Germany) and trimmed until the tissue was 
exposed. 4pm sections were then cut and mounted on clean glass 
slides. Sections were dried onto the slides in an oven at 60 °C for 1 
hour minimum (maximum 3 hours). The sections were then stained 
immediately or stored in a dust free dry environment for staining at a 
later date.
(c) STAINING -
(i) STAINING WITH HAEMATOXYLIN AND EOSIN
REFERENCE: Culling, C. (1974). Handbook of Histopathological and
Histochemical Techniques, 3rd Edition.
Sections prepared as described in Section 4.2.3(b) were stained with 
Harris’s haematoxylin and Eosin using the procedure described below. 
Dewax sections in xylene 1 - 2mins 
Dewax sections in xylene 2 - 2mins 
Hydrate sections through graded alcohols,
Alcohol 1 (100% I.M.S.) - 1 min 
Alcohol 2 ( 80% I.M.S.) - 1 min 
Alcohol 3 ( 60% I.M.S.) - 1 min 
Wash well in tap water.
Stain in Harris’s haematoxylin - 10 mins
Wash well in running tap water - until sections blue
Differentiate in 1% Acid alcohol - 5-10 sec.
Blue sections in Scott’s tap water substitute - 30 secs.
Check nuclear staining microscopically (nuclei blue/black, background 
clear).
Counterstain in 1% Eosin - 3-5 mins.
Wash in running tap water.
Dehydrate through graded alcohols.
Alcohol 4 (85% I.M.S.) - 30 secs 
Alcohol 5 (100% I.M.S.) - 1 min
Alcohol 6 (100% I.M.S.) - 1 min
Clear sections in xylene 3 - 2  mins 
Xylene 4 - 3  mins.
The sections were then mounted in D.P.X. (BDH Chemicals Ltd, Poole, 
Dorset, England) by placing a drop of the mountant on a clean 
coverslip, taking the slide from the xylene and inverting it over the
coverslip whilst pressing gently to spread out the mountant. After
leaving for 1 hour, until the DPX dried, the slides could then be 
examined microscopically.
(ii) STAINING WITH PERIODIC ACID SCHIFF REAGENT TO S T U D Y
GLYCOGEN DISTRIBUTION.
REFERENCE: Culling, C. (1974) Handbook of Histopatholigical and
Histochemical Techniques, 3rd Edition.
Two sections of liver from the same block were brought to water. One 
slide of each tissue was designated as a control. This negative control 
was incubated in 0.1% diastase for 30 minutes at 37 °C to digest
glycogen whilst the test section was left in distilled water for a
similar time. The test and control sides were then treated with 1% 
Periodic acid for 5 minutes, rinsed in distilled water and then treated 
with Schiff reagent for 15 minutes. Slides were then rinsed in running 
water for 5-10 minutes and nuclei were stained with Mayers Haemalum 
for 3 minutes. Finally, sections were blued by washing in Scott’s tap
water substitute for 1 minute, washed in tap water, and dehydrated in 
graded alcohols before being cleared in xylene and mounted in DPX.
(iii) PERLS PRUSSIAN BLUE REACTION FOR IRON
REFERENCE: Bancroft, J. (1975) Histochemical Techniques (2nd
Edition)
A 2% solution of potassium ferrocyanide (w/v) was prepared fresh
before use. The staining solution was prepared by mixing equal
volumes of this with 2% (w/v) hydrochloric acid. Sections were
rehydrated by taking through graded alcohols and into distilled water 
and then placed in the staining solution for 10 to 30 minutes. The 
sections were then washed in water, dehydrated through graded 
alcohols to xylene and mounted in DPX as described previously.
4.2.4 ELECTRON MICROSCOPY
(a) FIXATION OF TISSUES
REFERENCE: Prof S.Holt and Dr J. Fitzsimons (Personal communication) 
REAGENTS:
(1) Glutaraldehyde stock solution (25%: EM Purity) was purchased from
Taab Laboratories, Reading, Berkshire, England.
(2) Osmium tetroxide and Sodium Cacodylate (CH3)2As02Na3H20 were 
obtained from the Sigma Chemical Co Ltd, Poole, Dorset, England.
(3) Propylene oxide was obtained from BDH Chemicals Ltd, Poole, 
Dorset, England.
Tissues were excised rapidly from the animal at autopsy and slices 
0.5-1mm thick were cut using a microtome blade. These were diced 
(0.5-lmm cubes) and placed in a small jar containing 4% 
glutaraldehyde in 0.1M cacodylate buffer, pH7.4. Tissues were allowed 
to fix in this solution for 2 to 4 hours at room temperature. At the
end of the fixation time, the fixative was decanted off and the tissues 
were washed in 0.1M cacodylate buffer pH7.4 for at least 1 hour. This 
solution was then poured off and the tissues were counterfixed in 2% 
buffered osmic acid/O.lM cacodylate pH7.4 for 2 hours at room 
temperature. This procedure was carried out in a fume cupboard. The 
tissues were now charcoal black in colour and had a hard 
consistency . After the 2 hour fixation period the osmium tetroxide 
solution was pipetted off using a plastic pipette and the tissue blocks 
were dehydrated through a series of graded alcohols as described 
below. Each solution was left in contact with the tissue for at least 
10 minutes.
25% v/v Ethanol x 2 changes
50% v/v Ethanol x 2 changes
i >
75% v/v Ethanol x 2 changes
90% v/v Ethanol x 2 changes
Absolute Ethanol x 2 changes
Propylene Oxide/
Absolute Ethanol (1:1) x 2 changes
Propylene Oxide x 2 changes
The tissue blocks were then covered with a 1:1 mixture of propylene 
oxide and Epon 812 resin and left for 60 minutes. Meanwhile, capsules 
(Taab Laboratories, Reading, Berkshire, England) were filled with Epon 
812 resin. Small blocks of tissue were then transferred using a metal 
microspatula to the resin filled capsules. After two to three blocks 
had been placed in each capsule, the surface of the resin was stirred 
slightly to ensure that the blocks were not floating. The resin was
then polymerised for 48 hours at 60 °C.
(b) MOUNTING BLOCKS
The resin block was initially trimmed, then mounted into an ultra 
microtome (Reihardt-Jung, Austria). The blocks were further trimmed 
to expose the tissue and the sections were then cut using a diamond 
knife (Du Pont U.K. Ltd, Herts, England) to a thickness of 700A. The 
sections were then mounted on copper grids, and placed in a 
numbered grid box ready for counterstaining.
(c) MOUNTING GRIDS
REFERENCE: Frasca and Parks (1965) J.Cell Biol 25: 157-160 
Two stains were used:
(i) URANYL ACETATE (2%)
This was prepared daily by dissolving 0.2 grams of uranyl acetate in 
10ml H 2O water with the aid of an ultrasonicator. Before use, the 
solution was spun at 3,000rpm for 20 minutes in order to remove any 
particulate matter.
(ii) LEAD CITRATE (3%)
Lead nitrate (1.33g) and trisodium citrate (1.76g) were dissolved in 
30ml of distilled water. After 30 minutes standing, 8ml of 1M sodium 
hydroxide was added to dissolve any precipitate that had formed. The 
solution was then made up to 50ml with distilled water and centrifuged
as described for the previous stain.
In order to stain the sections, the grids were initially placed in a 
beam capsule (Taab Laboratories, Reading, Berkshire, England) 
containing 2% uranyl acetate solution, and placed in an oven at 60 °C 
for 20 minutes. After this period, grids were washed in distilled 
water, blotted on filter paper and then submerged in a bubble of lead
citrate on a petri dish. The dish was then placed on a tray
containing sodium hydroxide pellets, covered and left for 5 minutes.
After 5 minutes the grids were washed in distilled water, dried and 
stored until examined on either a Jeol 100B or a Phillips 400T electron 
microscope.
4.2.5 LIVER FRACTIONATION
REFERENCE: Based on De Duve, C. et al. (1959) Prog Biophys. Chem 9: 
325-345.
At autopsy, the liver was removed and weighed. It was then rinsed 
in an ice-cold medium of 0.25M sucrose 5mM Tris-HCl pH7.4 containing 
ImM EGTA for mitochondrial respiration studies but without the 
chelator for other biochemical studies. A known weight of tissue was 
then scissor-minced and homogenised in ice-cold medium using three 
strokes of a Potter-Elvenjhem homogeniser with the pestle rotating at 
2,000rev/min. The homogenate was then filtered through a coarse 
filter (tea-strainer) to remove unbroken tissue and diluted with 
ice-cold medium so that a 10% w/v suspension was made. This was 
then spun at 600xg in a Beckman TJ-6 centrifuge for 10 minutes to 
produce a Nuclear ("N") pellet. The supernatant was decanted off and 
spun at 10,000xg for 10 minutes in a MSE HS 18 centrifuge whilst the 
nuclear pellet was resuspended in 0.25M sucrose, 5mM Tris-HCl pH7.4. 
After the 10,000xg centrifugation, the post "ML" supernatant was 
decanted off and was spun for 1 hour at 105,000xg in a Centrikon T 
2055 (Kontron, Zurich, Switzerland) ultracentrifuge. For mitochondrial 
respiration studies the mitochondrial pellet was carefully resuspended 
using a hand held Potter-Elvenjhem homogeniser in 0.25M sucrose, 
5mM Tris-HCl, ImM EGTA (2ml/gram original tissue) and resedimented 
at 10,000xg for a further 10 minutes. After this wash, the pellet was 
finally resuspended in 0.25M sucrose, 5mM Tris-HCl without EGTA 
(0.5ml/gram original tissue) so that a uniform suspension was obtained.
FIGURE 4.1 SCHEME FOR LIVER FRACTIONATION
CELL HOMOGENATE (10%)
Centrifuge at l,000xg 
for 10 minutes
SUPERNATANT I NUCLEAR FRACTION
Resuspend in 0.25M sucrose, 5mM Tris-HCl pH7.4
Centrifuge at 10,000xg 
for 10 minutes
SUPERNATANT II MITOCHONDRIAL FRACTION
(mitochondria, peroxisomes, lysosomes)
Resuspend in 0.25M sucrose, 5mM Tris-HCl pH 7.4, ImM EGTA
Centrifuge at 105,000xg 
for 1 hour
Centrifuge at 10,000xg 
for 10 minutes
CYTOSOL
WASHED MITOCHONDRIAL FRACTION
Resuspend in 0.25M sucrose, 5mM Tris-HCl pH7.4
MICROSOMAL FRACTION
(endoplasmic reticulum, vesicles derived from 
plasma membrane and Golgi apparatus)
Resuspend in 0.25M sucrose, 5mM Tris-HCl pH7.4
Centrifuge at 105,000xg 
for 1 hour
Resuspend and store in 0.25M sucrose, 5mM Tris-HCl pH7.4, 5.4mM EDTA
This mitochondrial suspension was then ready for respiration studies. 
For other biochemical studies, the original "M L ” pellet was 
resuspended in 0.25M sucrose, 5mM Tris-HCl, pH7.4 without a wash 
step.
After 1 hour in the ultracentrifuge the post "ML" supernatant has 
separated into a supernatant (cytosol) and pellet (microsomes). The 
supernatant was decanted off and the pellet was resuspended in 0.25M 
sucrose, 5mM Tris-HCl pH7.4. Marker enzyme (Section 4.2.6) activities 
were then determined for all fractions (i.e. homogenate, nuclear, 
mitochondrial, microsomal, cytosol).
For cytochrome P450 studies resuspended microsomes were washed by 
centrifugation at 105,000xg for a further hour in the Centrikon 
ultracentrifuge. The supernatant was then decanted off and the pellet 
was resuspended in 0.25M sucrose, 5mM Tris-HCl pH7.4 containing 
5.4mM EDTA. This was then aliquoted into 1ml alpha vials (Alpha 
Laboratories, Eastleigh, Hampshire, England) and stored at -80°C until 
analysis. This liver fractionation scheme is summarised in Figure 4.1.
4.2.6 MARKER ENZYMES
(a) MITOCHONDRIAL ENZYMES
(i) SUCCINATE DEHYDROGENASE
REFERENCE: Pennington, R. (1981) Biochem J. 80: 649-654 
METHOD
On the day of the assay, 2-(p-iodophenyl)-3-(p-nitrophenyl) - 5
phenyltetrazolium chloride (I.N.T) was dissolved in 0.3M sodium 
phosphate solution, pH7.4 to give a concentration of 1.5mg/ml. Glass 
test tubes were set up in duplicate as follows.
0.5ml Tissue sample
0.25ml 0.3M sodium succinate pH7.4
0.25ml I.N.T in 0.3M phosphate buffer pH7.4
Blank
0.5ml Tissue sample
0.25ml 0.3M sodium malonate pH7.4
0.25ml I.N.T in 0.3M phosphate buffer pH7.4
The tubes were mixed on a Whirlymixer (Fisons Ltd, UK) and incubated 
at 37 °C for between 5 and 20 minutes until a red colour was visible. 
The reaction was then stopped by the addition of 1.5ml of 6% T.C.A. ( 
At this stage the tubes could be stored frozen at -20 °C for up to 7 
days). After the reaction was stopped, 4ml of ethyl acetate was added 
to each tube. The tubes were covered with a piece of polythene sheet 
and shaken to extract the red colour into the ethyl acetate. The tubes 
were then centrifuged for 5 minutes at l,500xg and the upper red 
layer was carefully transferred to a glass spectrophotometer cuvette. 
Absorbances were then measured at 490nm on a Perkin-Elmer Lambda 
5 recording spectrophotometer and the enzyme activity was calculated 
using the molar extinction coefficient of 20.1 x 103.
(ii) MONOAMINE OXIDASE
REFERENCE: Based on that of Norris (1973) PhD Thesis University of 
Surrey, England.
METHOD
Duplicate tubes containing 200pl of tissue sample, 800pl of 0.2M sodium 
phosphate buffer pH7.4 and 500pl of kynureihine dihydrobromide 
(100pg/ml) were set up. Blank samples containing distilled water
instead of tissue samples were also set up. Tubes were incubated for 
30 minutes in a shaking water bath and stopped by the addition of 
lml of 0.5M perchloric acid. The tubes were then centrifuged at 
l,500xg for 5 minutes and lml of the supernatant was added to 2ml of 
1M sodium hydroxide. The fluorescence was measured immediately with 
the emission wavelength set at 380nm and the excitation wavelength of 
315nm.
A standard curve was set up by diluting a stock solution of 10pM 
4-hydroxyquinoline with distilled water to produce a range of 
concentrations, lml of these was added to 2ml of 1M sodium hydroxide 
and the fluorescence measured as above. Monoamine oxidase activity 
was then expressed as the amount of 4-hydroxyquinoline produced per 
minute per mg protein.
(iii) CYTOCHROME C OXIDASE
REFERENCE: Errede, B. et al. (1978) Methods Enzymol. 53: 40-45 
REAGENTS
(1) BUFFER
40mM Tris-HCl, 0.1M Sodium Cacodylate, 10pM Sodium EDTA, pH6.0
(2) 2mM CYTOCHROME C
Cytochrome C was diluted in buffer to give a final concentration of 
2mM. To this was added a dilute solution of sodium dithionite until a 
brilliant red colour appeared. To remove the excess reductant the 
solution was passed down a sephadex G-25 column (Pharmacia, Uppsala, 
Sweden).
METHOD
To a plastic microcuvette (Hughes and Hughes Ltd, Romford, Essex, 
England), 1.3ml of buffer and lOOpl of cytochrome C were added. This 
acted as the reference cuvette. The test cuvette contained 1.3ml of 
buffer, lOOpl of reduced cytochrome C and lOpl of fresh tissue sample.
The cuvettes were then placed into the sample and reference sides of 
a Lambda 5 recording spectrophotometer and the change in absorbance 
was followed at 550nm for 5 minutes. The activity was then calculated 
using the E red-ox of lS.TnM^cm-1.
(b) LYSOSOMAL ENZYMES
(i) ACID PHOSPHATASE (SODIUM 13 GLYCEROPHOSPHATE PROCEDURE) 
REFERENCE: Dobrota et al. (1979) Eur. J. Biol. 19: 139-144 
METHOD
LP4 tubes (Luckham Ltd, Burgess Hill, Sussex, England) were set up 
in duplicate containing 0.5ml of tissue sample 0.3ml of 0.3M sodium 
acetate buffer pH5.0 and 0.1ml 0.016% (w/v) digitonin. These were all 
mixed and 0.1ml of 1M sodium 13 glycerophosphate pH5.0 was added. In 
addition, blanks as described below were set up.
Substrate Blank 
0.5ml Distilled water 
0.4ml Buffer 
0.1ml Sample
Tissue Blank 
0.5ml Tissue Sample 
0.4ml Buffer 
0.1ml Distilled water
Reagent Blank 
0.6ml Distilled water 
0.4ml Buffer
Both test and substrate blank tubes were incubated for approximately 
30 minutes at 37 °C in a shaking bath. The reaction was then stopped 
by the addition of 1.5ml of ice-cold trichloroacetic acid (TCA) and then 
the tubes were centrifuged at 2,000rpm for 5 minutes to remove the 
precipitated proteins. The inorganic phosphate in each tube was then 
estimated using a Technicon autoanalyser (Section 4.2.7) and the 
enzyme activity was calculated using the equation:
Activity = (E X P - T B )-(S B - R B ) pmoles/min/ml
incubation time (mins) x U . b
Where:
EXP is amount of phosphate in the experimental tube (pmoles)
TB is amount of phosphate in the tissue blank (pmoles)
SB is amount of phosphate in the substrate blank (pmoles)
RB is the amount of phosphate in the reagent blank (jimoles)
(ii) ACID PHOSPHATASE (p-Nitrophenylphosphate procedure)
REFERENCE: Manual adaption of Hinton,R and Norris, K (1972)
Anal.Biochem.348 : 247-258 
METHOD
LP4 tubes were set up in duplicate containing 0.5ml of tissue sample,
0.3ml of 0.3M sodium acetate buffer, pH5.0 and 0.1ml of 0.016% (w/v) 
digitonin. These were all mixed and 0.1ml of 50mM pNPphosphate was 
added. In addition, substrate and tissue blanks were constructed as 
previously described in Section 4.2.6b(i).
Both test and control tubes were then incubated at 378 C for approx. 10 
minutes in a shaking water bath. The reaction was then stopped with 
1.5ml of 0.1M NaOH and the amounts of p-nitrophenol released in each 
tube was measured at 400nm on a Lambda 5 recording
spectrophotometer using a standard curve constructed from a 
p-nitrophenol stock solution. The results were then calculated and 
expressed as yg p-nitrophenol released min-1 m g  protein -1
(iii) (3-GALACTOSIDASE
REFERENCE: Manual adaption of Hinton,R and Norris,K (1972) Anal. 
Biochem.348: 247-258.
METHOD
The method used was exactly as described in Section 4.2.6b(ii) except 
that pNP-Galactoside (5mM) was used as the substrate.
(c) PLASMA M E M B R A N E  ENZYMES 
(i) 5’NUCLEOTIDASE. (AMPase)
REFERENCE: Prospero, T. et al. (1973) Biochem J 132: 44<?-458 
METHOD
LP4 tubes were set up in duplicate containing 0.5ml of tissue sample 
and 0.4ml of 0.2M Tris-HCl containing 12mM MgCl2 and 25mM Na(+) 
tartrate pH7.7. These were mixed and 0.1ml of 0.05M adenosine 
monophosphate was added. Tissue, substrate and reagent blanks were 
set up according to the scheme set out in 4.2.6b(i). Both test and 
blank tubes were incubated for approximately 30 mins at 37 °C in a 
shaking water bath. The reaction was then stopped by addition of 
1.5ml of ice-cold 6% TCA and the tubes were centrifuged at 2000rpm 
for 5 mins to precipitate proteins. The inorganic phosphate present in 
each tube was then estimated using a technicon autoanalyser (Section 
4.2.7) and the enzyme activity was calculated using the equation :
Activity = (EXP-TB)-(SB-RB) pmoles/min/ml
incubation time (mins) x U .5
Where:
EXP is amount of phosphate in the experimental tube (pmoles)
TB is amount of phosphate in the tissue blank (pmoles)
SB is amount of phosphate in the substrate blank (pmoles)
RB is the amount of phosphate in the reagent blank (pmoles)
(d) ENDOPLASMIC RETICULUM ENZYMES
(i) Glucose-6-phosphatase.
REFERENCE: Prospero, T. et al. (1973) Advances with Zonal Rotors 
(Reid E Ed) 171-186 Longman, London.
METHOD
LP3 tubes were set up in duplicate containing 0.5ml of tissue sample
and 0.4ml of 0.3M dimethylglutarate containing 25mM EDTA and 25mM
sodium tartrate pH6.5. These tubes were all mixed and 0.1ml of 0.05M 
glucose-6-phosphate was added. Tissue, substrate and reagent blanks 
were set up according to the scheme set out in Section 4.2.6.b(i). Both 
test and blank tubes were incubated for approximately 30 minutes in a 
shaking water bath. The reaction was stopped by addition of 1.5ml of 
ice-cold TCA and the tubes were centrifuged at 2000rpm for 5 mins to 
precipitate proteins. The inorganic phosphate present in each tube 
was then estimated using a technicon autoanalyser (Section 4.2.7.) and 
the enzyme activity was calculated using the equation:
Activity = ( EXP-TB ) - ( SB-RB )_______  pmoles/min/ml
incubation time I mins) x U.o
Where:
EXP is amount of phosphate in the experimental tube (pmoles)
TB is amount of phosphate in the tissue blank (pmoles)
SB is amount of phosphate in the substrate blank (pmoles)
RB is the amount of phosphate in the reagent blank (pmoles)
(ii) CYTOCHROME P450
REFERENCE: Omura, T. and Sato, R. (1964), Journal of Biological
Chemistry 239: 279-285.
METHOD
0.3ml of liver microsomes was diluted in 2.7ml of 66mM Tris-HCl buffer 
pH7.4. The solution was mixed and a few crystals of sodium dithioniite 
were added to reduce the cytochrome suspension. The solution was 
mixed by inversion and divided equally between two cuvettes and 
scanned from 500nm to 400nm in a Perkin-Elmer Lambda 5 recording 
spectrophotometer to obtain a base-line. Carbon monoxide (BOC Ltd) 
was bubbled through the sample cuvette for 30 seconds. The sample 
was then rescanned and a difference spectrum of cytochrome P-450 was 
obtained. The amount of cytochrome P-450 present in the sample was 
then calculated using the peak absorbance at 450nm minus the 
absorbance at 490nm.
(e) PEROXISOMAL ENZYMES 
(i) CATALASE
REFERENCE: Chantrenne, H. (1955) Biochem Biophys Acta 16: 410-417. 
Automated Method by Leighton, F. et al. (1968) J. Cell Biol 37: 482-513. 
REAGENT:
(1) Titanium Oxysulphate.
To 82.5ml of 15% Ti(S04)2 (BDH Chemicals Ltd, Poole, Dorset, England) 
was added 43ml of concentrated sulphuric acid. Distilled water was 
then added to a final volume of 1 litre. This solution was then boiled 
for 30 minutes, cooled and filtered several times.
AUTOMATED METHOD
The autoanalyser (Technicon Instruments Ltd, New York, USA) was set 
up as in Figure 4.2 and the wavelength of the colorimeter was set to 
402nm. All feed lines were immersed in a beaker containing 0.05% 
BRIJ-35 (polyoxyethylene-23-lauryl ether) and the pump was turned on 
for at least 10 minutes to wash the lines. After 10 minutes washing 
the feed lines were placed in their respective solutions, i.e. 1% triton 
in 2% NaCl containing 0.33% Bovine serum albumin, titanium oxy sulphate 
diluted 16 fold, and BRIJ-35 wash. The substrate line was placed in a 
beaker containing 0.033M Imidazole buffer pH7.0 and a base line was 
set at 95% transmission and allowed to stabilise. Once stabilised 0.3ml 
of 30% H 2O2 were pipetted into the substrate beaker and a new base 
line was established between 10% and 20% transmission. (If the base 
line fell outside this range an appropriate adjustment to the 
concentration of hydrogen peroxide was made.) Tissue samples were 
then pipetted into plastic autoanalyser cups (Henleys Medical Supplies 
Ltd, London, England) and placed into the autoanalyser in sequence 
and separated with wash cups containing BRIJ-35.
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The sampler was then started after setting the sample time of at least 
1 minute 12 seconds and a wash time of 48 seconds. Catalase follows 
first order kinetics and so the activity can be described by the 
following equation.
Activity = log(A2-Ai)-log(A3-Ai)
Where Ai = Absorbance of base line in absence of H 2O 2 
Where A 2 = Absorbance of base line in absence of H 2O2 
Where A 3 = Absorbance obtained with sample
Units are arbitrary and depend upon details of the manifold used. 
MANUAL METHOD
If the number of samples to be analysed is limited it is often more 
convenient to assay the enzyme manually. For this a cuvette was set 
up containing 0.1ml of distilled water, 0.8ml of Triton/BSA/NaCl and 
1.6ml of Imidazole buffer pH7.0. To this was added 3.9ml of Titanium 
oxysulphate and the absorbance was measured at 400nm on a 
Perkin-Elmer Lambda 5 spectrophotometer against a water blank. 
(This absorbance represented the base line in the absence of H2O2.) 
70pl of 60% hydrogen peroxide (H2O2) were then added to a beaker 
containing 200ml of Imidazole buffer pH7.0 and 1.6ml of this was added 
to a cuvette containing 0.1ml of distilled water and 0.8ml of 
Triton/BSA/saline. 3.9ml of Titanium oxysulphate were then added and 
the absorbance at 400nm was again measured. (This absorbance 
represented the base line in the presence of H2O 2.)
Cuvettes were then set up containing 0.1ml of tissue sample, 0.8ml of 
Triton/BSA/saline and were incubated for various times up to 6 
minutes at 25 °C before the reaction was stopped and the colour was 
developed by the addition of 3.9ml Titanium oxysulphate.
The absorbances were then measured at 400nm and the incubation time 
which produced a suitable reduction in absorbance compared to the 
value obtained for the baseline in the presence of H 2O 2 was 
determined. All subsequent determinations were carried out using this 
incubation time and the activity of catalase was calculated as 
described previously.
(i) URICASE
REFERENCE: Beaufay, H. et al. (1959) Biochem J. 73: 628-637 
METHOD
A substrate solution of uric acid was prepared by dissolving 7.6mg of 
uric acid in 100ml of 0.1M phosphate buffer pH7.4. Once dissolved, 
Triton X-100 (0.3ml) was added. A blank diluent solution was 
prepared by the addition of 0.3ml of Triton X-100 with 100ml of 0.1M 
phosphate buffer pH7.4. The substrate and blank diluent solutions 
were equilibrated at 37 *C. Then into two test tubes labelled "TEST" 
and "BLANK” lml of the sample was pipetted. These were also 
equilibrated at 37 °C and lml of a 5mM phosphate buffer pH7.4 was 
added, lml of substrate and lml of blank solution were added to the 
TEST and BLANK tubes respectively. These were then transferred to 
silica cuvettes and the cuvette containing the test solution was placed 
in the test side, whilst the blank cuvette was placed in the reference 
side of a Perkin-Elmer Lambda 5 double beam recording 
spectrophotometer with a constant temperature sample block maintained 
at 37 #C. The change in absorbance was then measured at 292.5nm for 
at least 4 minutes. The activity was then calculated using the molar 
extinction coefficient of 12.2.
(ii) PALMITOYL COA OXIDATION
REFERENCE: Bronfman, M. et al. (1979) Biochem Biophys Res Comm
88: 1030-1036
METHOD
2ml of a cocktail containing palmitoyl COA (75pM), Coenzyme A (75pM), 
FAD (180pM), NAD* (555pM), nicotinamide (141nM) dithiothreitol (4.2mM) 
KCN (3mM) and bovine serum albumin (0.225mg/ml) dissolved in 60mM 
Tris-HCl pH8.3 were pipetted into an LP4 tube (Luckhams Ltd, Burgess 
Hill, Sussex, England). To this was added 0.96ml of 60mM Tris-HCl 
pH8.3 and the tube was equilibrated at 37 °C for 5-10 minutes. 50pl of 
tissue sample was then pipetted into an LP3 tube containing 50pl of 1% 
(w/v) Triton X-100 dissolved in 60mM Tris-HCl pH8.3. 40pl of this 
sample:triton mixture was then added to the LP4 tube containing the 
cocktail mixture. This was then mixed on a Whirlymixer and carefully 
transferred to a spectrophotometer cuvette. 20pl of palmitoyl COA 
(7.7mg in lml of Tris-HCl pH7.4) was then added to the test cuvette to 
initiate the reaction. The cuvette was placed in a Perkin-Elmer 
Lambda 5 dual beam recording spectrophotometer and the absorbance 
change was measured for at least 10 minutes at 340nm using an air 
blank. The results are expressed as pMol NAD* reduced minute-1 mg 
protein-1 assuming the molar absorbance of NADH at 340nm is 6.22 x 
103.
4.2.7 ESTIMATION OF INORGANIC PHOSPHATE USING AN AUTOANALYSER 
REFERENCE: Adaptation of procedure of Lowry, O. and Lopez, J. (1946)
J. Biol. Chem 162: 141-145 to the Autoanalyser by Marzban, M. and 
Hinton, R. (1970) Eur. J. Biochem 12: 360-361.
REAGENT:
(1) Molybdate Reagent
6g of ammonium molybdate was dissolved in 500ml of distilled water. 
54ml of 60% (w/v) perchloric acid were added and the volume was 
made up to 1,000ml.
METHOD
Standards ranging from 0.1-2pmoles/ml were prepared from a 2pmole/ml 
stock solution of phosphate (KH2PO4). The autoanalyser was then set 
up according to Figure 4.3 and the feed lines were placed in beakers 
containing molybdate reagent, 0.2% ascorbic acid (made fresh on the 
day of assay), 4% Trichloroacteic acid (TCA) wash, and distilled water. 
The colorimeter was set to 721nm and a sample time of 48 seconds with 
a wash time of 36 seconds were loaded. The base line was then set at 
95% and the solutions allowed to run through for at least 10 minutes 
to ensure that a steady baseline had been established. The 
autoanalyser was loaded up with the standards in pairs and the 
experimental samples in groups of 10. Between each set of standards 
and samples was placed a wash cap containing 4% TCA. The results 
obtained from the autoanalyser are in % transmissions. The amount of 
phosphate present in each sample was calculated as follows.
(i) The absorbance (2-logioT) was calculated for the base line, and 
each standard.
(ii) A curve of absorbance against amount of phosphate was plotted 
using the standards. This was used to determine the amount of 
phosphate present in each sample.
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4.2.8 ESTIMATION OF PROTEIN CONCENTRATIONS
(i) AUTOMATED LOWRY METHOD
REFERENCE: Lowry, p. et al. (1951) J. Biol Chem 193: 265-275 adapted 
for use on autoanalysers by Hinton, R. and Norris, K. (1972) Anal 
Biochem 48: 247-258.
REAGENTS
(1) LOWRY BUFFER
Sodium hydrogen carbonate (84g) and sodium hydroxide (25g) were 
dissolved in 1,000ml of distilled water.
(2) COPPER TARTRATE
Copper sulphate (0.1% w/v) and sodium tartrate (0.2% w/v) were added 
in equal proportions of 10ml and then made up to a volume of 100ml.
(3) FOLIN AND CIOCALTEAU REAGENT
(BDH Chemicals Ltd, Poole, Dorset, England) was diluted in the 
proportion 1 in 3 with distilled water.
METHOD
A stock solution of Bovine solution albumin (2mg/ml) was diluted to 
give a range of standards between 0.1-2mg/ml. The autoanalyser was 
set up according to Figure 4.4 and the feed lines were placed in 
beakers containing Lowry buffer, copper tartrate, Folin reagent, 
sodium hydroxide (0.66N) and distilled water. The colorimeter was set 
to 721nm and a sample time of 1 minute with a wash time of 36 
seconds were loaded. The base line was set at 95% and the solutions 
run through for at least 10 minutes to ensure that a steady base line 
had been established. The autoanalyser was loaded up with the 
standards in pairs and the experimental samples in groups of 10. 
Between each set of standards and samples was placed a water wash. 
The results were presented as % transmission and this was converted
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to absorbance units using the formula (2-logioT). A standard curve
was prepared and the amount of protein present in the samples
(mg/ml) was determined.
(ii) MANUAL LOWRY METHOD
REFERENCE: Adaptation of Lowry, 0. et al. (1951) J. Biol Chem 193: 265. 
REAGENTS
(1) Sodium Carbonate (3% in 0.1M NaOH)
(2) Copper Tartrate
0.4ml of 4% sodium potassium tartrate was added to 0.92ml of reagent 
(1). 0.4ml of copper sulphate was then added. This reagent was
prepared fresh just prior to assay.
(3) Folin and Ciocalteau Reagent
This was diluted in the proportion 1 in 3 with diluted water.
METHOD
A standard curve ranging from 0.1 to 2.0mg/ml was prepared from 
2mg/ml stock BSA. Tubes were prepared in duplicate containing lOpl 
of tissue sample diluted with 290pl of distilled water. 300pl of sodium 
carbonate (3% in NaOH) followed by 2ml of copper tartrate were added 
to each tube which were then left for 10 minutes at room temperature. 
Each tube was then vortex mixed and 200jil of diluted Folin reagent 
were added. Tubes were again vortex mixed and left a further 10 
minutes before the absorbances were measured at 660nm in 3ml plastic 
cuvettes. The amount of protein in each sample was determined by 
reference to the standard curve.
(iii) BIORAD METHOD
REFERENCE: Bradford, M. (1969) Anal Biochem 72: 248-254 
METHOD
Biorad Dye reagent (Bio-Rad Laboratories, Munich, West Germany) was 
diluted 1 in 5 with distilled water. This was then filtered to remove 
particulate matter. Duplicate tubes were set up containing 3.5ml of 
diluted Biorad Dye and 0.1ml of diluted tissue samples and BSA 
standards ranging from 0.1 to 2mg/ml were added. These were mixed 
on a vortex mixer and absorbances were measured at 595nm against a 
water reference. The protein concentration of the tissue samples was 
then determined using the standard curve.
4.2.9 ESTIMATION OF S E R U M  ENZYMES
(i) SERUM ALKALINE PHOSPHATASE
REFERENCE: Bessey O. et al. (1946) J. Biol Chem 164: 321.
METHOD
Blood was collected as described in Section 4.2.2 and was immediately 
placed in a container of cracked ice. Serum was separated from the 
clot by centrifugation at 2,000xg for 5 minutes at 4°C. The assay was 
then carried out using a Sigma Diagnostics kit (N°104). Duplicate 
tubes were set up containing 0.25ml of alkaline buffer solution (2 
amino-2-methyl 1-propanol, 1.5mM, pH10.3) and 0.25ml of p-nitrophenol 
phosphate substrate solution (40mg/10ml distilled water). These were 
placed in a 37 eC water bath to equilibrate and 50pl of distilled water 
was pipetted into the tubes labelled BLANK whilst 50pl of serum was 
pipetted into the tubes labelled TEST. These were mixed gently and 
replaced into the water bath. After exactly 15 minutes, 5ml of 0.05M 
NaOH was added to each tube which were mixed by inversion.
The absorbance of each tube was then measured at 410nm using the 
BLANKS as reference. 0.1ml of c.HCl was then added to each tube 
(acid removes colour due to p-nitrophenol leaving absorbance due to 
serum) and the absorbance of TEST using the BLANK as reference was 
again determined at 410nm. A range of standards was constructed 
from a p-nitrophenol standard solution (lOpM). Sodium hydroxide 
(0.02M) was added to develop the colour and absorbances were 
measured at 410nm using the 0.02M sodium hydroxide as reference. 
Using the standard curve, corrected serum alkaline phosphatase 
activities (International Units) were calculated by substrating the 
alkaline phosphatase activity in the presence of acid from that in the 
absence of acid.
(ii) BLOOD UREA NITROGEN
REFERENCE: Chaney, A. and Mar bank, E. (1962) Clin Chem 8: 130.
METHOD
Blood was collected and serum prepared as in Section 4.2.9(i). The 
assay was then carried out using a Sigma Diagnostics (N°640). Tubes 
were set up in duplicate and were labelled "BLANK", "STANDARD", 
"TEST 1”, "TEST 2", etc. To each tube was added 0.5ml of urease 
solution (10 units of Jack Bean urease/30ml distilled water) and the 
tubes were immersed in a water bath at 37 °C for 5-10 minutes. lOpl of 
distilled water was then added to the BLANK tubes, whilst lOpl of Urea 
Nitrogen standard solution (10.7mmol/l,000ml) was added to the 
STANDARD tubes and lOpl of serum was added to the tubes labelled 
TEST.
Tubes were then placed into the water bath for 5-10 minutes while the 
urea was hydrolysed to ammonia, lml of Phenol Nitroprusside solution 
(50g/l,000ml) followed by lml of alkaline Hypochloride (0.2% sodium 
hyprochlorite) and 5ml of distilled water were added to each tube.
The colour was then allowed to develop by leaving at room 
temperature for 20-30 minutes and the absorbances of TESTS and 
STANDARD were measured at 570nm using the BLANK as reference. 
Results were then calculated using a standard curve made from a 
150mg/dl stock Urea Nitrogen standard solution or using the equation 
below.
Serum Urea N (mg/dl) = Absorbance TEST x 30
Absorbance Standard
(iii) SERUM CREATININE
REFERENCE: Heinegard, D. and Tiderstrom, G. (1973) Clin. Chem. Acta 
43: 305.
METHOD
Blood was collected and serum prepared as in Section 4.2.9(i). The 
assay was then carried out using a Sigma Diagnostics kit (N°555). 
Duplicate cuvettes were set up labelled "BLANK", "STANDARD" and 
"TEST". 0.3ml of distilled water was added to the BLANK whilst 0.3ml 
- of Creatinine standard (0.26mM Creatinine in 0.2M hydrochloric acid) 
was added to the STANDARD cuvette and 0.3ml serum was added to the 
TEST cuvettes. 3ml of alkaline picrate solution (50ml Creatinine colour 
reagent plus 10ml 1M sodium hydroxide) was added to each cuvette 
which were then mixed by inversion and allowed to stand at room 
temperature for 10 minutes. The absorbances of TEST and STANDARD 
were then measured at 500nm against the BLANK. 0.1ml of acid 
reagent (a mixture of sulphuric and acetic acids) was then added to 
all cuvettes which were mixed and left for 5 minutes at room 
temperature. The absorbances of TEST and STANDARD were then 
measured again against the BLANK at the same wavelength used for 
the initial readings.
The concentration of Creatinine was then calculated using the 
equation:
Creatinine (md/dl) =
x______ fAbs. Test (-Acid)] - TAbs. Test (+Acid)1 ,
[Abs. Standard (-Acid)] - [A b s . Standard i+Acid)]
Prior to each run the limit of linearity of the instrument-cuvette 
system used was checked by construction of a standard curve 
prepared from a Creatinine stock solution (15mg/dl).
(iv) S E R U M  TRANSAMINASES
REFERENCE: Reitman, S. and Frankel, S. (1957) Am. J. Clin Pathol 
28: 56.
(a) ASPARTATE AMINOTRANSFERASE (GOT)
METHOD
Blood was collected and serum prepared as described in Section 
4.2.9(i). The assay was then carried out using Sigma Diagnostics kit 
(N°505). Duplicate test tubes were set up containing lml of Sigma
prepared substrate (DL-Aspartate, 0.2M and a ketoglutaric acid, 1.8mM 
in phosphate buffer, pH7.5)
0.2ml of serum was then added and the tubes were shaken gently 
before being placed in a water bath at 37 °C. Exactly 1 hour after 
adding serum, lml of Sigma colour reagent (20mg/dl 
2,4-Dinitrophenylhydrazine in acid solution) was added, the tubes were 
shaken and left at room temperature for 20 minutes. After 20 minutes, 
10ml of 0.4M sodium hydroxide was added and the tubes were mixed 
by inversion before the absorbances were measured at 505nm using a 
water blank as reference.
GOT activity was then determined from a standard curve constructed 
from a calibration solution (sodium pyruvate 1.5mM in phosphate 
buffer, pH7.5). Serum blanks were prepared by setting up test tubes
containing lml of substrate and lml of colour reagent to which 0.2ml 
of serum was added. These were incubated for 20 minutes at 25 °C and 
then 10ml of 0.4M sodium hydroxide was added and the absorbances 
measured at 505nm against a water reference.
(b) ALANINE AMINOTRANSFERASE (GPT)
METHOD
Blood was collected and serum prepared as described in Section 
4.2.9(i). The assay was then carried out using Sigma Diagnostics kit 
(N°505). Duplicate test tubes were set up containing lml of Sigma 
prepared substrate (DL-Alanine 0.2M and a ketoglutaric acid 1.8mM in 
phosphate buffer, pH7.5).
0.2ml of serum was added and the tubes were shaken gently before 
being placed in a water bath at 37 °C. Exactly 30 minutes later, lml of 
Sigma colour reagent was added and the tubes were left at room 
temperature for 20 minutes. 10ml of 0.4M sodium hydroxide was then 
added and the tubes were mixed by inversion before the absorbances 
were measured at 505nm using a water blank as reference. GPT 
activity was then determined from a standard curve constructed from 
a calibrated solution (sodium pyruvate 1.5mM in phosphate buffer, 
pH7,5) and serum blanks were constructed as described for GOT.
4.2.10 DISACCHARIDASE ACTIVITY IN RAT JEJUNAL M UCOSA  
REFERENCE: Based on method of Dahlqvist, A. (1968) Anal. Biochem 
22: 99.
REAGENTS
(1) 0.1M MALEATE BUFFER, pH6.14
O.IM sodium maleate and 0.1M maleic acid were mixed to give the 
required pH. (This required about twice as much sodium maleate as 
maleic acid.)
(2) SUCRASE SUBSTRATE BUFFER, pH6.14 (0.028M)
0.48g of anhydrous sucrose were dissolved in O.IM maleate buffer 
pH6.14 and made up to 50ml with buffer.
(3) TREHALASE SUBSTRATE BUFFER, pH6.14 (0.028M)
0.529g of D(+) Treholase dihydrate was dissolved in O.IM maleate 
buffer pH6.14 and made up to 50ml with buffer.
METHOD
Rat jejenum was removed at autopsy and food remnants removed by 
washing with 0.9% sodium chloride solution. The intestine was then 
stored at -18° C until required for analysis. On the day of the assay 
the intestines were thawed and opened up to expose the mucosa. This 
was then scraped off using a microscope slide and homogenised in an 
Ultra-Turrax (Janke and Kunkel) with an appropriate amount of 0.9% 
saline. (The mucosal preparation was kept on ice during the 
homogenisation.) Cell debris was then removed by centrifugation at 
2000xg for 10 minutes. Glass microtubes were labelled "TEST" and 
"BLANK" for each of the trehalase and sucrase and 25pl of the 
appropriate substrate was added. The BLANK tubes were then sealed 
whilst 25pl of the supernatant from the homogenate (diluted 1 in 5 with 
saline for trehalase and 1 in 3 for sucrase) were added to the 
appropriate TEST tubes. All tubes were then mixed and incubated at 
37#C for 1 hour in a shaking water bath. After 1 hour the tubes were 
removed and 25pl of the diluted supernatants was added to the
In order to determine how intact the mitochondria were (i.e. how 
tightly coupled respiration was to ATP synthesis), the respiratory 
control ratio (RCR) was determined for each mitochondrial preparation. 
This was calculated using the equation:
RCR = rate state III respiration 
rate state IV respiration
4.2.12 EMESIS TESTING IN FERRETS
(i) ANIMALS AND MANAGEMENT
Male and female polecat ferrets weighing approximately 1kg were 
singly housed with sawdust bedding. Food and water was allowed ad 
libitum and 12 hour dark, 12 hour light photoperiod from between 8am 
to 8pm was maintained. On receipt animals were inspected, weighed 
and then allowed a period of at least 7 days to acclimatise prior to 
the commencement of the experiment.
(ii) ADMINISTRATION OF TEST COMPOUNDS.
(a) INTRAVENOUS ADMINISTRATION
Three male ferrets were given an intravenous dose of 6mg/kg cisplatin 
in a dose volume of 3mls/kg of sterile 0.9% saline. The tails were 
shaved and the animals were placed in a box heated by two 60w light 
bulbs, to facilitate peripheral vasodilation prior to intravenous 
administration of compounds into the lateral tail vein.
(b) ORAL ADMINISTRATION
Six male and six female ferrets were randomly allocated to one of two 
groups and given an oral dose of either cisplatin or carboplatin. The 
initial dose was 50mg/kg cisplatin and 200mg/kg carboplatin suspended 
in a dose volume of lOmls/kg of 1.25% tragacanth, after which the 
animals were observed as described below for up to 14 days. Because 
of the clinical condition of the animals after these dose levels, lower
doses were subsequently used.
(iii) CLINICAL OBSERVATIONS
On the morning when the test compounds were to be administered the 
animals were weighed and food withdrawn. After administration of 
either an oral or intravenous dose the animals were observed 
continuously for 3 hours for signs of reaction to the treatment. If 
after this time continuing monitoring appeared unnecessary, the food 
was replaced and hourly inspections were performed for up to 12 
hours. Thereafter animals were examined twice daily for the next 13 
days. Written records of individual animal emetic reactions, including 
time after dosing, were made. If an interval of less than 60 seconds 
occurred between reactions, these two reactions were recorded as one 
single event. For autopsy, animals were given an overdose of sodium 
pentabarbitone and samples of stomach, liver and kidney were 
processed for histopathology as described in Section 4.2.3.
4.2.13 HAEMATOLOGY
(i) PREPARATION OF BLOOD FILM
Blood removed from the vena cava at autopsy was carefully placed 
into a 1ml EDTA pot (Teklab Ltd, Sacriston, Durham, England). Pots 
were then placed on a rotary mixer until blood was required for 
analysis. To prepare a blood film, a small drop of blood was placed in 
the centre line of a glass slide about l-2cm from one end. Another 
clean slide was used as a spreader. This spreader was placed at an 
angle of 45° to the slide on which the blood drop was placed. With; 
care the spreader was moved back to make contact with the blood 
drop. The drop was then spread out into a film 3-4cm in length by a 
smooth forward movement of the spreader.
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FIGURE 4.5
DISTRIBUTION OF PROTEIN AND MARKER 
ENZYMES IN MITOCHONDRIAL FRACTION 
OBTAINED FROM DIFFERENTIAL CENTRIFUGATION 
OF RAT LIVER HOMOGENATE
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FIGURE 4.6
ELECTRON MICROGRAPH OF MITOCHONDRIAL PELLET FIXED IN 4% 
GLUTARALDEHYDE BUFFERED WITH 0.1M SODIUM CACODYLATE pH 7.4, 
AND COUNTER FIXED IN 2% OSMIUM TETROXIDE BUFFERED WITH 0 . 1M 
SODIUM CACODYLATE pH 7.4
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l p M .
heart (kindly donated by G.Hartman, Biochemistry Dept, University of 
Surrey, England).
Sub-mitochondrial particles readily oxidise NADH. Addition of 10pl
aliquots of lOm M  N A D H  to incubation medium containing
sub-mitochondrial particles (7-8mg protein) gave an average daily
deflection X (millimetres of chart paper) equivalent to O.lpmol NADH:
i.e. X(mm) = 0.1 x 10‘6 mol NADH.
since 1 mol O 2 = 2mol NADH.
so: 1mm chart deflection = 0.05 x 10~6 mol O2
X '
Mitochondrial respiration was measured using D,L-(3“Hydroxybutyric
acid (20mM) and sodium succinate (20mM) as substrates. All incubations
were carried out at 25° C; each incubation containing 3-5mg of
mitochondrial protein in a total volume of 2ml of incubation medium.
Incubation medium
120mM KC1
2mM KH2PO4
ImM EGTA
5mM Tris-HCl pH7.4
Mitochondria were pre-incubated in buffer for 2 minutes and then 
reactions were started by the addition of substrate (state IV 
respiration). State IV respiration was recorded for 2 minutes, then a 
k n own amount of ADP (25mM) was added. This stimulated the 
respiration to give state III. After the ADP was used up the 
respiration returned to state IV. State III and IV respiration rates 
were then calculated as n.atoms oxygen/min/mg mitochondrial protein,
doses were subsequently used.
(iii) CLINICAL OBSERVATIONS
On the morning when the test compounds were to be administered the 
animals were weighed and food withdrawn. After administration of 
either an oral or intravenous dose the animals were observed 
continuously for 3 hours for signs of reaction to the treatment. If 
after this time continuing monitoring appeared unnecessary, the food 
was replaced and hourly inspections were performed for up to 12 
hours. Thereafter animals were examined twice daily for the next 13 
days. Written records of individual animal emetic reactions, including 
time after dosing, were made. If an interval of less than 60 seconds 
occurred between reactions, these two reactions were recorded as one 
single event. For autopsy, animals were given an overdose of sodium 
pentabarbitone and samples of stomach, liver and kidney were 
processed for histopathology as described in Section 4.2.3.
4.2.13 HAEMATOLOGY
(i) PREPARATION OF BLOOD FILM
Blood removed from the vena cava at autopsy was carefully placed 
into a 1ml EDTA pot (Teklab Ltd, Sacriston, Durham, England). Pots 
were then placed on a rotary mixer until blood was re<" aired for 
analysis. To prepare a blood film, a small drop of blood was placed in 
the centre line of a glass slide about l~2cm from one end. Another 
clean slide was used as a spreader. This spreader was placed at an 
angle of 456 to the slide on which the blood drop was placed. With 
care the spreader was moved back to make contact with the blood 
drop. The drop was then spread out into a film 3-4cm in length by a 
smooth forward movement of the spreader.
(ii) P R O C E D U R E  F O R  STAINING B L O O D  FILMS B Y  T H E  
MAY-GRUNWALD/GIEMSA TECHNIQUE
Blood films were rapidly dried with a hair drier and then fixed by 
immersion in methanol for 10 minutes. (Films that have been fixed may 
then be kept indefinitely before staining). After fixation, slides were 
then transferred to freshly prepared May-Grunwald stain. The stain 
was prepared by mixing equal parts of May-Grunwald reagent 
(R.A.Lamb, London, England) with distilled water buffered to pH6.5 
with Sorensen buffer. After five minutes in May-Grunwald stain the 
slides were removed, drained and then transferred to freshly 
prepared Giemsa stain. This was prepared by adding 1 part Giemsa 
(R.A.Lamb, London, England) to 9 parts buffered distilled water 
(pH6.5). After 10 minutes in the Giemsa stain the slides were removed 
and placed in buffered distilled water for differentiation, agitating the 
slides at intervals. Differentiation was carried out for up to 5 minutes 
when the appearance of the wet film was examined by low-power 
microscopy. The slides were then dried vertically in air and the films 
were examined using a X50 and X100 oil-immersion objective after 
having been temporarily mounted in cedar-wood immersion oil. The 
appearance of red blood cells, platelets and white blood cells was then 
studied.
(iii) RED BLOOD CELL COUNT (RBC)
REAGENT
(1) Formacalcitrate Solution:
10ml of 40% formalin was made up to 1 litre with 32g/litre of trisodium 
citrate.
METHOD
A one in two hundred dilution of blood in formacalcitrate solution was 
prepared by adding 20pl of blood to 4ml of diluting solution in a glass 
tube. This was mixed for at least 2 minutes by careful tilting and 
rotation of the tube. A sample was withdrawn by means of a capillary 
tube. This sample was then used to fill both sides of a Neubauer 
counting chamber. After settling for approximately 2 minutes, the 
numbers of cells in 4 or 8 of the horizontal rectangles (1mm x 0.05mm) 
of the Neubauer chamber were counted using a X40 objective. (Not 
less than 500 cells.)
CALCULATION
red cell count/lOOOml = no of cells counted x dilution x 106
volume counted (pi)
(iv) WHITE BLOOD CELL COUNT (WBC)
REAGENT
(1) 2% (v/v) aqueous acetic acid coloured pale mauve with a few 
crystals of gentian or methyl violet.
METHOD
50pl of freshly mixed sequestrened blood was pipetted into a LP3 tube 
containing 950pl of dilution reagent. This was mixed thoroughly and a 
sample was removed by means of a capillary tube. Both sides of a 
Neubauer counting chamber were filled with the diluted blood which 
was then allowed to settle for 2 to 3 minutes. The numbers of white 
cells in the 4 or 8 of the horizontal rectangles (1mm x 0.05mm) of the 
Neubauer chamber were then counted using a X40 objective. (Only 
white cells should be visible as the diluent should lyse the red cells
present.) The total count must be accompanied by a differential count 
for maximum value to be obtained.
CALCULATION
If N = total blood cells counted
number of 1mm squares counted
Then
Total WBC = N x 10 x 20 
= N x 200
(v) DETERMINATION OF PACKED CELL VO L U M E  (PCV)
Sequestrened blood was allowed to enter a capillary tube (75mm long, 
1mm internal diameter) by capillary action so that at least 15mm 
remained unfilled. The tube was then sealed by heating the dry end 
rapidly in a fire flame. The tube was then centrifuged for 5 minutes 
at 12,000rpm. The volume of the packed cells was then measured as a 
percentage of the total volume of the whole blood using a haematocrit 
reader (Clay-Adams Inc, New York, U.S.A.).
(vi) DETERMINATION OF HAEMOGLOBIN BY THE CYANMETHAEMOGLOBIN 
METHOD.
REAGENT
(1) Potassium cyanide and potassium ferricyanide (Drabkins reagent, 
BDH Chemicals Ltd, Poole, Dorset, England.)
METHOD
20pl of blood was added to 4ml of Drabkins reagent. The solution was 
then thoroughly mixed and left to stand for 10 minutes. After 
remixing, the absorbance of the solution was measured at 540nm using 
Drabkins as a blank. In order to calculate the amount of haemoglobin 
present in the sample the absorbance of a 57.2 mg/lOOml 
cyanmethaemoglobin standard (BDH Chemicals Ltd, Poole, Dorset, 
England) was also measured at 540nm.
CALCULATION 
Hb (g/lOOml) =
Absorbance of blood sample x c. standard x dilution factor 
Absorbance of standard 1000
Abs540 BLOOD x 57.2 x 201 
Abs540 STANDARD 1000
Abs540 BLOOD x 11.5
Abs540 STANDARD
(vii) PREPARATION OF BONE MARROW FILM 
REAGENT
(1) Albumin/EDTA solution. Prepare by adding 1ml of 6% bovine serum 
albumin to a standard 2.5ml EDTA pot.
METHOD
The femur was removed from the animal carcase as soon as possible 
and cleaned. It was then split longitudinally to provide two shallow 
troughs of bone. A small brush was then taken and dipped into the
albumin/EDTA solution. This was then used to take up fragments of 
marrow from the femur, and the cells thus obtained were painted onto 
a slide in 3 or 4 longitudinal streaks. The film was then air dried, 
fixed in methanol for 20 minutes and stained using the 
May-Grunwald/Giemsa process as described in section 4.2.13(h). After 
drying, the film was then examined microscopically unmounted under 
oil or mounted in DPX to preserve.
4.3 RESULTS
4.3.1 GASTROINTESTINAL TOXICITY
Oral administration of cisplatin (57mg/kg or 30mg/kg) or carboplatin 
(282mg/kg) resulted in a rapid loss of body weight (Figure 4.7). 
Anorexia persisted until 4 days after administration of 57mg/kg 
cisplatin, when the experiment was terminated due to the severe acute 
toxicity developed by the animals. Severe anorexia also developed 
after 30mg/kg cisplatin or 282mg/kg carboplatin but animals surviving 
the intoxication started to regain body weight 7 days after 
administration. Diarrhoea developed in 40% of cisplatin (57mg/kg) 
treated animals by day 4 but was present in 100% of carboplatin 
treated animals at the same time point (Table 4.1). Animals treated 
with the platinum based compounds became progressively more 
dehydrated as water consumption fell to 50% of that of controls (day 
7) after carboplatin and 15% of controls after 57mg/kg cisplatin 
(Figure 4.8b). Food consumption was also significantly lower in 
treated animals (Figure 4.8a) and probably accounted for the anorexia 
observed.
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FOOD AND WATER CONSUMPTION AFTER ORAL
ADMINISTRATION OF PLATINUM BASED PHARMACEUTICALS 
TO MALE WISTAR RATS.
(A) FOOD CONSUMPTION
80-
70-
60“
40- • Carboplatin (282mg/kg) 
a Cisplatin (57mg/kg)
10-
time after administration (days)
(B) WATER CONSUMPTION
90-
80-
70-
60-
• Carboplatin (282mg/kg.) 
▲ Cisplatin (57mg/kg.)
20
10-
time after administration (days)
TABLE 4.1
Macroscopic Pathology Summary
TISSUE/OBSERVATION TREATMENT/DOSE
CISPLATIN 57rag/kg 
DAY 
2 4
CARBOPLATIN 282mg/kg 
DAY
2 4
KIDNEYS
Enlarged
Pale area cortex
STOMACH
Distended with fluid 
Distended with food 
Gaseous distended
GASTROINTESTINAL TRACT
Contents dark/
haemorrhagic
Empty
Diarrhoea
CAECUM
Inflated
Atrophy/contracted
SPLEEN
Enlarged
Small
THYMUS
Small
NUMBER OF ANIMALS
A number of macroscopic pathological observations were made at 
autopsy. After both cisplatin and carboplatin treatment the small 
intestine was often empty or contained dark or haemorrhagic contents 
and the caecum was inflated with gas (Table 4.1). However, by far the 
most striking observation was gastric distention which persisted for 
up to 7 days after treatment. The stomachs were seen to be either 
bloated with food or contained gas or fluid. This peculiar toxic 
response was followed for up to 14 days after oral administration of 
cisplatin (30mg/kg) (Table 4.2). This single dose was seen to induce 
stomach bloat, increasing the average weights of the stomach (and 
contents) by >100% for up to 14 days after administration. By day 14 
the stomachs of treated animals had regained their normal proportions. 
Gastric distention was shown to have a significant effect on the 
release of cisplatin from the stomach and gastric emptying per se with 
13.5% and 2.5% of the dose being recovered from the gastric pouch 
after 1 and 3 days respectively (Table 4.3). It is obvious that this 
finding may have a profound effect on the pharmacokinetics associated 
with oral administration. As stomach bloat in rats has been suggested 
to have some bearing on the gastric nausea often experienced by 
patients receiving cisplatin (Roos et al. 1981), it was decided to assess 
the emetic effect of cisplatin and carboplatin in the ferret. 
Intravenous administration of 6mg/kg cisplatin to three ferrets caused 
some degree of retching in all animals, but no vomitus was expelled. 
The mean latent period of retching was found to be 34.6 minutes. 
Increasing the dose to 8mg/kg produced unequivocal emesis after a 
mean latent period of 37.5 minutes (Table 4.4). The maximum duration 
of response was found to be 2 minutes. After confirming that 
intravenous administration of cisplatin induced emesis, a single oral 
dose of either cisplatin or carboplatin was tested for an emetic
TABLE 4.2
Development of stomach distention in male wistar rats 
after oral administration of cisplatin
DOSE CISPLATIN MEAN STOMACH WEIGHTS (g/lOOg BODY WEIGHT) ON DAYS
(mg/kg) --------------------------------------------------------
+ 1 + 3  + 7  ♦ 14
30 3.37 ± 0.47 4.71 ± 1.80 2.29 ± 0.65 1.84 ± 0.30
0 2.02 ± 0.44 2.00 ±0.21 1.53 ± 0.05 1.71 ± 0.10
Results are means, ±SEM (n = 3)
TABLE 4.3
Effect of cisplatin induced stomach bloat on platinum release
DOSE CISPLATIN % DOSE REMAINING IN STOMACH ON DAYS
(mg/kg) ---------------------------------------------------- -
+ 1 + 3  + 7  + 1 4
30 13.42 ± 5.36 2.53 ± 1.26 0.84 ± 0.83 0.01 ± 0 .005
Results are means, ±SEM (n = 3)
TABLE 4.4
Emetic response of ferrets dosed intravenously with cisplatin
MEAN LATENT 
PERIOD (mins)
MEAN NUMBER OF 
EPISODES
MAXIMUM
DURATION (mins)
NUMBER OF 
ANIMALS
CISPLATIN 
6mg/kg 8mg/kg
34.6 ± 8.3
3 ± 2
37.5 ± 6.3
T w o  a n i n a l s  o n l y
4.5 ± 0.7
Results are means ±SD
response. Initially the compounds were administered at what was 
thought to be bioequivalent dose levels (50mg/kg cisplatin, 200 mg/kg 
carboplatin). A single oral dose of cisplatin (50mg/kg) to 3 ferrets 
induced emesis within 36 to 40 minutes with between 12 and 17 
episodes per animal during the 3 hour observation period (Table 4.5). 
Since this dose level was not compatible with survival beyond 48 
hours, 60% of this (viz 30mg/kg) was administered orally. This dose 
induced emesis in all 3 ferrets in a very similar manner (Table 4.5) 
and again all 3 animals died with 48 hours. Administration of a single 
oral dose of 200mg/kg carboplatin to 3 ferrets induced emesis in all 3 
animals after a latent period of between 2 and 3 hours (Table 4.5 ). 
The number of episodes per animal ranged from 1 - .5, but as retching 
and vomiting were noted in 2 ferrets more than 24 hours after 
administration, it is most probable that more episodes would have been 
observed over a longer observation period. Administration of a dose 
of 120mg/kg carboplatin to 3 ferrets produced emesis in 1 animal 
(Table 4.5). Only a single episode was observed at 2 hours 11 minutes 
after administration. As with the higher dose, transient diarrhoea was 
noted 24 hours after dosing. All 3 ferrets recovered uneventfully and 
14 days later were each given a further single oral dose of lOOmg/kg 
carboplatin. Apart from slight diarrhoea, this dose was well tolerated 
and no emesis was observed.
Histologically, oral administration of carboplatin (282mg/kg) to rats 
resulted in acute necrotic enteritis of the mucosa of the small 
intestine. The primary target for carboplatin cytotoxicity was dividing 
cells in the crypts of Lieberkuhn. On day 1, necrotic cells were 
found in a large proportion of the jejunal crypts (Figure 4.9a). 
Mitotic figures were extremely rare. This inhibition of mitosis 
apparently slowed migration of epithelial cells from the crypts to
TABLE 4.5
Emetic response of ferrets dosed orally with platinum 
based pharmaceuticals
CISPLATIN CARBOPLATIN
50Bg/kg 30mg/kg 200mg/kg 120ng/kg lOOag/kg
MEAN LATENT 
PERIOD (Bins) 38 ± 2  41 ± 2 158 ± 48 131 
One animal 
only
-
MEAN NUMBER OF 
EPISODES 15 ± 2.9 16.3 ± 2 2.6 ± 1.5 1 0
MAXIMUM
DURATION (Bins) 4 3 3 1 -
NUMBER OF 
ANIMALS 3 3 3 3 3
Results are means ±SD
Figure 4.9
PHOTOGRAPH OF FORMALIN F I X E D ,PARAFFIN WAX 
EMBEDDED INTESTINAL SECTIONS STAINED WITH 
HAEMATOXYLIN AND E O S I N .
(a) SECTION TAKEN FROM MALE WISTAR RAT KILLED 1 DAY AFTER 
RECEIVING CARBOPLATIN (282mg/kg) BY ORAL GAVAGE. 
Micrograph demonstrates widespread necrosis in crypts 
of lieberkuhn of jejenal mucosa. (x313)
(b) SECTION TAKEN FROM MALE WISTAR RAT KILLED 2 DAYS AFTER 
RECEIVING CARBOPLATIN (282mg/kg) BY ORAL GAVAGE. 
Micrograph demonstrates crypts and villi that are 
markedly atrophic.(x313)
(c) SECTION TAKEN FROM MALE WISTAR RAT KILLED 8 DAYS AFTER 
RECEIVING CARBOPLATIN (282mg/kg) BY ORAL GAVAGE. 
Micrograph demonstrates extensive loss of epithelium 
with only rudimentary villi remaining.The lumen is full 
with necrotic debris. (x313)
(d) SECTION TAKEN FROM MALE WISTAR RAT KILLED 8 DAYS AFTER 
RECEIVING CARBOPLATIN (282mg/kg) BY ORAL GAVAGE. 
Micrograph demonstrates ileal crypts that contain 
cells that are profoundly necrotic. Some of the crypts 
have taken on a cyst-like appearance (C) as a result of 
inhibition of normal cell replication.(x788)
(e) SECTION TAKEN FROM MALE WISTAR RAT KILLED 8 DAYS AFTER 
RECEIVING CARBOPLATIN (282mg/kg) BY ORAL GAVAGE. 
Micrograph demonstrates a region of ileum in which 
crypts are totally denuded of cells and appear as cysts
(x788).
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villus resulting in a flattening of the remaining cells to a cuboidal or 
squamous configuration to maintain an epithelial lining. By day 2, 
some crypts had atrophied and villi were shortened in height (Figure 
4.9b). The intestinal epithelium of rats surviving intoxication (typically 
90%) underwent regeneration with the cells lining the crypts showing 
evidence of increased mitotic activity by day 4. However, occasionally 
animals became moribund by days 7 - 8. Microscopic examination of 
the small intestine derived from these animals revealed cases of 
extremely severe enteritis that was probably not reversible. Almost 
all of the intestinal villi were atrophic and had the appearance of 
blunt stubby structures that were shortened to less than half their 
normal height. Many of these villi appeared to fuse partially with 
neighbouring villi in the base region and the intestinal lumen was 
often filled with necrotic debris (Figure 4.9c). Almost all of the ileal 
crypts were atrophic and still contained necrotic cells (Figure 4.9d). 
Many of them also appeared to be separated from the villus epithelium, 
forming round enclosures like cysts (Figure 4.9e ). Twenty-four days 
after dosing, histologically no abnormalities could be detected in the 
small intestines of surviving animals.
Disaccharidase activity in rat small intestinal mucosa was used as a 
functional test of the effect of orally administered carboplatin. Both 
sucrase and trehalase specific activities were measured with both 
showing a similar pattern. Carboplatin (282mg/kg) was shown to cause 
a time dependant reduction in the specific activity of intestinal 
disaccharidases, with sucrase values falling to 38% of that found in 
control preparations (Figure 4.10). The effect reached a nadir at 4 
days post-treatment but activities had recovered to within the normal 
range by day 8. This pattern broadly followed the time course of the 
intestinal lesion as observed histopathologically.
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FIGURE 4.10
THE EFFECT OF ORAL ADMINISTRATION OF 
CARBOPLATIN (282mg/kg) ON RAT INTESTINAL
DISACCHARIDASE ACTIVITY
a TREHALASE
• SUCRASE
TIME AFTER ADMINISTRATION (DAYS)
results are means,±sem(n=3)
significantly different from control (p<0.05)
Figure 4.11
PHOTOGRAPH OF FORMALIN FIXED,PARAFFIN WAX 
EMBEDDED PANCREATIC SECTIONS STAINED WITH 
HAEMATOXYLIN AND EOSIN.
(a) SECTION TAKEN FROM CONTROL MALE WISTAR RAT. (x79)
(b) SECTION TAKEN FROM MALE WISTAR RAT KILLED 8 DAYS AFTER 
RECEIVING CARBOPLATIN (282mg/kg) BY ORAL GAVAGE. 
Micrograph demonstrates enlarged zymogen granules that 
surround the islets of langerhans and pancreatic ducts.
: (x79)
(C) Detailed region of (b) demonstrating enlargement of 
zymogen granules around an islet of langerhans. (x313)
ab
c
Post-mortem examination of ferrets that received an oral dose of 
200mg/kg carboplatin showed dark or haemorrhagic areas in the 
gastric mucosa. Histological examination of these stomachs revealed 
areas of glandular mucosal necrosis and regeneration in 2 of the 3 
ferrets studied, with necrosis of the submucosal mucous gland in 1 of 
these. In 1 animal, the areas of regenerating mucosa were atrophic, 
demonstrating that the earlier episode of necrosis in this region had 
involved a substantial part of the glands.
Oral administration of carboplatin (282mg/kg) to rats also resulted in 
pathological changes to the pancreas. Histological examination of 
pancreatic tissues of rats found moribund 8 days after dosing 
revealed significant acinar atrophy and cellular necrosis in distal 
regions. However, the most striking observation was the enlarged 
zymogen granules that surrounded the islets of Langerhans and 
pancreatic ducts (Figure 4.11). This could be indicative of an 
inhibition of exocrine secretion. Although cisplatin induced changes in
pancreatic endocrine function have been reported (Goldstein et al.
1983), inhibition of exocrine secretion appears to be specific to the 
oral routes of administration and probably occurs in response to the 
damaged intestinal mucosa.
Oral administration of 30mg/kg cisplatin to rats and ferrets produced 
gastrointestinal lesions that were very similar to those observed after 
carboplatin, but appeared to be more frequent and severe. As early 
as 24 hours after dosing there was widespread necrosis in the crypt 
cell populations of the small intestine, and stomachs of treated animals 
frequently contained areas of necrosis in the mid-glandular region of 
the gastric mucosa (Figure 4.12a). As was observed after carboplatin 
treatment, drug induced lesions of the gastrointestinal tract were focal 
in nature, with distinctly necrotic areas being interspersed with
PHOTOGRAPH OF FORMALIN FIXED,PARAFFIN WAX
EMBEDDED SMALL INTESTINE AND STOMACH
SECTIONS STAINED WITH HAEMATOXYLIN
AND E O S I N .
(a) SECTION TAKEN FROM MALE WISTAR RAT KILLED 1 DAY AFTER 
RECEIVING CISPLATIN (30mg/kg) BY ORAL GAVAGE.
Micrograph demonstrates areas of necrosis in mid-glandular 
(arrows) region of gastric mucosa. (x400)
(b) SECTION TAKEN FROM MALE WISTAR RAT KILLED 3 DAYS AFTER 
RECEIVING CISPLATIN (30mg/kg) BY ORAL GAVAGE.
Micrograph demonstrates an area of total necrosis of 
the gastric glandular epithelium. (x200)
(c) SECTION TAKEN FROM MALE WISTAR RAT KILLED 7 DAYS AFTER 
RECEIVING CISPLATIN (30mg/kg) BY ORAL GAVAGE.
Micrograph demonstrates atrophic villi containing dilated 
lacteals and extensive dilitation of jejenal crypts. (x40)
(d) Detailed region of section (c) demonstrating extensive 
dilitation and depopulation of crypts of lieberkuhn, which 
take on a cyst-like appearance. (x200)
(e) SECTION TAKEN FROM MALE WISTAR RAT KILLED 7 DAYS AFTER 
RECEIVING CISPLATIN (30mg/kg) BY ORAL GAVAGE.
Micrograph demonstrates area of hyperplasia of keratinising 
squamous epithelium of the fore-stomach and associated 
micro-ulcer. (x100)
(f) SECTION TAKEN FROM MALE WISTAR RAT KILLED 7 DAYS AFTER 
RECEIVING CISPLATIN (30mg/kg) BY ORAL GAVAGE.
Micrograph demonstrates area of total glandular necrosis 
and erosion down to the muscularis mucosa forming an ulcer. 
(x100)
(g) SECTION TAKEN FROM MALE WISTAR RAT KILLED 14 DAYS AFTER 
RECEIVING CISPLATIN (30mg/kg) BY ORAL GAVAGE.
Micrograph demonstrates glandular epithelium of the stomach 
that contains many regenerating glands with dysplastic cells 
and numerous mitotic figures. (x200)
b
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normal tissue. This was also found at the electron microscopic level 
where normal cells were found immediately adjacent to cells containing 
fragmented, swollen mitochondria and Golgi with severe cisternal 
dilation. By day 3 there was an increase in the mitotic activity 
present in the crypts of the small intestine but there was severe 
villus atrophy. Damage to the stomach appeared to be mainly confined 
to the antrum where the glandular epithelium exhibited regions of 
extensive necrosis containing depopulated glands and total loss of 
differentiation (Figure 4.12b). Cisplatin induced gastrointestinal 
toxicity appeared to reach a nadir 7 days after dosing. The jejenum 
of treated animals took on the appearance noted in the most severe 
cases of carboplatin toxicity with the crypts being totally denuded 
and dilated into cyst-like structures (Figure 4.12c and d ). At this 
time point there was also a marked ulceration of the stomach , both in 
the forestomach (Figure 4.12e ) and in the glandular regions (Figure 
4.12f). Villus atrophy in the small intestine was still present 14 days 
after treatment but stomachs showed signs of recovery. This was 
demonstrated by a glandular epithelium containing many regenerating 
glands with numerous mitotic figures (Figure 4.12g).
The increased gastrointestinal toxicity observed after cisplatin 
treatment may be solely due to the amount of platinum taken up by 
the intestinal tissue when presented with the two compounds. 
Platinum concentration in the small intestine was shown to be 
significantly higher after cisplatin than after carboplatin 
administration (Figure 4.13), with elimination being biphasic and more 
complete over the first 48 hours.
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FIGURE 4.13
TIME COURSE OF DUODENAL (0-60cm from stomach) 
PLATINUM LEVELS (a) AFTER ORAL ADMINISTRATION 
OF PLATINUM BASED PHARMACEUTICALS.
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tissue was cleared of contents , 
washed with 0.9% saline,acid 
digested and resuspended in 
1% Hcl prior to analysis by 
atomic absorption spectroscopy.
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4.3.2 NEPHROTOXICITY
Perenteral administration of cisplatin results in dose limiting 
nephrotoxicity (Goldstein et al. 1983) whereas the preclinical feature of 
carboplatin was its failure to elicit nephrotoxicity in animals (Harrap 
et al. 1983, Levine et al. 1981). The results obtained in this study 
indicate that the toxicities associated with the parenteral use of these 
compounds also apply to the oral route of administration. 
Administration of a single dose of cisplatin (57mg/Kg) resulted in a 
rapid increase in the weights of the kidneys excised from treated 
animals at autopsy (Figure 4.14a). This effect was manifested 24 
hours after dosing and continued until 4 days when the experiment 
was terminated due to the acute toxicity developed by the animals. 
Kidney damage was also expressed by elevations in the serum 
concentrations of urea nitrogen (BUN) and creatinine. Creatinine 
values had a sharp increase 2 days after dosing, reaching a value 
230% of that found in control serum (Figure 4.15). Urea nitrogen 
levels, however, were elevated 24 hours after dosing and peaked by 
day 4 at 325% of control levels (Figure 4.16). It was very noticeable 
that there was a large variation in the responsiveness of individual 
animals to cisplatin treatment. This was illustrated by the 
considerable variability in the BUN and creatinine data, with some 
animals showing 3 fold increases in these parameters with others 
showing only minimal increases. Due to the extreme toxicity 
manifested after oral administration of 57mg/Kg cisplatin, the dose was 
lowered to 30mg/Kg. As was found with the higher dose, kidney 
weights of treated animals were consistently higher throughout the 
course of the experiment (Figure 4.14b). Kidney weights of treated 
animals were significantly higher than those of controls from 3 days 
after dosing and remained so upto 14 days after the single bolus
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dose. This time course of the development of the nephrotoxic lesion 
was also illustrated histopathologically. The first histopathological 
lesions were manifested 3 days after dosing with 30mg/Kg cisplatin. 
Pathological changes were characterised by widespread tubular 
necrosis and dilation of the corticomedullary region, predominantly in 
the third segment {S3) or straight portion of the proximal tubule. 
The lesion became more pronounced 7 days after dosing with proximal 
tubule necrosis resulting in extensive regions of tubular vacuolation 
and dilation due to the loss of tubular epithelium (Figure 4.17a and b 
). At this time point there was also evidence of necrosis in the loop of 
Henle with the ducts often containing casts that occluded their 
lumens. Fourteen days after dosing there was evidence of proximal 
tubular regeneration however, tubules were still extremely dilated 
(Figure 4.17c).
In contrast to cisplatin, oral administration of carboplatin (282mg/kg) 
resulted in little nephrotoxicity. Kidney weights (Figure 4.14a) and 
serum concentrations of B U N  (Figure 4.16) and creatinine (Figure 4.15) 
remained within normal ranges throughout the 14 day experiment. 
However, prominently enlarged nuclei were present in some of the 
cells of the loop of Henle and proximal tubules in the region of the 
corticomedullary junction up to 14 days after administration (Figure 
4.18). This observation was also made in ferrets after oral 
administration of lOOmg/Kg carboplatin.
Higher renal platinum levels were attained after oral administration of 
cisplatin (57mg.kg) than carboplatin (282mg/kg). Unlike intestinal and 
hepatic concentrations, renal platinum levels did not fall significantly 
with time which suggests a higher level of irreversible binding or 
affinity for this tissue (Figure 4.19).
Figure 4.17 
PHOTOGRAPH OF FORMALIN F I X E D ,PARAFFIN WAX 
EMBEDDED KIDNEY SECTIONS STAINED WITH 
HAEMATOXYLIN AND EOSIN.
(a) SECTION TAKEN FROM MALE WISTAR RAT KILLED 7 DAYS 
AFTER RECEIVING CISPLATIN (30mg/kg) BY ORAL GAVAGE. 
Micrograph demonstrates widespread tubular necrosis 
of the corticomedullary region.(x20)
(b)SECTION TAKEN FROM MALE WISTAR RAT KILLED 7 DAYS 
AFTER RECEIVING CISPLATIN (30mg/kg) BY ORAL GAVAGE. 
Micrograph is a detailed zone of (a) showing that 
necrosis is confined to the outer stripe of the 
medulla and is manifested primarily as dilation of 
the proximal tubule.(x100)
(c)SECTION TAKEN FROM MALE WISTAR RAT KILLED 14 DAYS 
AFTER RECEIVING CISPLATIN (30mg/kg) BY ORAL GAVAGE. 
Micrograph demonstrates widely dilated proximal tubules 
that are attempting to regenerate.(x200)
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Figure 4.18 
PHOTOGRAPH OF FORMALIN FIXED,PARAFFIN WAX 
EMBEDDED KIDNEY SECTIONS STAINED WITH 
HAEMATOXYLIN AND EOSIN.
(a) SECTION TAKEN FROM CONTROL MALE WISTAR RAT. (x500)
(b) SECTION TAKEN FROM MALE WISTAR RAT KILLED 6 DAYS 
AFTER RECEIVING CARBOPLATIN (282mg/kg) BY ORAL GAVAGE. 
Micrograph demonstrates nuclear enlargement (arrows) 
observed in proximal tubules in the region of the 
corticomedullary junction.(x788)
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FIGURE 4.19
TIME COURSE OF KIDNEY PLATINUM LEVELS ‘ ' 
AFTER ORAL ADMINISTRATION OF PLATINUM 
BASED PHARMACEUTICALS
60
• CISPLATIN,57mg/kg
CARBOPLATIN,282mg/kg
results are means,±sem (n=3)
tissues were acid digested and 
resuspended in 1%Hcl prior to 
analysis by atomic absorption 
spectroscopy.
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4.3.3 HEPATOTOXICITY
Although reports of hepatotoxicity associated with platinum based 
pharmaceuticals after per enteral administration are rare (Pollera et al. 
1987), the anatomical proximity of the liver to the blood supply from 
the gastro-intestinal tract could potentiate this problem after oral 
administration.
Oral administration of 57mg/Kg cisplatin resulted in a significant
. •
decrease in relative liver weights over a period of 4 days (Figure 
4.20). This decrease in liver weight was also observed 3 days after 
administration of cisplatin (30mg/Kg). However, by 7 days, 
hepatomegaly was observed which persisted until day 14 when the 
experiment was terminated (Figure 4.20). Although changes in relative 
liver weight were not as pronounced after carboplatin (283mg/Kg) 
treatment, a significant reduction was observed 4 days post-treatment 
(Figure 4.20).
In order to demonstrate the presence of liver injury a battery of 
serum enzymes were measured after a high dose of carboplatin 
(282mg/Kg). These included alkaline phosphatase, glutamic-oxaloacetic 
transaminase (GOT) and glutamic-pyruvic transaminase (GPT). Whereas 
elevation in the serum activity of the former is indicative of 
cholostatic injury, elevation in GOT or GPT primarily indicates hepatic 
injury of a cytotoxic nature. Figure 4.21 illustrates that oral 
administration of carboplatin (282mg/kg) did not result in an elevation 
of any of these enzymes but conversely resulted in a significant 
decrease in the activity of GOT 4-6 days after dosing. Since 
histologic changes characteristic of hepatotoxicity have been noted at 
doses of compounds that did not result in elevation of serum enzyme 
activity (Korsrud et al. 1973), it was decided to examine livers excised 
from cisplatin and carboplatin treated animals by both light and
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FIGURE 4.20
THE EFFECT OF ORALLY ADMINISTERED PLATINUM 
BASED PHARMACEUTICALS ON THE LIVER WEIGHT 
OF MALE WISTAR RATS.
y cisplatin,57mg/kg
O control
results are means,±sem (n=5)
▼ cisplatin,30mg/kg
O control
results are means,±sem (n=3)
■ carboplatin,282mg/kg
control
results are means,±sem (n=6)
TIME (DAYS)
* significantly different from control (p<0.05)
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FIGURE 4.21
EVALUATION OF HEPATIC FUNCTION AFTER 
ORAL ADMINISTRATION OF CARBOPLATIN (282mg/kg) 
BY REFERENCE TO SERUM ENZYMES.
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TIME AFTER ADMINISTRATION (days) 
ALKALINE PHOSPHATASE 
• — t —  • ASPARTATE AMINOTRANSFERASE (GOT)
 ALANINE AMINOTRANSFERASE (GPT)
results are means ±sem (n=3)
* significantly different from control at p<0.05
electron microscopy. In the rat the only abnormality observed by 
light microscopy that could be ascribed to cisplatin or carboplatin 
treatment was a periportal depletion of glycogen. This was observed 
first at 4 days post treatment, reached a nadir at 6 days and had 
recovered to normal by day 14 (Figure 4.22). This phenomena explains 
the dose related decrease in the relative liver weights that occurred 
after oral administration of the platinum complexes. Depletion in 
glycogen is probably a consequence of the severe anorexia developed 
by treated animals.
In the ferret, microscopic examination revealed cytoplasmic vacuolation 
of periportal hepatocytes that was consistent with lipid accumulation. 
Ultrastructural examination of rat liver excised from treated animals 
revealed a number of interesting morphological changes. As was 
found in the gastro-intestinal tract, lesions were focal in nature with 
profoundly abnormal cells often being interspersed with cells that 
were of "normal" morphology. Forty eight hours after oral 
administration of cisplatin (30mg/Kg), hepatocytes in the vicinity of 
the portal tract contained many swollen and degenerating mitochondria 
and numerous myelin-like figures (Figure 4.23). These myelin-like 
figures resembled the membranous whorls observed after 
cyclohexamide treatment (Daskal et al. 1975) and could originate from 
the collapse of rough endoplasmic reticulum or degenerating 
mitochondria. Hepatotoxicity associated with carboplatin treatment 
(282mg/Kg) was also manifested as gross mitochondrial swelling in 
periportal regions. In addition, hepatocytes often contained 
vesiculated endoplasmic reticulum (Figure 4.23).
Damage to endoplasmic reticulum is typically diagnosed by a 
depression in glucose-6-phosphatase; an enzyme closely associated 
with this organelle. Glucose-6-phosphatase activity in rat liver
Figure 4.22
PHOTOGRAPH OF FORMALIN FIXED,PARAFFIN WAX 
EMBEDDED LIVER SECTIONS STAINED WITH 
PERIODIC ACID SCHIFFS REAGENT (PAS).
(a) SECTION TAKEN FROM CONTROL MALE WISTAR RAT. (x79)
(b) SECTION TAKEN FROM MALE WISTAR RAT KILLED 6 DAYS 
AFTER RECEIVING CARBOPLATIN (282mg/kg) BY ORAL GAVAGE. 
Micrograph demonstrates loss of glycogen in periportal 
regions. (x79)
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FIGURE 4.23
ELECTRON MICROGRAPHS OF LIVER SECTIONS FIXED IN 4% 
GLUTARALDEHYDE BUFFERED WITH 0.1M SODIUM CACODYLATE 
pH 7.4 ,AND COUNTER-FIXED IN 2% OSMIUM TETROXIDE 
BUFFERED WITH 0. 1M SODIUM CACODYLATE pH 7.4.
(a) SECTION TAKEN FROM CONTROL MALE WISTAR RAT.
■(b); SECTION TAKEN FROM MALE WISTAR RAT KILLED 48 
HOURS AFTER RECEIVING CISPLATIN (30mg/kg) BY 
ORAL GAVAGE.
Micrograph demonstrates extensive mitochondrial 
swelling and degeneration.Myelin-like figures 
appear to originate from degenerating mitochondria.
(c) SECTION TAKEN FROM MALE WISTAR RAT KILLED 48 
HOURS AFTER RECEIVING CARBOPLATIN (37mg/kg) BY 
ORAL GAVAGE.
Micrograph demonstrates vesiculation of endoplasmic 
reticulum and numerous swollen mitochondria.
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homogenate was not depressed at any time point between 1 and 28 
days after administration of carboplatin (282mg/kg) or cisplatin 
(30mg/kg). However, the activity was significantly depressed 2 and 4 
days after administration of 57mg/kg cisplatin (Table 4.6). 
Glucose-6-phosphatase is not the sole microsomal enzyme adversely 
affected by hepatotoxins. A host of chemicals that produce liver 
injury can alter the hepatic mixed function oxidase (MFO) system, 
especially its terminal oxidase cytochrome P450. Measurement of the 
total P450 content of rat liver microsomes after oral administration of 
cisplatin (30mg/kg) revealed an increase in the content of this 
haemoprotein 1 day post-treatment that led to a marked depression at 
3 and 7 days and recovery to normal values by day 14 (Table 4.7). 
Hence it appears that although ultrastructurally carboplatin was seen 
to induce vesiculation of the endoplasmic reticulum, biochemically a 
lesion to this organelle could only be detected after cisplatin 
administration.
The other notable platinate associated ultrastructural liver lesion was 
gross mitochondrial swelling. This was studied biochemically by 
measuring the distribution and activities of mitochondrial marker 
enzymes, succinate dehydrogenase and monoamine oxidase after 
classical fractionation of rat liver homogenate prepared from cisplatin 
treated rats. Concurrently the effect of cisplatin on other organelles 
was investigated by measuring 4 other hepatic enzymes: acid
phosphatase (lysosomes); catalase (peroxisomes); glucose-6-phosphatase 
(endoplasmic reticulum) and 5’-nucleotidase (plasma membrane). One 
day after dosing with cisplatin (30mg/Kg) the distribution of succinate 
dehydrogenase and monoamine oxidase in treated animals took on an 
abnormal pattern (Figure 4.24). In livers of control animals the 
recovery of these enzymes in the "ML" (mitochondrial / lysosomal)
TABLE 4.6
The effect of oral administration of platinum based 
pharmaceuticals on the activity of glucose-6-phosphatase 
in rat liver homogenate
DAY TREATMENT
CONTROL CARBOPLATIN CONTROL CISPLATIN CONTROL CISPLATIN
282mg/kg 57mg/kg 30ag/kg
1 36.60il.70 34.5+3.30 43.9±L0.70 32.37±3.4 77.5+1.50 67.0i4.55
2 55.80+S.30 54.li5.80<b> 34.7± 0.87 25.30±1.7* ND ND
3 ND ND ND ND 59.3i3.93 47.li7.45
4 49.80i4.99 48.9i5.00<b> 37.3± 2.61 24.00i3.7* ND ND
7 27.60i2.37 31.7±3.40 ND ND 52.9i5.40 41.0i3.40
14 28.60tl.27 30.5iD.55 ND ND 49.2i2.70 42.9i2.23
28 36.77±1.69 35.0i2.00 ND ND ND ND
a) results are presented as means (pmoles/min /g p r o t e i n ) ±SEM
unless stated otherwise each group consisted of three animals
(b) six animals
* significantly different from control at p<0.05 
ND not determined
TABLE 4.7
The effect of oral administration of cisplatin (30mg/kg) 
on the amount of cytochrome P4 50 in rat liver 
microsomes
DAY CONTROL ( a ) CISPLATIN <b >
1 0.522 ± 0.056 147.0*
3 0.633 ± 0.028 80.0*
7 0.670 ± 0.020 74.6*
14 0.575 ± 0.057 111.0
(a) Units of activity are nmoles/mg microsomal 
protein ±SEM
(b) Percent of control
Unless otherwise stated, each group consists 
of three animals
* Significantly different from control at p<0.05
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THE EFFECT OF ORAL ADMINISTRATION OF CISPLATIN (30mg/kg) 
ON THE PERCENTAGE DISTRIBUTION YIELD OF PROTEIN,AND 
MARKER ENZYMES IN THE CLASSICAL SUBFRACTIONS OF 
RAT LIVER.
1 day after administration
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N = NUCLEAR FRACTION.
ML = MITOCHONDRIAL FRACTION. 
M = MICROSOMAL FRACTION.
CY = CYTOSOLIC FRACTION.
Results are presented as means of 3 determinations.
fraction was between If and 2 times that found in the nuclear fraction. 
However in cisplatin treated livers, monoamine oxidase and succinate 
dehydrogenase were almost equally distributed between the "ML" and 
nuclear fractions. This abnormal distribution was also seen 3 and 7 
days after dosing, but had recovered to normal by day 14 (Figure 
4.24). The distribution of all other marker enzymes after cisplatin 
treatment was consistent with that found in controls. It is likely that 
the co-sedimentation of mitochondria with nuclei and cellular debris, 
as indicated by the shift in the distribution of mitochondrial marker 
enzymes, is indicative of an increase in the size or density of the 
organelle. Thus this biochemical observation may confirm the 
existence of grossly swollen liver mitochondria that were observed 
morphologically after oral cisplatin treatment. Although cisplatin could 
induce swelling in liver mitochondria it appeared to have little effect 
on the activities of several mitochondrial enzymes. The specific 
activity of monoamine oxidase, an enzyme located mainly on the inner 
face of the mitochondrial outer membrane was unaffected after 
cisplatin (30mg/Kg) (Table 4.8). However, succinate dehydrogenase 
was inhibited 7 days after 30mg/kg and 2 days after 57mg/kg 
cisplatin (Table 4.9). Another enzyme located on the inner 
mitochondrial membrane, cytochrome c oxidase, was significantly 
inhibited 1 day after oral administration of cisplatin (30mg/Kg) (Table 
4,10) but this result may be spurious due to the unusually high 
activity recorded for the controls at this time point. No other 
changes in the specific activities of marker enzymes that could be 
directly attributed to cisplatin treatment were observed (Table 4.8). 
It has been reported that platinum based pharmaceuticals could 
accumulate within peroxisomes of the liver (Makita et al. 1985). This 
accumulation was said to accompany a slight proliferation of this
TABLE 4.8
Specific activities of marker enzymes in the homogenate (H) 
and classical fractions of the rat liver after oral 
administration of cisplatin (30mg/kg)
(a) 1 DAY AFTER ADMINISTRATION
H N ML Mic SUP
SDH T 10.87 ± 0.300 14.91 + 0.780 25.73 ±1.130 2.80 ± 0.185* 0.171 + 0.100
C 11.77 ± 0.420 15.21 + 1.090 33.15 ± 2.750 5.14 ± 0.510 0.145 + 0.070
MAO T 2.57 ±0.160 3.12 + 0.280 5.72 ± 0.197 1.36 ± 0.090 0.145 + 0.017
C 2.53 ± 0.100 2.96 + 0.170 5.38 ± 0.370 1.70 ± 0.150 0.159 + 0.005
CAT T 1.21 ± 0.121 0.526 + 0.009 2.05 ± 0.387 0.48 ± 0.090 1.240 + 0.070
C 1.34 ±0.039 0.669 + 0.050 1.75 ± 0.207 0.79 ± 0.140 1.410 + 0.090
G-6-P T 67.00 ± 4.550 91.60 + 18.00 51.80 ± 1.760 205 ± 10.90 11.00 + 0.300
C 77.50 ± 4.500 78.00 + 2.380 41.60 ±4.300 208 ±7.500 13.20 + 5.900
5’ Nuc. T 46.53 ± 2.150 113.0 + 3.180 12.42 ± 2.720 41.0 ± 2.310 10.32 + 1.880
C 45.73 ± 3.070 109.0 + 7.630 16.26 ±2.900 56.3 ± 11.50 6.37 + 0.250
Acid P. T 50.50 ± 4.300 46.6 + 3.850 122.0 ± 12.42 60.5 ± 6.900 32.60 + 3.200
C 55.80 ± 3.440 50.4 + 1.390 111.0 ± 10.20 68.7 ± 4.200 26.30 + 1.130
(b) 3 DAYS AFTER ADMINISTRATION
H N ML Mic SUP
SDH T 10.70 ± 0.240 20.20 + 2.300* 30.4 + 1.310 2.68 + 0.500 0.780 + 0.020
C 9.54 ± 1.470 11.24 + 1.770 29.2 + 2.800 2.87 + 0.180 0.790 + 0.050
MAO T 1.45 ± 0.780 3.46 + 0.340* 4.68 + 0.190 1.30 + 0.130 0.074 + 0.010
C 2.32 ± 0.440 2.40 + 0.100 4.87 + 0.130 1.25 + 0.110 0.064 + 0.002
CAT T 0.97 ± 0.140 0.53 + 0.040* 1.17 + 0.130 0.28 + 0.050* 1.010 + 0.120*
C 1.36 ± 0.160 0.78 + 0.060 1.44 + 0.050 0.57 + 0.050 1.740 + 0.050
G-6-P T 47.10 ± 7.450 52.2 + 7.900 40.60 + 6.430 149.0 + 4.400 9.720 + 0.140*
C 59.30 ± 3.900 70.0 + 11.86 56.20 + 12.00 169.0 + 15.00 12.50 + 0.630
5 ’ Nuc. T 50.60 ± 7.300 121.0 + 4.000 25.60 + 8.470 41.40 + 7.500 9.920 + 1.600
C 50.00 ± 4.620 136.0 + 9.900 19.60 + 4.900 49.00 + 0.810 8.860 + 1.080
Acid P. T 75.40 ±9.600 44.2 + 2.610 116.0 + 10.00 88.00 + 6.000 19.90 + 0.930*
C 61.00 ± 11.70 57.5 + 11.00 115.3 + 12.30 95.00 + 3.700 25.90 ± 1.380
(c) 7 DAYS AFTER ADMINISTRATION
H N ML Mic SUP
SDH T 7.16 ± 0.380* 17.56 + 4.10 23.50 ± 1.36 2.46 + 0.410 0.700 ± 0.0860
C 10.73 ± 0.910 11.62 + 0.64 23.80 ±1.33 3.60 + 0.480 0.550 ± 0.0300
MAO T 1.75 ± 0.110 3.03 + 0.78 3.47 ± 0.20 0.80 + 0.020 0.103 ± 0.0090
C 2.05 ± 0.150 2.03 + 0.15 3.47 ± 0.02 0.83 + 0.020 0.087 ± 0.0040
CAT T 1.23 ± 0.010* 0.92 + 0.20 2.02 ± 0.28 0.45 + 0.020* 1.320 ± 0.2700
C 1.79 ± 0.140 0.94 + 0.05 1.95 ± 0.12 0.85 + 0.130 1.630 ± 0.1210
G-6-P T 40.90 ± 3.400 54.20 + 11.50 25.40 ± 1.67 113.00 + 10.300 8.270 ± 1.0800
C 52.90 ± 5.400 48.10 + 4.80 36.00 ± 3.93 118.00 + 5.400 7.090 ± 2.0400
5* Nuc. T 40.70 ± 3.280* 122.00 + 8.90 18.30 ± 5.69 25.70 + 6.500 8.760 ± 1.9500
C 65.60 ± 4.530 134.00 + 18.20 19.30 ± 4.60 52.10 + 15.000 9.750 ± 3.4300
Acid P. T 67.50 ± 5.500 66.70 + 10.70 151.00 ±16.00 70.70 + 17.000 29.600 ± 4.7000
C 80.90 ± 9.570 68.10 + 6.50 134.00 ± 6.40 103.00 + 14.000 23.200 ± 6.0000
(d) 14 DAYS AFTER ADMINISTRATION
H N ML Mic SUP
SDH T 8.97 ± 0.280 10.96 + 0.44 26.10 ± 1.36 2.84 + 0.490 0.225 ± 0.0900
C 9.57 ± 0.100 12.60 + 1.70 25.70 ± 0.50 4.40 + 1.380 0.217 ±0.1400
MAO T 2.60 ± 0.030 2.74 + 0.06 6.16 ± 0.26 1.31 + 0.070 0.067 ± 0.0050
C 2.57 ± 0.150 3.26 + 0.37 6.49 ± 0.40 1.33 + 0.050 0.053 ± 0.0025
CAT T 1.34 ± 0.025 0.85 + 0.02 1.85 ± 0.21 0.61 + 0.068 1.390 ± 0.0850
C 1.36 ± 0.070 0.86 + 0.08 1.61 ± 0.06 0.59 + 0.040 1.490 ± 0.1200
G-6-P T 42.98 ± 2.230 53.60 + 0.43 40.70 ± 4.46 147.00 + 8.300 5.650 ± 0.8000
C 49.00 ± 2.600 69.70 + 6.49 43.90 ± 2.27 141.00 + 10.400 6.150 ± 0.7600
5* Nuc. T 74.60 ± 4.180 197.00 + 7.43 30.70 ±5.10 66.40 + 3.470 7.300 ± 1.0500
C 74.40 ± 3.460 181.00 + 20.00 26.40 ± 3.90 63.30 + 6.500 6.500 ± 1.9000
Acid P. T 61.50 ±2.870 63.00 + 1.35 146.00 ±5.20* 94.30 + 5.300 16.000 ± 0.3000
C 52.70 ±2.800 64.40 + 1.75 122.00 ± 2.46 95.60 + 13.000 16.200 ± 1.1900
Results are means ±5EM for n = 3
Specific activities are pmoles/min/g protein except MAO 
(nmol/min/mg protein), and CAT (units/mg protein).
Abbreviations are: fractions, H (homogenate), N (nuclear)
ML (mitochondrial/lysosome), Mic (microsomes), SUP (cytosol).
Enzymes, SDH (succinate dehydrogenase), MAO (monoamine oxidase), 
CAT (catalase), G-6-P (glucose-6-phosphatase),
5’ Nuc (5’ nucleotidase) and Acid P (acid phosphatase).
T (test), C (control).
* significantly different from control at p<0.05
TABLE 4.9
The effects of oral administration of platinum based 
pharmaceuticals on the activity of succinate dehydrogenase 
in rat liver homogenate
DAY TREATMENT
CONTROL CARBOPLATIN
282mg/kg
CONTROL CISPLATIN
57mg/kg
CONTROL CISPLATIN
30mg/kg
1 6.05±3.26 5.02±D.41 5.43±0.31 5.23±0.69 11.7±).42 10.87lD.30
2 5.38±0.11 5.16±0.28 5.97±).12 4.7liD.30* ND ND
3 ND ND ND ND 9.44±L.47 10.7iD.24
4 5.491D.09 4.6liD.19* 7.35±).13 7.95±0.28 ND ND
7 ND ND ND ND 10.73+D.91 7.16iD.38*
14 5.22±0.36 5.43+0.32 ND ND 9.57iD.ll 8.97iD.20
(a) results are presented as means (pmoles/min/g protein) ±SEM 
unless stated otherwise each group consists of three animals. 
* significantly different from control at p<0.05 
ND not determined
TABLE 4.10
The effect of oral administration of cisplatin (30mg/kg) 
on the activity of cytochrome C oxidase in rat liver 
mitochondrial fraction
DAY CONTROL*a > CISPLATIN*b >
1 100.00 ± 1.11 5 7*
3 48.80 ± 2.64 155
7 42.10 ± 2.91 107
14 47.09 ± 5.40 121
(a) Units of activity are nmoles/min/mg protein ±SEM
(b) Percent of control
Unless otherwise stated, each group consists of three animals 
* Significantly different from control at p<0.05
organelle along with other indices of hepatic cytotoxicity such as 
swelling of mitochondria and dilation of smooth endoplasmic reticulum. 
Since cisplatin appeared to have no effect on the peroxisomal enzyme 
catalase (Table 4.8) it was decided to use a high dose of carboplatin 
(282mg/kg) to investigate the possibility of platinum induced 
peroxisomal lesions.
Peroxisome proliferation is typically diagnosed by a marked induction 
of the enzymes catalase, uricase and palmitoyl CoA oxidation (Moody et 
al. 1976). Carboplatin did not cause significant induction of any of 
these enzymes over a 35 day period but cyanide insensitive palymitoyl 
CoA oxidation was typically lower than that found in controls 
throughout the course of the study (Figure 4.25).
In a further attempt to determine whether platinum based 
pharmaceuticals did cause a degree of hepatotoxicity that was initially 
manifested as mitochondrial damage, mitochondria were isolated from 
cisplatin treated animals and their respirative capacity studied using a 
Clark oxygen electrode. 1 day after dosing, the succinate (Figure 
4.26) and fl-hydroxybutyrate (Figure 4.27) stimulated oxidative 
phosphorylation of mitochondria isolated from treated animals was not 
significantly different from that found in controls. However 3 days 
after dosing, using
I3-hydroxybutyrate as substrate, state 4 (resting) oxygen consumption 
(AO2) when compared to controls rose from 6.12±0.98 to 8.30±1.0 n 
atoms/min/mg protein (p<0.05) but state 3 (ADP dependent) AO2 did 
not change (Figure 4.27). This effectively reduced the respiratory 
control associated with liver mitochondria isolated from treated animals 
and is consistent with an uncoupling action of cisplatin. This finding 
could well explain the ultrastructural appearance of rat liver 
mitochondria observed 48 hours after oral administration of cisplatin
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TIME COURSE OF RAT LIVER 
PLATINUM LEVELS &  AFTER ORAL 
ADMINISTRATION OF PLATINUM BASED 
PHARMACEUTICALS
—  cisplatin,57mg/kg (p.o)
- carboplatin,282mg/kg (p.o)
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(a> tissues were acid digested and resuspended 
in 1% Hcl prior to analysis by atomic 
absorption spectroscopy.
results are means,±sem (n=3)
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as agents known to have an uncoupling action have been shown to 
induce gross mitochondrial swelling in vivo (Cain et al. 1987). It must 
be noted that although the respiratory control ratio of succinate 
stimulated oxidative phosphorylation was lower in rat liver 
mitochondria isolated 3 days after cisplatin treatment than in controls, 
uncoupling did not reach significance (Figure 4.26). The uncoupling 
effect per se may have been lower in these isolated mitochondrial 
preparations than in vivo since, as was described previously in this 
chapter, swollen mitochondria tend to pellet out in the nuclear fraction 
after centrifugation. Hence the more damaged mitochondria (i.e. the 
more swollen organelles exhibiting uncoupled respiration ) would not 
be present in the mitochondria preparation used in oxygen electrode 
studies and any toxic effect will have been effectively diluted by 
normal organelles.
As was found with intestinal platinum levels, cisplatin was rapidly 
eliminated from the liver between 24 - 48 hours post dosing (Figure
4.28). This tissue clearance was much more rapid than in the kidney 
so that by 48 hours, platinum concentrations were 4 times lower 
("12iig/g dry weight) than found in the kidney (~ 50pg/g dry weight). 
Consistent with all the other tissues analysed, platinum tissue 
deposition in the liver was far greater after cisplatin (30mg/kg) than 
carboplatin (282mg/kg).
4.3.4 HAEMATOLOGY
A summary of the peripheral blood haematology associated with oral 
cisplatin treatment is shown in Table 4.11. The most obvious lesion 
was pronounced erythrocytosis which reached a nadir on the 4th day 
after dosing when the experiment was terminated. This condition was 
manifested as an elevation in the red cell count, haemoglobin
concentration and packed cell volume to levels significantly above the 
normal range. The total leukocyte count (WBC) was consistently lower 
than control values throughout the 4 day post treatment period, 
although significance was not reached. There was however a 
significant change in the neutrophil/lymphocyte ratio, with an increase 
in the peripheral blood total neutrophil count (neutrophilia) and a 
concurrent decrease in circulating lymphocytes (lymphopenia) (Figure
4.29). Accompanying the lymphopenia was a general involution of 
lymphoid tissue. This was most evident in the thymus. Moderate 
atrophy was noted by day 2 with further involution through day 4. 
As the thymus underwent this involution, the cortical aspect shrunk 
somewhat more than the medulla, and during the period of cortical 
contraction the lymphocytes appeared more numerous in the medulla 
than the cortex. This tended to reverse the normal histologic pattern. 
Cisplatin treatment also caused a progressive reduction in the size of 
the spleen resulting from a disappearance of lymphocytes from the 
Malpighian corpuscles (white pulp). Histologically spleen atrophy was 
also recognised by thickened irregular splenic capsules and increases 
in haemosiderin deposition as identified by the Peris prussian blue 
stain (Figure 4.30). Studies on the bone marrow morphology after a 
single oral dose of cisplatin (57mg/kg) revealed a degree of myeloid 
cell hyperplasia (Table 4.12). However, overall there was a mild 
reduction in the total bone marrow cellularity (hypoplasia) resulting 
from a significant decrease in erythroid cell numbers. Therefore bone 
marrow derived from cisplatin treated animals had greatly increased 
myeloid to erythroid cell ratios when compared with control values 
(Figure 4.31). Cisplatin treatment also caused a marked decrease in 
the number of megakaryocytes originating from the marrow (Table
TABLE 4.11
oy
Peripheral blood haematolgy results after oral administration
of cisplatin (57mg/kg) to male wistar rats
DAY TREATMENT HB<a > RBC<b) pcy(c) WBC<d ) ]L<e >
1 Cisplatin 14.79 ± 0.67 7.41 ± 0.71 47.0 ± 0.57 6960 ± 1891 49 ± 18.00 49 + 18.00
Control 11.13 ± 1.71 6.79 ± 0.34 42.0 ± 0.33 7866 ± 988 17 + 3.71 80 + 4.50
2 Cisplatin 15.39 ± 0.38 6.10 ± 0.62 46.0 ± 1.03 4080 ± 1073 52 + 14.00 48 + 5.00
Control 13.00 ± 0.22 6.53 ± 0.41 41.0 ± 1.50 7773 ± 1570 20 + 0.33 79 + 2.08
4 Cisplatin 22.85 ± 3.40 11.73 ± 0.85 61.0 ± 5.90 5760 ±1109 64 + 14.0 32 ± 13.00
Control 14.08 ± 0.21 7.70 ± 0.65 42.0 ± 0.57 9629 ± 1975 31 + 8.5 61 + 9.00
Results are means ±SEM for n = 3 animals per group.
ABBREVIATIONS
Hb = haemoglobin RBC = red blood cell count
PCV = packed cell volume WBC = white blood cell count
N = neutrophil count L = lymphocyte count
(a) g/dl
(b) x 106/pl
(c) %
(d) x 103/pl
(e) %  total WBC
TABLE 4.12
Bone marrow morphology after oral administration
of cisplatin (57mg/kg) to male wistar rats
MORPHOLOGY CISPLATIN 
DAY 
1 2
CONTROL
DAY
2
CELLULARITY
Normal
Reduced
PREDOMINANT CELL
Adult normoblasts/myeloid
Adult normoblasts/neutrophil
Mature myeloid
Myeloid precursor
Adult neutrophil
Mature erythroid/neutrophil
ERYTHROBLAST
Normal
Few
GRANULOCYTES
Normal
Increased
LYMPHOCYTES
Normal
Few
Increased
MONOCYTES
Normal
Few
Increased
PLASMA CELL
Normal
Few
Increased
MEGAKARYOCTES
Normal
Few
OTHER FEATURES 
Many atypical cells 
Abnormal mitotic figures
NUMBER OF ANIMALS
A d e c re a se  in  th e s e  p la te le t  p r e c u r s o r s  in d ic a te s  t h a t  c is p la t in  t r e a te d  
a n im a ls  w o u ld  h a v e  d e v e lo p e d  th ro m b o c y to p e n ia  i f  th e  e x p e r im e n t had  
p ro g re s s e d  p a s t  4 d a y s .
C a rb o p la t in  t r e a te d  a n im a ls  d e v e lo p e d  h a e m a to lo g ic a l le s io n s  th a t  w e re  
s im ila r ,  y e t  m ild e r  th a n  fo u n d  a f te r  c is p la t in  a d m in is t ra t io n  (T a b le  
4 .13 ). E r y th r o c y to s is  w as e v id e n t  fro m  4 d a y s  a f t e r  a d m in is t ra t io n  , 
re a c h e d  a n a d ir  7 d a y s  a f t e r  t re a tm e n t y e t  w as r e v e r s ib le  w i th  
" n o rm a l”  v a lu e s  o f  re d  c e ll c o u n t,  h a e m o g lo b in  c o n c e n tra t io n  a n d  
p a c k e d  c e ll v o lu m e  b e in g  o b ta in e d  b y  14 d a y s . N e u tro p h i l ia  w as 
e v id e n t  1, 2, 4 a n d  7 d a y s  a f t e r  t r e a tm e n t  a n d  a s s o c ia te d  ly m p h o p e n ia  
d e v e lo p e d  b y  d a y  2 t h r o u g h  to  d a y  7. As w i t h  th e  e r y th r o c y to s is  
t h i s  d r u g  in d u c e d  r e d u c t io n  in  th e  ly m p h o c y t e / n e u t r o p h i l  r a t io  
re a c h e d  a n a d ir  7 d a y s  a f t e r  a d m in is t ra t io n  b u t  re c o v e re d  to  n o rm a l 
v a lu e s  b y  d a y  14 (F ig u re  4 .29). A lth o u g h  th e r e  w as no tim e  re la te d  
p a t te r n  in  th e  le u k o c y te  c o u n t  o f c a rb o p la t in  t r e a te d  a n im a ls  b o th  th e  
th y m u s  a n d  s p le e n  (T a b le  4 .1) show ed  a t im e  re la te d  in v o lu t io n  t h a t  
w as m axim al b y  d a y  4. T he  s p le e n s  o f  r a ts  s u r v iv in g  th e  in to x ic a t io n  
e x h ib ite d  ly m p h o id  re g e n e ra t io n  w ith  e n la rg e m e n t o f th e  M a lp ig h ia n  
c o rp u s c le s  in d ic a t in g  th a t  th e  c a rb o p la t in  in d u c e d  h a e m o p o ie tic  le s io n s  
w e re  r e v e r s ib le  a t  th e  dose a d m in is te re d  (2 8 2 m g /k g ) .
TABLE 4.13
0
Peripheral blood haematolgy results after oral administration
of carboplatin (282mg/kg) to male wistar rats
DAY TREATMENT HB<a > RBC<b > PCV<c ) WBC^d ) N (eJ
1 Carboplatin 13.28 ± 0.33 6.56 ± 0.71 39.3 ± 1.33 5253 ± 430 14.6 ± 1.8 83 ± 1 . 7 3
Control 13.10 ± 0.20 7.08 ± 0.80 39.5 ±  1.50 5940 ± 1223 27.0 ± 7.0 71 ± 7.50
2 Carboplatin 13.58 ± 0.11 7.44 ± 0.03 41.3 ±  0.88 7506 ± 1319 40.0 ±10.1 56 ± 11.80
Control 13.63 ± 0.45 5.69 ±  0.01 42.0 ± 1.00 5360 ± 521 19.0 ± 2.0 75 ± 2.50
4 Carboplatin 14.78 ± 0.90 7.91 ± 0.88 47.0 ± 1.63 6386 + 1835 27.0 ± 7.5 68 ± 7.30
Control 13.66 ± 1.03 7.58 ± 0.28 42.0 ± 1.00 10480 ± 682 17.0 ± 1.4 78 ± 1.60
7 Carboplatin 17.45 ± 1.08 8.79 ± 0.03 51.0 ±  2.30/ 8480 ± 227 38.0 ± 7.0 52 ±10.40
Control 13.12 ± 0.08 6.37 ± 0.04 39.5 ± 0.50 5780 ± 220 15.0 ± 1.0 83 ± 3.00
14 Carboplatin 13.93 ± 0.40 6.71 ± 0.76 41.0 ± 0.57 8413 ± 237 22.0 ± 2.0 73 ±  2.60
Control 13.82 ± 0.68 6.47 ± 0.28 40.5 ± 1.50 6080 ± 80 18.0 ± 3.5 81 ± 2.50
28 Carboplatin 13.82 ± 0.77 8.26 ± 0.76 42.0 ± 1.00 5920 ± 65 15.5 ± 1 . 5  81 ± 2.00
Control 14.37 ± 0.14 7.65 ±0.51 41.0 ± 0.57 7080 ± 2319 22.0 ± 1.0 76 ± 2.50
Results are means ±SEM for n = 3 animals per group.
ABBREVIATIONS
Hb = haemoglobin
PCV = packed cell volume
N = neutrophil count
(a) g/dl
(b) x 106/pl
(c) %
(d) x 103/pl
(e) % total WBC
RBC = red blood cell count 
WBC = white blood cell count 
L = lymphocyte count
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FIGURE 4.29
MEAN LYMPHOCYTE/NEUTROPHIL RATIO IN 
MALE WISTAR RATS FOLLOWING ORAL ADMINISTRATION 
OF PLATINUM BASED PHARMACEUTICALS.
upper limit of control
lower limit of control
TIME (DAYS)
carboplatin; 282nig/kg(p.o) 
cisplatin ; 57mg/kg(p.o)
Figure 4.30
PHOTOGRAPH OF FORMALIN FIXED,PARAFFIN WAX 
EMBEDDED SPLEEN SECTIONS
(a) SECTION TAKEN FROM CONTROL MALE WISTAR RAT AND STAINED 
WITH PERLS PRUSSIAN BLUE. (xlOO)
(b) SECTION TAKEN FROM MALE WISTAR RAT KILLED 8 DAYS AFTER 
RECEIVING CARBOPLATIN (282mg/kg) BY ORAL GAVAGE.STAINED 
WITH PERLS PRUSSIAN BLUE.
Micrograph demonstrates a relative increase in haemosiderin 
deposition. (xlOO)
(c) SECTION TAKEN FROM MALE WISTAR RAT KILLED 8 DAYS AFTER 
RECEIVING CARBOPLATIN (282mg/kg) BY ORAL GAVAGE.STAINED 
WITH HAEMATOXYLIN AND EOSIN.
Micrograph demonstrates a thickened irregular splenic 
capsule. (x79)
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FIGURE 4.31
MYELOID/ERYTHROID RATIOS IN BONE MARROW 
OF MALE WISTAR RATS AFTER ORAL ADMINISTRATION 
OF CISPLATIN(57mg/kg).
4.0-
3.0.
2.0
limits of untreated control
TIME (DAYS)
results are means (n=3)
4.4 DISCUSSION
The results presented in this chapter appear to indicate that the 
toxicities associated with oral administration are in general consistent 
with the effects of the parenteral use of platinum complexes. Oral 
administration does however potentiate drug induced gastrointestinal 
toxicity and could possibly result in a higher incidence of hepatotoxic 
responses. As has been demonstrated after perenteral administration, 
in general target organ toxicity was less profound after carboplatin 
than cisplatin.
4.4.1 GASTROINTESTINAL TOXICITY
Gastrointestinal toxicity after oral administration of cisplatin or 
carboplatin was typically manifested as acute necrotizing enteritis 
initially involving cellular necrosis of the proliferating cells of the 
crypts of Leiberkiihn. Following this phenomena, the villus height 
became stunted and mucosal function, as measured here by 
dissacharidase activity, was diminished. Carboplatin was typically less 
toxic than cisplatin, with compensatory hyperplasia and regeneration 
of intestinal epithelium occurring by day 4 and total recovery of 
mucosal function 8 days post treatment. Since maximal crypt cell 
necrosis seen on days 1 and 2 seemed to be related to the high tissue 
content of platinum on these days, the relatively higher tissue 
concentrations of platinum attained after cisplatin may account for its 
greater gastrointestinal toxicity. Similar effects on the small intestinal 
mucosa have been observed after perenteral administration of cisplatin 
(Kociba et al. 1971, Choie et al. 1981a,Allan et al. 1986) and closely 
parallel those reported for other forms of treatment such as 
X-irradiation (Lesher et al. 1977) or chemotherapy with radiomimetic 
compounds (Meyn et al. 1980).
Thus it is highly likely that the mechanism of intestinal cytotoxicity of 
platinum compounds involves a direct interaction with DNA.
Rats treated orally with either cisplatin or carboplatin exhibited 
varying degrees of gastric distention. Such an effect has also been 
observed after perenteral administration (Roos et al. 1981) and could 
be attributed to hypercontractility of the pyloric sphincter, since 
cisplatin has been shown to induce hypercontractility in gastric 
smooth muscle in vitro (San Antonio et al. 1984). This was thought to 
occur by a mechanism involving alterations in calcium homeostasis due 
to cisplatin induced efflux of calcium from mitochondria in the smooth 
muscle cells. Stomach bloat was shown to cause a significant retention 
of the platinum complexes within the gastric pouch. This resulted in 
necrosis of extensive regions of the glandular epithelium and marked 
ulceration of the stomach up to 14 days post treatment. This 
observation itself raises the question of whether these compounds 
could ever be administered in an oral dosage form to man. Oral 
administration of the two compounds at a bioequivalent dose to an 
animal capable of eliciting an emetic response, namely the ferret, 
clearly showed that carboplatin was less emetic. This finding is in 
agreement with the results obtained following intravenous 
administration of the compounds to ferrets (Schurig et al. 1984). The 
short latent period for cisplatin (of approximately 40 minutes) 
suggests that emesis was induced, at least in part, by a direct 
mechanism mediated via the gastric mucosa. In contrast the latent 
period for carboplatin was more than 3 times longer (ie. 2-3 hours) 
which implies that emesis occurred only after significant absorption of 
the drug. In these circumstances it is reasonable to propose that 
emesis was mediated by a central effect (ie. by direct action on the 
chemoreceptor trigger zone).
No such difference in latent period occurred following intravenous 
administration of these two compounds (Shurig et al. 1984). The 
substantial difference in latent period between carboplatin and 
cisplatin following oral administration would have a profound effect on 
the pharmacokinetics as a higher percentage of an oral dose of 
carboplatin would be absorbed than would be likely to occur after a 
similar dose of cisplatin. Hence on the basis of reduced 
gastrointestinal toxicity, carboplatin appears to be better suited to 
oral delivery than cisplatin. However, the development of a pro-drug 
(in which the active parent compound is regenerated only after 
transport across the gastrointestinal mucosa), would offer significant 
advantages.
4.4.2 NEPHROTOXICITY
After oral administration, nephrotoxicity was typically manifested as 
elevations in the serum concentrations of B U N  and creatinine. The 
first histopathologic lesions were observed 3 days post dosing and 
were present at up to 14 days. These were as previously described 
for perenteral administration of cisplatin (section 1.5.1.) and took the 
form of acute tubular necrosis and dilatation of the corticomedullary 
junction, predominantly in the S3 portion of the proximal tubule. 
Unlike the parent compound, carboplatin did not elicit gross necrotic 
changes in the kidney. However, oral administration of this compound 
did result in larger than normal numbers of enlarged nuclei in the 
cells of the loop of Henle and the proximal tubule. The presence of 
Karyomegaly in these specific regions on the renal tubules may 
indicate inhibition of mitosis in cells which were attempting to 
re-populate the adjacent damaged nephron segments.
While this observation is not in itself remarkable, considering the 
cytotoxic nature of these compounds, it would be interesting to 
establish the fate of such abnormal cells. The lack of gross pathologic 
changes in the kidney after carboplatin has also been reported after 
perenteral administration of the compound to animals (Harrap et al. 
1980, Levine et al. 1981) and man (Calvert et al. 1984). Attempts to 
correlate the differential nephrotoxicity of cisplatin and carboplatin 
with the degree of active tubular handling in their clearance has 
yielded conflicting results. Fractional clearance values in excess of one 
have been reported for cisplatin (Siddik et al. 1986,Osman and 
Litterst. 1983. Daley-Yates and McBrien. 1982b ) indicating that
excretion involves renal secretion ( peritubular transport.) as well as 
glomerular filtration. However whereas Siddik et al. (1986) have 
indicated that carboplatin is cleared exclusively by glomerular 
filtration (with a fractional clearance of approx. one),the measurements 
made by Daley-Yates and McBrien (1985) indicate that renal secretion 
is also involved. It may be significant that urinary excretion of 
carboplatin is predominantly as unchanged drug (Newell et al. 1984) 
indicating its superior chemical stability compared to cisplatin. Thus, 
nephrotoxicity may therefore be unrelated to clearance but may only 
be due to the relative ability of the two compounds to interact with 
essential intracellular ligands whilst in transit through the kidney.
4.4.3 HEPATOTOXICITY
Oral administration of O.lmmole/kg of either cisplatin (30mg/kg) or 
carboplatin (37mg/kg) to rats resulted in a number of hepatic lesions 
that could be observed at the ultrastructural level. Such lesions were 
seen 48 hours after administration and were focal in nature (typically 
in the vicinity of the portal tract) consisting of swollen and
degenerating mitochondria and numerous myelin-like figures (Binks 
and Dobrota 1986). In the case of carboplatin the hepatocytes 
contained areas of endoplasmic reticulum that was extremely 
vesiculated. Barni et al. (1985) have reported similar morphological 
changes 24 hours after subcutaneous administration of cisplatin (5pg/g. 
body weight) to 10 day old rats. However considering that the liver 
is second only to the kidney in its ability to take up cisplatin, there 
have been relatively few reports of cisplatin induced hepatotoxicity 
(Prestayko et al. 1980). Although no reports of carboplatin induced 
hepatic lesions exist, Daskal et al (1980) noted that a number of 
second generation platinum complexes (eg Iproplatin) induced hepatic 
lesions at the ultrastructure level that are consistent with those 
reported here after oral administration.
The fact that many of the myelin-like figures appeared to originate 
from degenerating mitochondria provides evidence that the 
mitochondrion is the target subcellular structure of the liver which is 
initially effected by oral administration of platinum based 
pharmaceuticals. Although the oral administration of cisplatin had 
little effect upon the specific activity of several mitochondrial 
enzymes, the existence of swollen, enlarged mitochondria was 
demonstrated by an alteration in the distribution pattern of 
mitochondrial marker enzymes after differential pelleting. When these 
mitochondria were isolated and their respiratory capacity studied with 
an oxygen electrode, it was found that 3 days post dosing there was a 
significant increase in the rate of fl-hydroxybutyrate stimulated state 4 
respiration. This is similar to an apparent uncoupling of oxidative 
phosphorylation and may indicate a profound modification of the 
mitochondrial inner membrane. Such an effect is often found in 
agents that cause mitochondrial swelling and has been observed after
addition of cis-Platinum (II) diaminotoluene to isolated rat liver 
mitochondria in vitro (Binet et al. 1977). To date cisplatin induced 
mitochondrial alterations have only been demonstrated in vivo in the 
kidneys of treated animals (Gordon et al. 1986, Simmons and Humesfl 979) 
and have been implicated as the primary pathogenic event in cisplatin 
nephrotoxicity. Whether mitochondrial damage in the liver is such an 
important pathogenic event is debatable since little evidence of hepatic 
malfunction was observed either at the light microscopic level or using 
diagnostic serum enzymes.
The other ultrastructural liver lesion that was observed after oral 
administration of platinum complexes was a vesiculation of the 
endoplasmic reticulum. Like the mitochondrial lesion, glycogen 
depletion and accumulation of lipid (in the ferret) this pathological 
change was only observed in cells in the periportal region of the 
liver. The cells in this zone are notable in that they receive, fresh 
blood from the gastrointestinal tract and hence will be exposed to 
higher concentrations of exogenous material absorbed from the small 
intestine. Thus the toxic response elicited by cells in this region may 
be due to the fact that they receive higher concentrations of the 
platinum complexes than cells that are midzonal or centrilobular. 
Biochemical evidence of the endoplasmic recticulum lesion that was 
observed ultrastructurally was sought by assaying enzymes closely 
associated with this organelle; namely glucose-6-phosphatase and 
cytochrome P450. Oral administration of cisplatin (30mg/Kg) initially 
resulted in an increase in total hepatic P450 levels, but by 3 days 
post-treatment there was a significant decrease in levels. This was 
maintained until 14 days after administration. A similar dose related 
decrease in hepatic cytochrome P450 levels has been reported by 
Holbrook et al. (1976) after i.p. administration of PtCU to rats.
However, Litterst et al (1983) indicated that hepatic cytochrome P450 
levels were unchanged after i.p. administration of 8mg/Kg cisplatin. 
One of the coordination valencies of the iron of the haem moiety of 
cytochrome P 450 is saturated by a thiol ligand. This sulphur 
containing ligand is responsible for the function of the haemprotein. 
Thus, cisplatin may elicit an effect on hepatic tissue by binding to 
this thiol group resulting in the formation of cytochrome P420, an 
unstable derivative of P450, devoid of functional activity. Apart from 
a depression in hepatic cytochrome P450 content, cisplatin induced 
endoplasmic reticulum damage was also detected, as a depression in 
glucose-6-phosphatase activity. Thus like mitochondria, the 
endoplasmic reticulum also appears to be a target in cisplatin induced 
hepatotoxicity. Such ultrastructural changes within a cell ultimately 
progress to the complete degradation of cell components that are 
visible by light microscopy. It is interesting to speculate w h y  no 
such gross hepatic lesions were observed after oral administration of 
platinum complexes and it must be of importance to extend the time 
course of the ultrastructural observations to establish the fate of the 
damaged organelles.
4.4.4 HAEMATOLOGICAL TOXICITY
The most obvious haematological lesion associated with oral 
administration of cisplatin or carboplatin was severe erythrocytosis. 
This was manifested as elevations in red cell count, haemoglobin and 
packed cell volume that were significantly above the normal range. It 
it clearly important to distinguish a true increase in the circulating 
red cell mass from an apparent increase due to a diminished plasma 
volume such as commonly occurs in dehydration (relative 
polycythemia).
There are two main conditions in which there is a true increase in red 
cell mass; primary and secondary polycythemia. The former is a myelo 
proliferative disorder characterised by uncontrolled proliferation of 
erythroid, myeloid and megakaryocytic bone marrow elements, whereas 
the latter is a result of enhanced erythropoietin release in response 
to tissue hypoxia. The evidence presented here suggests against 
primary polycythemia as cisplatin administration caused a marked 
decrease in .bone marrow cellularity. Although secondary polycythemia 
could be caused by cisplatin induced renal lesions, most evidence 
indicates that erythrocytosis was due to a dehydration related 
decrease in plasma volume. Dehydration was probably brought on 
because of decreased water intake and polyuria brought about by an 
impaired renal concentration mechanism. Gordon et al. (1982) have 
suggested that such a cisplatin induced impairment of renal 
concentration is due to impaired release or synthesis of vasopressin 
followed by decreased interstitial tonicity.
As was found after i.v. administration (Rose et al. 1985), oral cisplatin 
also caused a marked elevation in bone marrow myeloid to erythroid 
cell ratios, a decrease in megakaryocytes, neutrophilia and 
lymphopenia with associated involution in lymphoid tissue. The
increase in the peripheral blood neutrophil count could well be as a 
consequence of tissue lesions such as occurred in the gastrointestinal 
tract. Unlike cisplatin, oral administration of carboplatin did not
result in a white blood cell count that was consistently lower than 
found in controls. In this case, experimental values oscillated about 
normal values, however dose related lymphopenia did occur. The
lymphocyte/neutrophil ratio fell and reached a nadir 7 days
post-treatment. Recovery was complete within 14 days. In general 
carboplatin (282mg/Kg) animals developed haematological lesions that
were similar yet milder than found after cisplatin (57mg/Kg). As was 
mentioned for the gastrointestinal lesions, haematological toxicity 
developed after oral administration of cisplatin or carboplatin is very 
similar to that reported for X-irradiation and radiomimetic drugs and 
is probably a consequence of a direct interaction with DNA. It may be 
significant that although both compounds did produce a degree of 
myelosuppression, the decrease in total white blood cell count was not 
as severe as reported after perenteral administration of these 
compounds (Rose et al. 1985).
CHAPTER 5
INTRACELLULAR LOCALISATION OF CISPLATIN 
AFTER ORAL ADMINISTRATION
5.1 INTRODUCTION
To understand the toxic and therapeutic effects of an agent it is 
useful to know its sites of localisation and concentration within the 
cell and the molecular species with which it interacts. Table 1.3 
illustrated that the highest tissue levels of platinum after parenteral 
administration of cisplatin, are found in the kidneys although the liver 
also retains a substantial amount of the injected dose. At the 
subcellular level, Choie et al. (1980), Sharma et al. (1983) and Litterst 
et al. (1986) have shown that cisplatin is associated with cell fractions 
of the nucleus, microsomes, mitochondria and cytosol of both the 
kidney and the liver. Siddik et al.(1986) showed that although 
platinum was localised largely in the cytosol of the rat kidney the 
mitochondrial/lysosomal fraction contained the highest concentrations 
of the metal.
Isolated cells in tissue culture have been used to investigate the 
subcellular distribution of platinum by x-ray microprobe analysis. 
Kahn and Sadler (1978) detected platinum in HeLa cells treated with 
cisplatin and found platinum only in electron dense deposits within 
the nucleus. This observation was later repeated by Daley-Yates 
(1981) using Chinese Hamster ovary (CHO) cells. The subcellular 
localisation of cisplatin has also been studied in vivo using 
microanalytical techniques. Berry et al. (1982) and Makita et al. (1985) 
showed that platinum accumulated in lysosomes or possibly microbodies 
in epithelial cells of rat kidney proximal tubules after administration 
of cisplatin. Makita et al. (1985) also reported that platinum may be 
present within microbodies of the liver.
As oral administration of platinum based pharmaceuticals is such a 
novel concept no work on the subcellular distribution of platinum 
after administration by this route has been undertaken. The aims of
this study were therefore to examine the subcellular sites of 
accumulation of platinum after oral administration of cisplatin, to 
compare the results with those found after perenteral administration 
and to relate this to any difference in toxicity exhibited. Whereas all 
work to date has been either fractionation studies or microanalytical 
techniques this study utilizes both methods concurrently in order to 
determine sites of subcellular localisation of platinum within tissues.
5.2 MATERIALS AND METHODS
All chemicals and biochemicals were of analytical grade except where 
otherwise stated and were obtained from either BDH Chemicals Ltd, 
Poole, Dorset, England or from the Sigma Chemical Co Ltd, Poole, 
Dorset, England. Test compounds were the kind gifts of Johnson 
Matthey Research Centre, Sonning Common, Berkshire, England.
5.2.1 ANIMAL HUSBANDRY
Male University of Surrey strain wistar rats (200-250g) were housed 
and maintained as described in Section 4.2.1. Cisplatin was 
administered by orogastric gavage either suspended in a tragacanth 
mucilage for bolus dosing or dissolved in sterile 0.9% saline for daily 
dosing.
5.2.2 LIVER FRACTIONATION
Animals were dosed with 30mg/kg cisplatin suspended in a tragacanth 
mucilage by orogastric gavage. Twenty-four hours later the animals 
were killed by cervical dislocation and the livers were quickly excised, 
weighed and placed in a beaker containing ice-cold 0.25M sucrose, 5mM 
Tris-HCl pH7.4. A 10% (w/v) homogenate was produced and the
classical subfractions Nuclear (N), mitochondrial/lysosomal (ML),
microsomal (mic) and cytosolic (cyt) were prepared as described in 
Section 4.2.5. Marker enzyme activities (Section 4.2.6) were then 
determined for each fraction. At this stage, the fractions were then 
stored at -18 °C until required for platinum determinations. To 
determine the platinum content of each fraction, the fraction was 
thawed and an appropriate volume was wet ashed and then subjected 
to atomic absorption spectrophotometry as described in Section 
2.2.3(d).
5.2.3 KIDNEY FRACTIONATION
REFERENCE: Andersen, K.J. et al. (1987) Kidney Int 31: 886-897. 
DIFFERENTIAL CENTRIFUGATION
Cisplatin was administered to male University of Surrey strain wistar 
rats (200-250g) by orogastric gavage either as a bolus dose 
(57mg/kg), or daily (2mg/kg) for 28 days. Twenty-four hours after the 
bolus dose or the last of the daily administrations, the animals were 
killed by cervical dislocation. The kidneys were quickly excised, 
weighed and placed in ice-cold 0.25M sucrose, 5mM Tris-HCl pH7.4. 
Entire cortices were carefully dissected free and homogenised in 0.25M 
sucrose 5mM Tris-HCl pH7.4 using a Potter-Elvenjhem homogeniser 
power driven at 1,000 rev/min. The 10% (w/v) homogenate was filtered 
through a coarse sieve to remove unbroken tissue and then spun at 
l,000xg (1,500 rev/min) in a Beckman TJ-6 centrifuge for 2 minutes. 
This produces a nuclear pellet (N) which was resuspended in 0.25M 
sucrose, centrifuged again, and the combined supernatants spun at 
10,000xg (10,000 rev/min) in an HS 18 centrifuge for 3 minutes to 
pellet the mitochondrial/lysosomal fraction (ML). This procedure has 
been found to improve the recovery of lysosomes in the "ML" fraction. 
The nuclear pellet was finally resuspended in 0.25M sucrose, 5mM
FIGURE 5.1 SCHEME FOR KIDNEY FRACTIONATION
CELL HOMOGENATE (10%)
Centrifuge at l,000xg 
for 2 minutes
SUPERNATANT I NUCLEAR PELLET
Resuspend in 0.25M sucrose, 5mM
Combine with supernatant II
Centrifuge at l,000xg 
for 2 minutes
NUCLEAR FRACTIONSUPERNATANT II
Resuspend in 0.25M sucrose, 5mM Tris-HCl pH7.4
Centrifuge at 10,000xg 
for 3 minutes
SUPERNATANT III MITOCHONDRIAL FRACTION
(mitochondria, peroxisomes & lysosomes)
Resuspend in 0.25M sucrose, 5mM Tris-HCl pH7.4
Spin at 104,000xg 
for 1 hour
CYTOSOL
Load on to ZONAL ROTOR for 
density gradient centrifugation
MICROSOMAL FRACTION
(endoplasmic reticulum, vesicles derived from 
plasma membrane and Golgi apparatus)
Resuspend in 0.25M sucrose, 5mM Tris-HCl pH7.4
Tris-HCl pH7.4 and kept on ice until required for marker enzyme 
analysis whilst the "ML" fraction was being prepared. After the "ML" 
pellet had been produced, the supernatant was decanted off and the 
pellet was resuspended in about 20-25ml of 0.25M sucrose, 5mM 
Tris-HCl pH7.4 with a hand operated homogeniser. A 2ml aliquot was 
retained for marker enzyme analysis and the remainder was kept for 
the HS zonal spin. The post "ML" supernatant that had been 
decanted off was then spun at 105,000xg (40,000 rev/min) in a Kontron 
Centrikon T-2055 ultracentrifuge for one hour.
The microsomal pellet produced was resuspended in 0.25M sucrose, 
5mM Tris-HCl pH7.4 using a Potter type homogeniser powered at 1,000 
rev/min. This was then retained along with the supernatant (cytosol) 
for marker enzyme analysis. After marker enzyme activities (Section 
4.2.6) had been determined for all fractions, they were stored at -18°C 
until required for platinum determination by atomic absorption 
spectrophotometry. This was achieved after wet ashing as described in 
Section 2.2.3(d). The kidney fractionation scheme is summarised in 
Figure 5.1.
DENSITY GRADIENT CENTRIFUGATION
The "ML" fraction was resuspended in the isotonic buffered sucrose 
and further subfractionated by rate sedimentation in an HS zonal 
rotor (MSE Scientific Instruments, Crawley, Sussex, England) in order 
to resolve the various lysosomal populations and other organelles of 
the kidney cortex. 550ml of an exponential sucrose (with 5mM Tris-HCl 
pH7.4) gradient ranging from 0.5M to 1.7M,and 150ml of 2M sucrose as 
the cushion were loaded into the rotor. The resuspended "ML" 
fraction was then placed into a 50ml syringe and carefully loaded into 
the centre of the rotor. This was then displaced from the centre core 
by 45ml of 0.1M sucrose and the rotor was accelerated to 8,000
rev/min and spun for one hour. After the hour, the rotor was 
decelerated to 1,500 rev/min and 35, 20ml fractions were collected by 
displacement with 2M sucrose. Marker enzyme activities and platinum 
concentrations (after wet ashing) were then determined for each 
fraction as previously described (Sections 4.2.6 and 2.2.3(d) 
respectively).
5.2.4 DETERMINATION OF KIDNEY LYSOSOMAL LATENCY 
Animals were dosed with 30mg/kg cisplatin suspended in a tragacanth 
mucilage by orogastric gavage. Control animals received tragacanth 
alone. At the appropriate time point (1, 3, 7 and 14 days after 
dosing) animals from both test and control groups were killed by 
cervical dislocation and the kidneys were rapidly removed. These 
were weighed, placed in ice-cold 0.25M sucrose 5mM Tris-HCl pH7.4 and 
the cortices were carefully excised and pooled into test and control 
groups. 10% (w/v) homogenates were made and "ML" fractions were 
prepared as previously described (Section 5.2.3).
The effect of cisplatin upon lysosomal membranes integrity was then 
determined in the "ML" fraction by measurements of latency. Two 
separate methods were used to study the latency.
(a) SEDIMENTATION
Acid hydrolase activity (Section 4.2.6b) was first determined in the 
whole "ML" suspension. This was then spun at 10,000xg in an HS 18 
centrifuge for a further 3 minutes to produce a pellet and 
supernatant. The volume of the supernatant was noted and the pellet 
was gently resuspended using a hand held Potter type homogeniser in 
10ml of isotonic buffered sucrose. The acid hydrolase activity was 
then determined in both the resuspended pellet and the supernatant.
Latency was then determined as a percentage using the following 
equation.
Latency = "total" activity - 11 free11 activity x 100
total activity
Where "total" activity = acid hydrolase activity of whole "ML" 
suspension.
Where "free" activity = acid hydrolase activity of supernatant after 
lysosomes removed by sedimentation.
(b) DETERGENT
A more common way of determining latency is to assay an appropriate 
acid hydrolase in the presence of detergent (this gives total activity) 
and in the absence of detergent (this gives free activity). For this 
method the activity of acid hydrolases, acid phosphatase and 
£}-Galactosidase, was determined in the "ML" suspension as described in 
Section 4.2.6b with and without the presence of digitonin. It was 
important that the incubation time was kept to a minimum so that 
minimal autolytic breakage of intact lysosomes occurred during the 
incubation period. Latency was calculated from the total and free 
activities using the same equation as above.
5.2.5 G-75 CO L U M N  CHROMATOGRAPHY OF KIDNEY CYTOSOLIC FRACTION
(i) CHROMATOGRAPHY
REAGENT
(1) AMMON I U M  FORMATE BUFFER. A 1M stock solution was made by 
addition of 6.30g of ammonium formate to 100ml of distilled water to 
give a 0.015M working buffer at pH8.0. A few crystals of chlorbutol 
were then added to this to give bacterioside protection.
METHOD
Frozen cytosols obtained from the fractionation of kidneys excised 
from cisplatin treated rats (Section 5.2.3) were thawed and particulate 
matter removed by passage through an Acrodisc 0.45 micron filter 
assembly (Gelman International Ltd, Northampton, England). 1.5ml of 
the filtered cytosol was then applied to the top of a 24 x 1.0cm G-75 
sephadex column (Pharmacia Ltd, Uppsala, Sweden). The sample was 
then eluted from the column with 0.015M ammonium formate buffer 
pH8.0 at such a rate that fifty, 2ml fractions could be collected. This 
was achieved using a LKB ultrarack fraction collector. Absorbance of 
the eluent was continually monitored at 254nm throughout the run 
using a LKB uvicord 2 colorimeter. Before each run the G-75 column 
was calibrated with the use of standards of a known molecular weight. 
The standards chosen in this case were Blue dextran (Mwt. 2,000,000), 
RNase (Mwt.14,000), Cd-thionein (Mwt.7,000), reduced glutathione 
(Mwt.307) and 5*-AMP (Mwt.365).
(ii) ANALYSIS OF THE METAL CONTENT OF FRACTIONS COLLECTED
FROM G-75 COLUMN
REAGENTS
(1) Pt(NH3)4Cl2 stock solution (lmg Pt/ml)
172mg of Pt(NH3)4Ch were dissolved in lOmls of 6M HC1. Distilled water 
was then added to make the volume up to 100ml.
(2) Zinc chloride stock solution (5mM) spectrosol grade. BDH Chemicals 
Ltd, Poole, Dorset, England.
(3) Copper chloride stock solution (5mM) spectrosol grade. BDH 
Chemicals Ltd, Poole, Dorset, England.
METHOD
Platinum levels in undiluted fractions were determined by 
electrothermal atomic absorption spectroscopy using matrix matched 
platinum standards as described in Table 2.2. Copper and zinc levels 
were also determined.For this, fractions were diluted 1 in 5 with 
reverse osmosis deionised water and analysed by aspiration into the 
flame of an IL.353 using the programs listed in Table 5.1. As with the 
platinum analysis, the zinc and copper chloride standards were matrix 
matched with the samples by addition of the appropriate volume of 
ammonium formate buffer.
5.2.6 X-RAY MICROPROBE ANALYSIS
Cisplatin (lmg/kg) was administered by orogastric gavage daily for 35 
days to 3 male albino wistar rats. Control animals received an 
equivalent volume of 0.9% saline. The animals were killed by cervical 
dislocation. The kidneys, liver, duodenum and ileum were rapidly 
excised. Slices of tissue 0.5-lmm thick, were cut using a microtome 
blade. These were then diced and placed into jars containing ice-cold 
4% glutaraldehyde solution buffered with 0.1M cacodylate buffer pH7.4 
for 2 hours. The samples were then washed in cacodylate buffer for 
20 minutes before being divided into two groups. One group was 
taken into osmium and processed for electron microscopy as described 
in section 4.2.4, whilst the other group was taken directly into 25% 
alcohol omitting the osmium counterfixation before being processed as 
described previously.
After ultra thin sections had been cut the osmium fixed samples were 
mounted on to copper grids and stained with both uranyl acetate and 
lead citrate. However, the unosmicated sections were mounted on 
aluminium grids and either left unstained or were stained with uranyl
TABLE 5.1
Instrumental operating conditions used for the 
analysis of copper and zinc by atomic absorption 
spectroscopy on the IL.353 flame atomic absorption 
spectrophotometer.
Copper Zinc
Lamp current (m A ) 5 10
Wavelength (nm) 324.8 213.9
Slit width 320 320
Photomultiplier 
voltage (v)
530 530
Flame
(air/acetylene)
Stoichiometric Stoichiometric
acetate alone. These conditions were found to be necessary as 
osmium, lead and copper interfere and effectively mask the signal 
given by platinum when analysed by x-ray microprobe techniques. 
Both sets of sections were then studied under a Phillips 400T 
Transmission electron microscope at 80KV and later x-ray microprobe 
analysis was carried out on the microscope fitted with a Link systems 
AN 10,000 multichannel analyser at 80KV with a live counting time of 
400 seconds.
5.3 RESULTS
5.3.1 SUBCELLULAR LOCALISATION OF CISPLATIN IN RAT LIVER
(i) HOMOGENEITY OF SUBCELLULAR FRACTIONS
Table 5.2 lists the percentage recoveries of marker enzymes, and 
proteins in the classical fractions of the rat liver 24 hours after oral 
administration of cisplatin (30mg/kg). The highest proportions of 
succinate dehydrogenase, monoamine oxidase, catalase and acid 
phosphatase were found in the "ML” fraction, 55-nucleotidase (AMPase) 
in the nuclear fraction, and glucose-6-phosphatase in the microsomal 
fraction. These relative proportions of marker enzymes and protein in 
the classical subfractions are similar to the distributions observed 
with normal control livers (Figure 4.24), except that the relative 
proportions of succinate dehydrogenase and monoamine oxidase were 
higher in the nuclear fraction of the cisplatin treated livers. Also, 
catalase levels were proportionally higher in the cytosolic fraction of 
control animals, whereas treated animals contained higher levels in the 
"ML" fraction.
TABLE 5.2
Percent recoveries <a > of protein and marker enzymes 
in the classical subfractions of rat liver 24 hours 
after oral administration of 30mg/kg cisplatin
FRACTION SDH MAO ACID P* AMP* G-6-P CAT. PROTEIN
NUC 40.00i3.40 35.00i2.60 27.00i3.00 70.00±1.66 33.00i2.70 12.70i3.10 29.00±1.45
ML 42.00iD.60 39.00i2.50 43.00i3.30 5.60±L.99 14.00+1.40 30.00+2.40 18.00iD.80
MIC 3.70iD.15 7.70iD.73 21.00il.36 14.00+1.70 44.00i2.70 5.80+1.10 14.40iD.36
CYT 0.12 ±3.06 1.18iD.10 14.90iD.10 5.50iD.90 3.50iD.30 25.00i3.60 23.00il.35
(a) Recoveries are presented as a percentage
of the total homogenate v a l u e .Results are means (±SEM) n = 3 
Abbreviations are:
The fractions: NUC (nuclear); ML (mitochondrial/lysosomal); 
MIC (microsomal) and CYT (cytosol).
The enzymes: SDH (succinate dehydrogenase); MAO 
(monoamine oxidase); ACID P* (acid phosphatase);
AMP* (5 *-nucleotidase); G-6-P (glucose-6-phosphatase); 
and CAT (catalase).
TABLE 5.3
Distribution of platinum in subcellular fractions of
the rat liver 24 hours after oral administration of
30mg/kg cisplatin.
FRACTION % RECOVERY* a ) PLATINUM C O N C .* b )
HOM - 13.22 + 3.14
NUC 23.50 ± 2.70 10.13 + 0.99
ML 21.80 ± 5 . 6 0 23.02 + 0.90
MIC 12.70 ± 2.09 8.47 + 1.66
CYT 15.50 ± 0.50 9.36 + 1.33
(a) Recoveries are presented as a mean percentage 
of the total homogenate value.
(b) Concentration presented as mean (ng platinum/mg protein)
± standard error of three determinations.
Abbreviations are: the fractions, HOM (homogenate); NUC 
(nuclear); ML (mitochondrial/lysosomal); MIC (microsomal) 
and CYT (cytosol),
(ii) SUBCELLULAR LOCALISATION OF CISPLATIN
Tissue platinum levels were assayed to estimate the concentrations of 
cisplatin and its metabolites in the liver. The methodology employed 
however did not permit definition of chemical forms of cisplatin in the 
tissue. After oral administration of 30mg/kg cisplatin approximately 
0.15% of the dose is retained in the liver 24 hours after 
administration. This corresponds to a tissue platinum concentration of 
13.22±3.14ng platinum/mg protein (Table 5.3). The total recovery of 
platinum in isolated subfractions was 60-95%. Table 5.3 shows that the 
greatest proportion of platinum was associated with the nuclear (23.5%) 
and "ML" (21.8%) fractions with the cytosolic fraction containing 15.5% 
and the microsomal fraction representing 12.7%.
The specific concentrations of platinum in the subfractions were 
similar (~10ng platinum/mg protein) except in the "ML" fraction which 
contained by far the higher concentration (23ng platinum/mg protein).
5.3.2 SUBCELLULAR LOCALISATION OF CISPLATIN IN RAT KIDNEY 
CORTEX
(i) HOMOGENEITY OF SUBCELLULAR FRACTIONS
Table 5.4 lists the percentage recoveries of marker enzymes and 
protein found in the classical fractions of the kidney cortex excised 
from cisplatin treated animals. The highest proportions of succinate 
dehydrogenase and acid phosphatase were found in the "ML" fraction, 
glucose-6-phosphatase in the microsomal fraction and catalase in the 
cytosolic fraction. Unlike the liver, the highest proportion of 
5’-nucleotidase was found in the microsomal fraction. These relative 
proportions of marker enzymes and protein in the classical 
subfractions are similar to distributions observed with normal, 
untreated kidney cortex (Andersen et al. 1987).
TABLE 5.4
Percent recoveries of protein and marker enzymes
in the classical subtractions of rat kidney cortex 
24 hours after oral administration of;
BOLUS 57mg/kg cisplatin
FRACTION SDH ACID P’ AMP* G-6-P CAT. PROTEIN
NUC 12.10 9.93 16.33 19.80 3.71 14.90
ML 68.10 42.42 18.39 17.23 10.80 27.50
MIC 11.90 14.57 39.80 41.40 8.44 16.60
CYT 1.58 21.70 8.50 4.60 78.70 30.90
) DAILY 2mg/kg cisplatin
FRACTION SDH ACID P ’ AMP’ G-6-P CAT. PROTEIN
NUC 6.71 5.40 8.69 14.49 6.80 13.24
ML 49.70 29.00 17.70 19.32 24.40 23.70
MIC 20.30 15.16 43.53 46.70 15.60 16.09
CYT 5.90 28.80 10.56 8.90 59.00 37.70
(a) Recoveries are presented as a percentage of the 
total homogenate value.
Abbreviations are:
The fractions: NUC (nuclear); ML (mitochondrial/lysosomal) 
MIC (microsomal) and CYT (cytosol).
The enzymes: SDH (succinate dehydrogenase);
ACID P* (acid phosphatase); AMP* (5 *-nucleotidase); G-6-P 
(glucose-6-phosphatase) and CAT (catalase).
(ii) RATE SEDIMENTATION OF CORTICAL LYSOSOMES
Following the rate zonal sedimentation of the "ML" fraction, the 
distribution patterns of protein and marker enzymes indicate three 
main regions (Figure 5.2):
(a) the peak at fraction 1-4 represents the initial sample position and 
hence contains the soluble protein and very small particles which do 
not sediment under these conditions.
(b) this is the major protein peak (fractions 10-22) which is composed 
of mitochondria, brush border membranes, small lysosomes, etc.
(c) the most rapidly sedimenting material, found in fractions 30-32 
contains large lysosomes.
Close examination of the major protein peak (fractions 10-22) reveals 
that the peak of catalase (fraction 14) does not coincide with the 
peaks of succinate dehydrogenase (fraction 17) or 5*-nucleotidase 
(fraction 18) indicating that although peroxisomes, mitochondria and 
brush border membranes are found in this broad band, they are 
partially resolved.
(iii) SUBCELLULAR LOCALISATION OF CISPLATIN AS IDENTIFIED BY 
FRACTIONATION
As with the liver, tissue platinum levels were assayed to estimate the 
concentrations of cisplatin and its metabolites present in the various 
fractions. Twenty-four hours after oral administration of cisplatin 
(57mg/kg) approximately 0.19% of the dose was retained by the 
kidneys. Although this is a similar percentage to that found in the 
liver a far higher tissue platinum concentration was attained (83ng 
platinum/mg protein), even accounting for the higher dose in this 
study. Multiple daily dosing of cisplatin (2mg/kg orally for 28 days) 
resulted in kidney platinum concentrations of 64.95ng platinum/mg 
protein. The total recovery of platinum in the isolated subfractions
PlUUKU D.Z DISTRIBUTION OF PLATINUM AND MARKER ENZYMES 
FOLLOWING RATE ZONAL SEDIMENTATION OF THE CORTICAL M L  
FRACTION.
Regions indicated represent:
(1) initial sample position (soluble, unsedimentable material)
(2) peroxisomes
(3) mitochondria, small lysosomes and brush border plasma 
membrane
(4) large lysosomes (protein droplets)
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TABLE 5.5
Distribution of platinum in subcellular fractions of the rat 
kidney cortex 24 hours after oral administration of cisplatin.
BOLUS 57mg/kg Cis-Pt DAILY 2mg/kg CIS-Pt
FRACTION X RECOVERY*a > Pt. CONC. 
ng/mg protein
X RECOVERY*®) Pt. CONC. 
ng/mg protein
HOM / - 83.05 64.95
NUC 9.50 53.26 8.70 43.04
ML 59.00 176.36 45.70 131.00
MIC 11.39 56.80 12.10 49.10
CYT 23.50 63.22 37.20 67.04
(a) Recoveries are presented as a percentage of the total homogenate value. 
Abbreviations are (fractions);
HOM (homogenate); NUC (nuclear); ML (mitochondrial/lysosomal);
MIC (microsomal) and CYT (cytosol).
from both dosage regimes was 104%. Unlike the liver, the highest 
proportion of platinum was associated with the "ML” fraction (45-60%), 
with less than 10% being found in the nuclear fraction (Table 5.5). The 
microsomal fraction contained approximately 12% of the platinum after 
both dosage regimes, however multiple dosing resulted in an increased 
proportion of platinum in the cytosolic fraction. The highest platinum 
concentration was, like the liver, found in the "ML'’ fraction with 
176ng platinum/mg protein being found after a bolus dose and 131ng 
platinum/mg protein after multiple dosing (Table 5.5). Relatively high 
platinum concentrations were also found in the cytosolic fraction 
(63-67ng platinum /mg protein) whereas the nuclear fraction contained 
the smallest amount of platinum (43-53ng/mg protein).
Further subfractionation of the "ML" fraction by rate zonal 
sedimentation showed that the platinum associated with this fraction
was localised primarily in fractions 1-4, 13-18 and 29-30 (Figure 5.2).
This distribution closely resembles that of acid phosphatase indicating 
a close association with the various populations of lysosomes. This 
close association was consistently obtained with the single and multiple 
doses.
(iv) SUBCELLULAR LOCALISATION OF CISPLATIN AS IDENTIFIED BY 
X-RAY MICROPROBE ANALYSIS.
Examination of kidney cortices obtained from cisplatin treated animals 
by transmission electron microscopy revealed an abundance of large 
lysosomes in the proximal tubule. Many of these lysosomes were seen 
to contain electron dense deposits (Figure 5.3a). X-ray microprobe 
analysis (EDX) of these deposits in the osmium fixed samples showed 
that they contained a large quantity of iron, but no platinum peaks 
could be discerned due to the masking effect of the osmium fixative.
These large iron-containing lysosomes were not unique to treated
FIGURE 5.3
ELECTRON MICROGRAPH OF KIDNEY PROXIMAL TUBULE FROM 
MALE WISTAR RAT THAT HAD RECEIVED CISPLATIN BY ORAL 
GAVAGE AT A DOSE'OF 2mg/kg. DAILY FOR 35 DAYS.
(a) KIDNEY SECTION FIXED IN GLUTARALDEHYDE (4%),COUNTER 
FIXED IN OSMIUM (2%),AND STAINED WITH URANYL ACETATE 
AND LEAD CITRATE.
Micrograph shows lysosomes (L) containing electron 
dense deposits.
(b) KIDNEY SECTION FIXED IN GLUTARALDEHYDE (4%) AND THEN 
STAINED WITH URANYL ACETATE .
Micrograph shows nucleus (N) and lysosome (L) containing 
electron dense deposits that were subjected to electron 
microprobe analysis (E.D.X).E.D.X spectrum of these depos 
is shown in figure 5.4(a).
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FIGURE 5.4
ELECTRON MICROPROBE ANALYSIS OF RAT KIDNEY TUBULES.
(a) EDX SPECTRUM OF ELECTRON DENSE DEPOSITS FOUND IN 
LYSOSOMES OF RAT KIDNEY PROXIMAL TUBULE.RATS WERE TREATED 
WITH CISPLATIN (2mg/kg) FOR 35 DAYS.
SECTION WAS TREATED AS DESCRIBED FOR FIGURE 5 . 3(b). 
Spectrum shows;
A1 (K®*) 1.49Kev. (specimen grid)
P (K*0 2.01Kev.
S (K«) 2.31Kev.
Cl (K®*) 2.62Kev.
Fe (K®0 6.40Kev.
Fe (K/0 7.05Kev.
Pt (L®0 9.44Kev.
Pt (Kys) 11 OKev.
(b)EDX SPECTRUM OF CELL CYTOPLASM ADJACENT TO LYSOSOME 
WHOSE SPECTRUM IS PRESENTED IN FIGURE 5.4(a).
No platinum peaks are evident and iron, chlorine 
sulphur,and phosphorus peaks are lower than found in 
lysosome.
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animals as they were also identified in the cortex of control animals.
Lysosome-like structures containing electron dense deposits were also
seen in unosmicated sections taken from treated animals (Figure 5.3b).
By means of microprobe analysis (Figure 5.4a) these electron dense
deposits were seen to be rich in iron (Ka 6.40Kev, KB 7.05Kev) and
platinum (La 9.44Kev, L/3 11.06Kev). Other elements associated with these
electron dense deposits at levels higher than found in the
neighbouring cytosol (cell background; Figure 5.4b) were sulphur (Ka
2.31Kev), phosphorus (Ka 2.01Kev) and chlorine (Ka 2.62Kev). No such
platinum-rich deposits were identified in kidney sections from control
' *
animals. Also, careful examination and probe analysis of liver and 
intestinal sections taken from cisplatin treated animals failed to 
demonstrate the presence of platinum. The accumulation of platinum 
after oral cisplatin treatment thus seems to be unique to the rat 
kidney and more specifically to the lysosome since no platinum was 
detected in mitochondria, nuclei or plasma membranes of kidney 
cortical cells. This evidence strongly supports and confirms the 
findings of the fractionation study that platinum is localised in 
lysosomes of the rat kidney cortex after oral administration of 
cisplatin.
(v) EFFECT OF PLATINUM ACCUMULATION ON LYSOSOMAL LATENCY 
Latency measurements are a convenient way of expressing the fragility 
of the lysosomal membrane which may be altered by the intralysosomal 
accumulation of an exogenous agent. Two methods were used to study 
the latency of lysosomes prepared from kidneys excised from cisplatin 
treated and control animals.
Theoretically there should be no free activity in a perfect preparation 
(i.e. 100% latency) and latency values obtained for control lysosomes 
using the sedimentation method were always in excess of 80%
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FIGURE 5.5
LYSOSOMAL LATENCY IN RAT KIDNEY CORTEX 
AFTER ORAL ADMINISTRATION OF CISPLATIN 
AS DETERMINED BY THE SEDIMENTATION METHOD,
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FIGURE 5.6
LYSOSOMAL LATENCY IN RAT KIDNEY CORTEX 
AFTER ORAL ADMINISTRATION OF CISPLATIN 
AS DETERMINED BY THE DETERGENT METHOD.
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indicative of a good preparation (Figure 5.5). In contrast, latency 
values for control lysosomes obtained using the detergent method were 
variable and low, ranging from 40 - 65% (Figure 5.6). This data 
implies that the sedimentation protocol reduces the autolytic breakage 
of intact lysosomes and is therefore superior for the study of the 
effect of exogenous compounds on the lysosomal membrane.
Apart from the measurement of Na-8-glycerophosphatase activity using 
the detergent method where lysosomal latency in test preparation was 
consistently higher than found in controls (Figure 5.6), the 
experimental evidence indicated that cisplatin increased the fragility of 
the lysosomal membrane. The sedimentation method illustrated that 
oral administration of cisplatin (30mg/kg) caused a decrease in the 
latency of rat kidney lysosomes with the nadir occurring 7 days after 
dosing (Figure 5.5). It is significant that pathological lesions to the 
kidney were most marked at this time point after oral administration 
of the complex (Section 4.3.2). Hence accumulation of large amounts of 
platinum within lysosomes of the kidney cortex, resulting in disruption 
of the lysosomal membrane and subsequent release of lysosomal 
enzymes, may be responsible in part for the widespread proximal 
tubular necrosis seen after cisplatin treatment.
(vi) BINDING OF PLATINUM TO CYTOSOLIC LIGANDS
The 254nm absorbance and trace metal elution profiles for the kidney 
cytosolic preparations obtained from animals receiving a single bolus 
dose or multiple daily doses of cisplatin are shown in Figures 5.7 and 
5.8 respectively. The cytosolic protein (OA254nm) resolved into high 
molecular weight material (albumin, haemoglobin, etc.) which eluted at 
or soon after the void volume and low molecular weight material that 
appeared around fraction 34. With the test sample from the multiply 
dosed animals this low molecular weight material formed two distinct
to
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peaks.
Platinum separated into two components; one which appeared with the 
void volume and presumably corresponded to albumin bound metal, 
with the second being a 'broadl peak that eluted around fraction 32 
with low molecular weight material. Very similar patterns were 
obtained after multiple or single doses of cisplatin and in general the 
amount of platinum recovered in the kidney cytosols after both dosage 
regimes was comparable.
Unlike the platinum pattern, different elution profiles were found for 
zinc distribution after the two dosage regimes. With the material from 
the single bolus dose, zinc eluted with albumin at fraction 14. The 
cytosol obtained after multiple doses had this component, but also a 
second that eluted at fraction 23 (which corresponded to a standard 
of Cd-thionein). It is important to note that the total zinc content of 
this cytosol was higher than found after a single bolus dose.
The copper elution profile obtained after both dosage regimes was 
similar and was characterised by three compounds that peaked at 
fraction 14 (albumin), 23 (Cd-thionein) and 30 (low molecular weight 
material).
5.4 DISCUSSION
The results of the fractionation study demonstrate that after oral 
administration of cisplatin the highest proportion of platinum is 
localised in the classical "ML" fraction of the rat kidney with small 
amounts of platinum in the other particulate soluble fractions (Table
5.5). Whilst Siddik et al. (1986) and Sharma et al. (1983) have
reported similar high platinum concentrations in the "ML" fraction of 
the rat kidney after parenteral administration of the compound, these 
groups found higher recoveries of platinum associated with the
cytosol. In contrast to the kidney, cisplatin apparently does not 
exhibit such significant association with the hepatic "ML" fraction and 
appears to be fairly evenly distributed throughout the various 
subfractions of the liver. Rate zonal centrifugation and x-ray 
microprobe analysis implicated the lysosomal population rather than 
the mitochondria to be the more important components within the 
kidney "ML” fraction as regards platinum accumulation. This finding 
is similar to those obtained in other studies of metal localisation and 
toxicity. The metals chromium (Berry et al. 1978), uranium (Ghadially 
et al. 1982), aluminium (Galle et al. 1980) and gold (Taylor et al. 1987) 
have also been shown to concentrate in the lysosomes of kidney 
tubules. It has been proposed (Fowler et al. 1975) that renal 
lysosomes play an integral role in protecting the organ from toxic 
metal poisoning as after sequestration the metals are unable to damage 
other sensitive cellular organelles such as mitochondria. This binding 
of metals and metal complexes such as cisplatin by lysosomes may be 
stimulated by chronic low level exposure, and the accumulation may be 
due to one of several mechanisms, including lysosomal endocytosis of a 
metal protein complex, autophagy of intoxicated organelles such as 
mitochondria, and/or binding of the metal to acidic lipoproteins within 
the lysosome. De Duve et al. (1974) proposed that there are 
essentially 4 mechanisms by which exogenous compounds m a y  
accumulate within lysosomes;
(i) Weakly basic compounds rapidly accumulate in lysosomes because 
the proton pump of the lysosomal membrane allows them to enter but 
not exit.
(ii) Permeable molecules may be modified, by the action of lysosomal 
enzymes, into forms which become impermanent.
(iii) A wide variety of small molecules which are readily bound to 
macromolecules may be delivered to lysosomes by the powerful process 
of receptor-mediated endocytosis. This is sometimes referred to as 
’piggy-back* endocytosis.
(iv) Some small molecules may reach the lysosome directly by 
endocytosis.
The term lysosomotropism was later coined to describe this 
phenomenon.
Galle et al. (1974, 1983) envoked mechanism (ii) in order to explain the 
accumulation and precipitation of the metals aluminium, gallium and 
indium within lysosomes of the kidney proximal tubule. The local 
presence of acid phosphatases within lysosomes of the proximal tubule 
leads to the liberation of phosphate ions from such substrates as ATP. 
The liberated phosphate ions can precipitate with elements such as 
aluminium to form insoluble phosphate salts and thus remove them 
from the cytoplasm. The elements are eventually released as the 
lysosomes lyse and spill their contents into the cytoplasm resulting in
cellular necrosis or else are discharged into the tubular lumen and
are eliminated with the urinary flux. The existence of phosphorus in 
platinum containing lysosomes, as indicated by microprobe analysis, 
might suggest that a comparison between the lysosomal handling of
aluminium and platinum can be made. However unlike elements of
group III of the periodic table, platinum phosphate salts are likely to 
be soluble (B. Murrer, personal communication) and therefore will not 
readily form precipitates.As well as phosphorus, platinum was also 
associated with sulphur; the same element that has been shown to be 
associated with precipitates of gold (Elder et al. 1979) in previous 
microanalytical studies. The significance of the large amounts of iron 
detected in platinum containing lysosomes, which has also been
reported by other workers (Makita et al. 1985, Berry et al. 1982), 
remains unclear but may be irrelevant since iron was also detected in 
electron dense granules in the kidney lysosomes of control animals. 
Hence although microprobe analysis demonstrated the existance of 
renal lysosomes containing precipitates of platinum, iron, phosphorus 
and sulphur, the exact structure and composition of such insoluble 
deposits is unknown.
Evidence for the protective mechanism of sequestration of platinum by 
the renal lysosomal system was obtained from histopathological studies 
which indicated that proximal tubular necrosis was far more profound 
in kidneys taken from animals that received a single bolus dose 
(30mg/kg) than repeated daily doses (lmg/kg for 35 days) of cisplatin. 
This could be due to the fact that exposure to the high bolus dose 
totally overwhelmed the lysosomal system, resulting in binding to 
essential macromolecules and subsequent manifestation of cellular 
response to injury. Further support for this idea could be attained 
from a careful dose-response study and it would also be of immense 
interest to determine whether chronic doses of cisplatin induce the 
same disruption of the lysosomal membrane that was observed after a 
large bolus dose (section 5.3.2vi). It is clear that much more research 
is currently needed to ascertain the possible role of the lysosome in 
in vivo storage and inactivation of platinum based pharmaceuticals.
It has been demonstrated by G-75 sephadex column chromatography 
that platinum can bind to a relatively low weight region of the kidney 
cytosol of cisplatin treated rats corresponding to a 109Cd-binding 
protein or metallothionein (Mason et al. 1984, Sharma et al. 1983, 
Zelazawski et al. 1984, Litterst et al. 1986). However, in this study 
little association with the region corresponding to metallothionein was 
observed either after a single bolus dose or repeated daily dosing of
cisplatin. This is consistent with the results of Webb (1982) who 
reported that platinum only binds to particulate components of the 
renal tissue. Cytosolic platinum binding was however demonstrated 
within a low molecular weight species that eluted at a region 
corresponding to a standard of reduced glutathione and with a high 
molecular weight material. The latter could represent albumin, 
haemoglobin or polymerised metallothionein. The lack of platinum 
association with monomeric metallothionein may be due to the fact that 
a reducing agent such as mercaptoethanol which is important for good 
chromatographic resolution of metallothionein (Overneil 1984) was not 
included in the homogenate, cytosol nor the elution buffer. These 
results therefore do not exclude the possibility that platinum may be 
associated with metallothionein.
Multiple daily dosing of cisplatin resulted in a redistribution of 
platinum from the kidney "ML" fraction to the cytosol. Although this 
could be due to an increase in binding to induced metallothienein it is 
more likely to be artefactual due to release of platinum from the 
endosomal/lysosomal compartment during homogenisation. Latency 
measurements illustrated that the lysosomal membrane becomes 
increasingly more fragile and susceptible to rupture after accumulation 
of platinum. Moreover, classical subfraction of kidneys excised from 
animals that had received multiple doses of cisplatin revealed that acid 
phosphatase was evenly distributed throughout the "ML" and cytosolic 
fractions indicating a large degree of lysosomal rupture. Lysosomal 
rupture during homogenisation may also explain why other groups 
(Siddik et al. 1986, Sharma et al. 1983) have reported such high 
cytosolic platinum levels after perenteral administrations of the drug 
to rats. Although platinum binding to monomeric renal metallothionein 
could not be demonstrated it is clear that multiple oral administrations
of cisplatin may have indirectly perturbed the normal function of the 
protein in the regulation of zinc metabolism. This was manifested as 
an increase in the cytosolic total zinc content of the kidney with a 
concurrent increase in the amount of zinc associated with 
metallothionein. An effect analogous to that described for sodium 
aurothiomalate on copper metabolism (Taylor et al. 1987).
In both having reactive sulphydryl groups, glutathione and 
metallothionein are potentially able to firmly bind cisplatin thus 
rendering it unavailable for interaction with other functionally 
important metal sensitive sites within the nephron. Thus like the 
lysosome these sulphur containing species may, by sequestration of 
the active platinum complex, play an important role in the 
detoxification of cisplatin. Observations that appear to support this 
hypothesis were recently reported by Litterst et al. (1986). This 
study showed that depletion of tissue levels of glutathione by 
pretreatment of diethymaleate resulted in a marked increase in 
cisplatin induced nephrotoxicity whereas elevation of renal 
metallothionein by pretreatment with cadmium chloride afforded 
significant protection against the toxic response.
In conclusion, the work presented in this chapter has illustrated that 
by following the subcellular localisation of an agent and the molecular 
species with which it interacts one can get a valuable insight into 
understanding its mechanism of toxicity.
CHAPTER 6
CONCLUSIONS AND S U M M A R Y
In general, each chapter has been, to a greater or lesser extent, 
discussed in the body of the work. It may now be helpful to 
condense these discussions into a chapter of conclusions and then to 
summarise the work.
The primary objective of this study was to investigate the absorption 
of transition metal pharmaceutical compounds from the gut and to 
determine the toxicology associated with oral administration. The 
study was initiated after reports by Siddik et al. (1984) that oral 
administration of cisplatin significantly reduced the incidence of 
nephrotoxicity associated with the drug when given to rats and 
moreover that oral cisplatin was active against the ADJ/PC6A 
plasmacytoma in mice and the Walker 256 Carcinosarcoma in rats. In 
the rat Walker 256 model the median lethal dose (LD50) for cisplatin 
and carboplatin after oral administration was reported to be 114mg/kg 
and 566mg/kg respectively. The dose required to get a 90% 
therapeutic effect (ED90) against the Walker 256 carcinosarcoma was 
59mg/kg and 400mg/kg for orally administered cisplatin and 
carboplatin respectively. It was therefore decided, using these 
figures to study the toxicology associated with oral administration of 
the two compounds at equitoxic doses that would still have significant 
antitumour activity. Hence the doses of 57mg/kg cisplatin and 
282mg/kg carboplatin were initially used.
Cisplatin at this dose level was shown to be acutely toxic and the 
study had to be abandoned 4 days after administration due to the 
poor condition of the animals. Toxicity was manifested as acute 
necrotizing enteritis and associated anorexia, ulceration of the 
stomach, erythrocytosis and myelosuppression. At this dose and at a 
subsequent lower dose (30mg/kg) deaths were preceded by indications 
of severe nephrotoxicity.
A degree of mild hepatotoxicity was indicated ultrastructurally and 
mitochondria isolated from the livers of cisplatin treated animals 
exhibited modifications in the permeability of the inner membrane that 
was manifested as an uncoupling of respiration from ATP synthesis. 
This lesion was only studied upto 3 days post-dosing and it could be 
of importance to extend the time course to determine the fate of 
hepatocytes containing such mitochondria.
In the ferret, oral administration of cisplatin resulted in a very 
marked emetic response. Due to the short latent period (of 
approximately 40 minutes) absorption of the compound from the 
gastrointestinal tract into the peripheral blood is likely to have been 
impaired. Hence in this species, and probably in man, plasma levels of 
cisplatin are unlikely to correspond to the dose administered. The 
toxicity associated with oral administration of carboplatin to rats was 
far less profound than that after cisplatin. As has been found after 
parenteral administration, little nephrotoxicity was associated with this 
compound. However, in common with cisplatin, oral administration 
resulted in profound lesions of the gastrointestinal tract and a degree 
of myelosuppression. Although hepatotoxicity could not be 
demonstrated biochemically or by light microscopy, hepatocytes 
surrounding the portal tract were seen to contain vesiculated 
endoplasmic reticulum and swollen mitochondria when liver morphology 
was studied ultrastructurally. The nadir for the toxic responses 
associated with carboplatin appeared to be 7 days after dosing, with 
full recovery in most cases by day 14. Like cisplatin, oral 
administration of carbopatin resulted in stomach bloat in rats upto 7 
days post treatment.
Gastric distention was shown to have a significant effect on the 
release of the compounds from the stomach and it was proposed that 
in the acid conditions present carboplatin could form the more toxic 
parent compound. This possible conversion in the gastric pouch 
would have profound effects on the pharmacokinetics, toxicity and 
antitumour activity of the compound when given orally. It is 
important therefore that future work be conducted into any 
biotransformations that occur due to administration by the oral route. 
This could include HPLC of compounds incubated in conditions that 
mimic those found in the gastric pouch and analysis of metabolites 
that appear in portal blood after absorption from the small intestine. 
The other consequence of prolonged exposure of the gastric mucosa to 
cisplatin and carboplatin was the development of gastric ulcers. 
Although carboplatin was shown to be far less emetic than cisplatin 
after oral administration to the ferret, gastric ulcers were formed at 
non-emetic doses. It would therefore be of use to compare the dose 
response relationship for the gastric ulcerogenicity of cisplatin and 
carboplatin in another non-rodent species in which the gastric 
anatomy resembles that of the human.
Although both cisplatin and carboplatin administration resulted in 
varying degrees of acute toxicity, absorption from the gastrointestinal 
tract was relatively poor when compared to an established metal 
containing compound designed for oral administration (ie. Auranofin). 
When equimolar concentrations of the two compounds were 
administered to rats by oral gavage, cisplatin was absorbed more 
rapidly and to the greatest extent as indicated by the higher blood 
platinum levels that were attained. However, in both cases by far the 
greatest proportion of the dose was excreted in the faeces (>75%).
The greater capacity for absorption from the gastrointestinal tract of 
cisplatin was also demonstrated in vitro using everted sacs of 
intestine and in situ. Everted sac experiments also gave some insight 
into the mechanism of absorption of the complexes across the intestinal 
mucosa. No evidence for active or carrier mediated transport could be 
found and therefore it was concluded that the transport was by a 
passive diffusion mechanism. Although the everted gut sac technique 
was shown to be a good model for screening purposes, it was 
concluded that more detailed mechanistic information concerning 
absorption could be ascertained with the use of isolated intestinal 
membranes vesicles. It was quite noticeable that the differences in 
the absorption capacity of cisplatin and carboplatin was amplified in 
the isolated intestinal preparation that bypassed the stomach. This 
could be explained by the delayed gastric emptying and possible 
metabolism that might occur in the stomach in the in vivo situation.
By studying the absorption of a series of platinum (IV) mixed amines 
it was shown that transport across the intestinal mucosa could be 
enhanced by modification of the ligands attached to the platinum atom. 
Regrettably, too few compounds were studied for definitive 
structure-activity relationships to be determined.
As has been found after parenteral administration of platinum 
complexes; the highest concentrations of tissue platinum after oral 
administration was discovered in the kidney. Whereas, hepatic and 
intestinal platinum was rapidly removed, clearance of tissue platinum 
was slower in the kidney. Oral administration of cisplatin always 
resulted in higher levels of tissue platinum than after administration 
of carboplatin. This can be explained both in terms of greater amount 
of cisplatin that is absorbed from the gastrointestinal tract and its 
greater chemical reactivity.
Carboplatin when absorbed remains relatively unreactive due to the 
stability of the CBDCA ligand and hence is rapidly cleared unchanged 
in the urine. In contrast cisplatin rapidly reacts, possibly after 
aquation, with a variety of macromolecules resulting in high levels of 
tissue deposition.
In an attempt to explain the prolonged retention of cisplatin in the 
kidney, the intracellular localisation of the compound was studied in 
rat kidney, liver and intestine. Using electron microprobe analysis 
(EDX) no sites of concentration of platinum could be identified either 
in the liver or the intestine after oral administration of cisplatin. 
However, accumulation of platinum in lysosomes of the kidney proximal 
tubule was identified. This observation was confirmed after 
subcellular fractionation and subsequent atomic-absorption 
spectrophotometric analysis of the various fractions obtained from 
kidneys excised after cisplatin treatment. Hence, it can be 
hypothesised that the prolonged retention of platinum in renal tissue 
could be due to accumulation within lysosomes of the kidney tubule. 
This process may play an integral role in protecting the kidney from 
toxic metal poisoning since once within the lysosomal compartment the 
toxic species is unable to damage other sensitive cellular organelles 
such as mitochondria.
To conclude, although oral administration of platinum based 
pharmaceuticals would be a major breakthrough in the clinical 
management of patients, the results presented in this thesis indicate 
that the goal is a long way away. Unfortunately the exciting results
of Siddik et al. (1984) in which oral administration of cisplatin
appeared to offer a way of modulating its inherent nephrotoxicity 
could not be repeated and it was shown that the toxicities associated 
with the parenteral route of the complexes would also apply to the
oral route. Moreover, oral administration also appears to potentiate 
drug induced gastrointestinal toxicity and could possibly result in a 
higher incidence of hepatotoxicity.
Thus, oral administration of cisplatin and carboplatin does not appear 
to be justified in terms of a reduction in toxicity and a more 
thoughtful approach such as the synthesis of pro-drugs needs to be 
adopted.
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APPENDIX I
CONSTITUENTS OF'..LABORATORY ANIMAL DIET 
USED IN PHARMACOKINETIC ,IN VITRO AND 
TOXICOLOGY STUDIES.
Proximate
C o n s t i tu en t s
Ash
Found by Analysis 
A .9 *
Contaminants
Arsenic
Found by 
Analys is  
mg/kg 
0.80
Limit o f  
Detect ion
0.2 .;
Crude Fat 4.2  % Cadmi urn 0.13 0.05
Crude Fibre 1.6 % F luor ine 13.2 1.0
Crude P ro te in 21.5 % Lead 0.35 0.25 .
Moisture 9-7 % Mercury < 0.01 0.01
" N i t r a t e  as NaNO^ 49.0 1.0
Minera ls : N i t r i t e  as NaNOg <1.0 1.0
Calcium 1 .07 % Selenium 0.33 0.02
Chlor ine 0.51 %
Copper 10. mg/kg D ie ld r in 0.003 0.001
Iron 175 mg/kg Lindane N.D. 0.001
Magnesium 0.14 % Heptach lor 0.001 0.001
Manganese 4 5  mg/kg Malathion N.D. 0.02
Phosphorus O. 7 1  % Total  PCB N.D. 0.001
Potassium 0.60 % Total  DOT 0.005 0.001
Sodium 0.23 %
Zinc 62 mg/kg Total  Af l a to x ins N.D. 1 mcg/kg each 
■ ofBl,B2,G1,G2
Vitamins :
Vitamin A 1 3 ,000 iu/kg
Vitamin E 60,.0 mg/kg Microb iologica l
Contaminants Uni t s /g U ni t s /g
Total  Viable 
Organisms <1.0 x 103 N 2
1000
Mesophi l ic  Spores (2 .50 x 10
Salmonel la Species  N.D. 
Presumpt ive E. ColiN.D.
E. Co 1i Type 1 N.D. 
Fungal Uni ts  N.D.
A n t i b i o t i c  A c t iv i t y  N.D.
- = Not determined
NO = None detec ted
100
(Absent i n : )  
20g 
lOg 
lOg 
lOg
20g
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